Primerica (PRI) 10-K 28 Feb 23 2022 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2022	Jan. 31, 2023	Jun. 30, 2022
Cover [Abstract]
Entity Registrant Name	Primerica, Inc
Entity Central Index Key	0001475922
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Document Type	10-K
Document Period End Date	Dec. 31, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Trading Symbol	PRI
Amendment Flag	false
Entity Common Stock, Shares Outstanding		36,645,594
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$ 4,501,224,081
Entity Interactive Data Current	Yes
Entity Shell Company	false
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Document Annual Report	true
Document Transition Report	false
Title of 12(b) Security	Common Stock
Security Exchange Name	NYSE
Entity File Number	001-34680
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	27-1204330
Entity Address, Address Line One	1 Primerica Parkway
Entity Address, City or Town	Duluth
Entity Address, State or Province	GA
Entity Address, Postal Zip Code	30099
City Area Code	770
Local Phone Number	381-1000
Auditor Firm ID	185
Auditor Name	KPMG LLP
Auditor Location	Atlanta, GA
Documents Incorporated by Reference	Certain information contained in the Proxy Statement for the Company’s Annual Meeting of Stockholders to be held on May 17, 2023 is incorporated by reference into Part III hereof.

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Investments:
Fixed-maturity securities available-for-sale, at fair value (amortized cost: $2,801,415 in 2022 and $2,621,388 in 2021)	$ 2,495,456	$ 2,702,567
Fixed-maturity security held-to-maturity, at amortized cost (fair value: $1,340,265 in 2022 and $1,551,113 in 2021)	1,444,920	1,379,100
Short-term investments available-for-sale, at fair value (amortized cost: $69,393 in 2022 and $85,246 in 2021)	69,406	85,243
Equity securities, at fair value (historical cost: $29,430 in 2022 and $34,255 in 2021)	35,404	42,551
Trading securities, at fair value (cost: $4,229 in 2022 and $24,769 in 2021)	3,698	24,355
Policy loans and other invested assets	48,713	30,612
Total investments	4,097,597	4,264,428
Cash and cash equivalents	489,240	392,501
Accrued investment income	20,885	18,702
Reinsurance recoverables	4,015,909	4,268,419
Deferred policy acquisition costs, net	3,081,886	2,943,782
Renewal commissions receivable	200,043	231,751
Agent balances, due premiums and other receivables	254,276	257,675
Goodwill	127,707	179,154
Intangible assets, net	185,525	195,825
Deferred income taxes	101,333	81,799
Operating lease right-of-use assets	40,500	47,942
Other assets	428,259	441,253
Separate account assets	2,305,717	2,799,992
Total assets	15,348,877	16,123,223
Liabilities:
Future policy benefits	7,390,800	7,138,649
Unearned and advance premiums	15,422	16,437
Policy claims and other benefits payable	538,250	585,382
Other policyholders’ funds	483,769	501,823
Notes payable - Short term		15,000
Notes payable - Long term	592,905	592,102
Surplus note	1,444,469	1,378,585
Income tax payable	36,876	15,311
Deferred income taxes	91,457	226,000
Operating lease liabilities	45,995	53,920
Other liabilities	580,780	615,710
Payable under securities lending	100,938	94,529
Separate account liabilities	2,305,717	2,799,992
Commitments and contingent liabilities (see Commitments and Contingent Liabilities note)
Total liabilities	13,627,378	14,033,440
Temporary Stockholders’ Equity
Redeemable noncontrolling interests in consolidated entities		7,271
Equity attributable to Primerica, Inc.:
Common stock ($0.01 par value; authorized 500,000 in 2022 and 2021; issued and outstanding 36,824 shares in 2022 and 39,368 shares in 2021)	368	394
Paid-in capital		5,224
Retained earnings	1,973,403	2,004,506
Accumulated other comprehensive income (loss), net of income tax:
Unrealized foreign currency translation gains (losses)	(11,404)	8,611
Net unrealized investment gains (losses) on available-for-sale securities	(240,868)	63,777
Total permanent stockholders’ equity	1,721,499	2,082,512
Total liabilities and temporary and permanent stockholders’ equity	$ 15,348,877	$ 16,123,223

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Investments:
Equity securities, at fair value, historical cost	$ 29,430	$ 34,255
Trading securities, amortized cost	$ 4,229	$ 24,769
Equity attributable to Primerica, Inc.:
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	36,824,000	39,368,000
Common stock, shares outstanding	36,824,000	39,368,000
Fixed Maturities
Investments:
Fixed-maturity securities available for sale, amortized cost	$ 2,801,415	$ 2,621,388
Fixed-maturity security held to maturity, fair value	1,340,265	1,551,113
Trading securities, amortized cost	4,229	24,769
Short-Term Investments
Investments:
Fixed-maturity securities available for sale, amortized cost	$ 69,393	$ 85,246

Consolidated Statements of Inco

Consolidated Statements of Income - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Revenues:
Direct premiums	$ 3,230,120	$ 3,122,148	$ 2,907,149
Ceded premiums	(1,629,892)	(1,616,264)	(1,580,766)
Net premiums	1,600,228	1,505,884	1,326,383
Commissions and fees	944,676	1,042,813	751,271
Investment income net of investment expenses	156,987	142,795	141,287
Interest expense on surplus note	(63,922)	(62,207)	(57,473)
Net investment income	93,065	80,588	83,814
Realized investment gains (losses)	1,444	4,665	1,359
Other investment gains (losses)	(2,439)	1,207	(6,355)
Investment gains (losses)	(995)	5,872	(4,996)
Other, net	83,159	74,575	61,069
Total revenues	2,720,133	2,709,732	2,217,541
Benefits and expenses:
Benefits and claims	665,749	722,753	615,569
Amortization of deferred policy acquisition costs	356,143	251,179	224,321
Sales commissions	462,764	522,308	376,636
Insurance expenses	235,405	202,605	188,117
Insurance commissions	30,261	34,532	32,134
Contract acquisition costs	68,431	52,788
Interest expense	27,237	30,618	28,839
Goodwill impairment loss	60,000	76,000
Loss on extinguishment of debt		8,927
Other operating expenses	320,394	296,851	245,195
Total benefits and expenses	2,226,384	2,198,561	1,710,811
Income before income taxes	493,749	511,171	506,730
Income taxes	125,775	139,191	120,566
Net income (loss)	367,974	371,980	386,164
Net income (loss) attributable to noncontrolling interests	(5,038)	(1,377)
Net income (loss) attributable to Primerica, Inc.	$ 373,012	$ 373,357	$ 386,164
Earnings per share attributable to common stockholders:
Basic earnings per share	$ 9.77	$ 9.41	$ 9.60
Diluted earnings per share	$ 9.74	$ 9.38	$ 9.57
Weighted-average shares used in computing earnings per share:
Basic	37,997	39,530	40,065
Diluted	38,106	39,652	40,185

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Statement Of Income And Comprehensive Income [Abstract]
Net income	$ 367,974	$ 371,980	$ 386,164
Unrealized investment gains (losses) on available-for-sale securities:
Change in unrealized holding gains (losses) on investment securities	(385,735)	(78,348)	78,533
Reclassification adjustment for realized investment (gains) losses included in net income	(1,387)	(3,849)	2,614
Foreign currency translation adjustments:
Change in unrealized foreign currency translation gains (losses)	(20,015)	7,033	7,343
Total other comprehensive income (loss) before income taxes	(407,137)	(75,164)	88,490
Income tax expense (benefit) related to items of other comprehensive income (loss)	(82,477)	(17,846)	17,582
Other comprehensive income (loss), net of income taxes	(324,660)	(57,318)	70,908
Total comprehensive income	43,314	314,662	457,072
Net income (loss) attributable to noncontrolling interests	(5,038)	(1,377)
Comprehensive income attributable to Primerica, Inc.	$ 48,352	$ 316,039	$ 457,072

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock [Member]	Paid-in Capital [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Redeemable Noncontrolling Interests in Consolidated Entities/Temporary Stockholders' Equity [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member] Retained Earnings [Member]
Balance, beginning of period at Dec. 31, 2019		$ 412		$ 1,593,281	$ 58,798
Cumulative effect from the adoption of new accounting standards, net at Dec. 31, 2019							$ (1,240)
Repurchases of common stock		(22)	$ (29,076)	(208,073)
Share-based compensation			29,079
Net issuance of common stock		3	(3)
Net income	$ 386,164			386,164
Dividends				(64,346)
Change in foreign currency translation adjustment, net of income tax expense (benefit)					7,343
Change in net unrealized investment gains (losses)during the period, net of income taxes:					63,565
Balance, end of period at Dec. 31, 2020	$ 1,835,885	393		1,705,786	129,706
Dividends declared per share	$ 1.60
Repurchases of common stock		(1)	(25,817)
Share-based compensation			31,043
Net issuance of common stock		2	(2)
Net income	$ 373,357			373,357
Dividends				(74,637)
Change in foreign currency translation adjustment, net of income tax expense (benefit)					7,033
Acquisition of noncontrolling interest						$ 8,438
Net income (loss) attributable to noncontrolling interests	(1,377)					(1,377)
Changes in noncontrolling interests in consolidated entities, net						210
Change in net unrealized investment gains (losses)during the period, net of income taxes:					(64,351)
Balance, end of period at Dec. 31, 2021	$ 2,082,512	394	5,224	2,004,506	72,388	7,271
Dividends declared per share	$ 1.88
Cumulative effect from the adoption of new accounting standards, net at Dec. 31, 2021	$ 2,004,506
Repurchases of common stock		(28)	(41,079)	(320,332)
Redemption of noncontrolling interest in consolidated entities			2,233			(2,233)
Share-based compensation			33,624
Net issuance of common stock		2	$ (2)
Net income	373,012			373,012
Dividends				(83,783)
Change in foreign currency translation adjustment, net of income tax expense (benefit)					(20,015)
Net income (loss) attributable to noncontrolling interests	(5,038)					$ (5,038)
Change in net unrealized investment gains (losses)during the period, net of income taxes:					(304,645)
Balance, end of period at Dec. 31, 2022	$ 1,721,499	$ 368		$ 1,973,403	$ 252,272
Dividends declared per share	$ 2.20

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities:
Net income	$ 367,974	$ 371,980	$ 386,164
Adjustments to reconcile net income to cash provided by (used in) operating activities:
Change in future policy benefits and other policy liabilities	225,896	462,733	574,060
Deferral of policy acquisition costs	(503,336)	(552,192)	(512,634)
Amortization of deferred policy acquisition costs	356,143	251,179	224,321
Deferred tax provision	(79,980)	(25,593)	266
Change in income taxes	26,414	1,426	(5,008)
Investment (gains) losses	995	(5,872)	4,996
Accretion and amortization of investments	3,329	5,118	751
Depreciation and amortization	34,174	29,836	17,697
Change in reinsurance recoverables	231,902	8,312	(100,185)
Change in agent balances, due premiums and other receivables	(475)	6,046	(32,348)
Change in renewal commissions receivable	19,845	(23,459)	(3,144)
Trading securities sold, matured, or called (acquired), net	19,962	(8,817)	26,694
Share-based compensation	22,361	16,842	19,027
Goodwill impairment loss	60,000	76,000
Loss on extinguishment of debt		8,927
Change in other operating assets and liabilities, net	(27,539)	34,490	42,760
Net cash provided by (used in) operating activities	757,665	656,956	643,417
Available-for-sale investments sold, matured or called:
Fixed-maturity securities — sold	23,628	131,953	67,760
Fixed-maturity securities — matured or called	359,717	454,135	429,147
Short-term investments — sold	28,251	50,065
Short-term investments — matured or called	85,302	40,000
Equity securities - sold	16	718	2,581
Equity securities - matured or called	3,063
Available-for-sale investments acquired:
Fixed-maturity securities	(580,485)	(901,591)	(522,123)
Short-term investments	(97,415)	(176,125)
Equity securities — acquired	(187)	(3,391)	(3,272)
Purchases of property and equipment and other investing activities, net	(25,805)	(24,688)	(27,622)
Cash collateral received (returned) on loaned securities, net	6,409	22,375	43,431
Sales (purchases) of short-term investments using securities lending collateral, net	(6,409)	(22,375)	(43,431)
Purchase of business, net of cash acquired	3,867	(494,459)
Net cash provided by (used in) investing activities	(200,048)	(923,383)	(53,529)
Cash flows from financing activities:
Dividends paid	(83,783)	(74,636)	(64,346)
Common stock repurchased	(356,306)	(18,751)	(231,431)
Proceeds from revolving credit facility		125,000
Repayment of revolving credit facility		(125,000)
Proceeds from issuance of debt		597,300
Debt issuance costs		(5,332)
Repayment of debt		(383,691)
Payment on note issued to seller of business	(12,364)
Tax withholdings on share-based compensation	(5,135)	(6,652)	(5,739)
Finance leases	(262)	(264)	(274)
Net cash provided by (used in) financing activities	(457,850)	107,974	(301,790)
Effect of foreign exchange rate changes on cash	(3,028)	3,385	2,595
Change in cash and cash equivalents	96,739	(155,068)	290,693
Cash and cash equivalents, beginning of period	392,501	547,569	256,876
Cash and cash equivalents, end of period	489,240	392,501	547,569
Supplemental disclosures of cash flow information:
Income taxes paid	178,218	154,812	123,305
Interest paid	$ 27,060	33,905	$ 27,853
Non-cash activities:
Increases in note issued to seller of business		$ 15,000

Description of Business, Basis

Description of Business, Basis of Presentation, and Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2022
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Description of Business, Basis of Presentation, and Summary of Significant Accounting Policies	(1) Description of Business, Basis of Presentation, and Summary of Significant Accounting Policies Description of Business. Primerica, Inc. (the “Parent Company”), together with its subsidiaries (collectively, “we”, “us” or the “Company”), is a leading provider of financial products to middle-income households in the United States and Canada through a network of independent contractor sales representatives (“independent sales representatives” or “independent sales force”). We assist our clients in meeting their needs for term life insurance, which we underwrite, and mutual funds, annuities, managed investments and other financial products, which we distribute primarily on behalf of third parties. We acquired 80 % of e-TeleQuote Insurance, Inc. and subsidiaries (collectively, “e-TeleQuote”) through our subsidiary, Primerica Health, Inc. (“Primerica Health”) on July 1, 2021 and the remaining 20 % of e-TeleQuote on July 1, 2022 . e-TeleQuote markets Medicare-related insurance products underwritten by third-party health insurance carriers to eligible Medicare participants through its licensed health insurance agents. Refer to Note 20 (Acquisition) for more information regarding the acquisition of e-TeleQuote. Our other primary subsidiaries include the following entities: Primerica Financial Services, LLC (“PFS”), a general agency and marketing company; Primerica Life Insurance Company (“Primerica Life”), our principal life insurance company; Primerica Financial Services (Canada) Ltd., a holding company for our Canadian operations, which includes Primerica Life Insurance Company of Canada (“Primerica Life Canada”) and PFSL Investments Canada Ltd. (“PFSL Investments Canada”); and PFS Investments Inc. (“PFS Investments”), an investment products company and broker-dealer. Primerica Life, domiciled in Tennessee, owns National Benefit Life Insurance Company (“NBLIC”), a New York insurance company. Peach Re, Inc. (“Peach Re”) and Vidalia Re, Inc. (“Vidalia Re”) are special purpose financial captive insurance companies and wholly owned subsidiaries of Primerica Life. Peach Re and Vidalia Re have each entered into separate coinsurance agreements with Primerica Life whereby Primerica Life has ceded certain level-premium term life insurance policies to Peach Re and Vidalia Re (respectively, the “Peach Re Coinsurance Agreement” and the “Vidalia Re Coinsurance Agreement”). Basis of Presentation. We prepare our financial statements in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). These principles are established primarily by the Financial Accounting Standards Board (“FASB”). Use of Estimates. The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect financial statement balances, revenues and expenses and cash flows, as well as the disclosure of contingent assets and liabilities. Management considers available facts and knowledge of existing circumstances when establishing the estimates included in our financial statements. The most significant items that involve a greater degree of accounting estimates and actuarial determinations subject to change in the future are the valuation of investments, deferred policy acquisition costs (“DAC”), future policy benefit reserves and corresponding amounts recoverable from reinsurers, renewal commissions receivable, income taxes, and valuation of intangible assets and goodwill. Estimates for these and other items are subject to change and are reassessed by management in accordance with U.S. GAAP. Actual results could differ from those estimates. Consolidation. The accompanying consolidated financial statements include the accounts of the Company and those entities required to be consolidated under U.S. GAAP. All material intercompany profits, transactions, and balances among the consolidated entities have been eliminated. Reclassifications. Certain reclassifications have been made to prior-period amounts to conform to current-period reporting classifications. These reclassifications had no impact on net income or total stockholders’ equity. Foreign Currency Translation. Assets and liabilities of our Canadian subsidiaries are translated into U.S. dollars using year-end exchange rates, and the translation adjustments are reported in other comprehensive income (loss). Revenues and expenses of our Canadian subsidiaries are translated monthly at amounts that approximate weighted-average exchange rates. Investments. Investments are reported on the following bases: • Available-for-sale (“AFS”) fixed-maturity securities, including bonds and redeemable preferred stocks, are carried at fair value. • Our held-to-maturity fixed-maturity security is carried at amortized cost. • Equity securities, including common and nonredeemable preferred stocks, are carried at fair value. Changes in fair value of equity securities are included in realized investment gains (losses) in the period in which the change occurred. • Trading securities, which primarily consist of bonds held by PFS Investments, are carried at fair value. Changes in fair value of trading securities are included in realized investment gains (losses) in the period in which the change occurred. • Policy loans are carried at unpaid principal balances, which approximate fair value. Investment transactions are recorded on a trade-date basis. We use the specific-identification method to determine the realized gains or losses from securities transactions and report the investment gains or losses in the accompanying consolidated statements of income. Unrealized gains and losses on AFS securities are included as a separate component of other comprehensive income (loss), except for credit loss impairment discussed below, in the accompanying consolidated statements of comprehensive income. For an AFS security with an amortized cost that exceeds its fair value, we first determine if we intend to sell or will more-likely-than-not be required to sell the security before the expected recovery of its amortized cost. If we intend to sell or will more-likely-than-not be required to sell the security, then we recognize the impairment as a credit loss in our consolidated statements of income by writing down the security’s amortized cost to its fair value. If we do not intend to sell or it is not more-likely-than-not that we will be required to sell the security before the expected recovery of its amortized cost, we recognize the portion of the impairment that is due to a credit loss, if any, in our consolidated statement of income through an allowance. The portion of the impairment that is due to factors other than a credit loss is recognized in other comprehensive income in the consolidated statement of comprehensive income as an unrealized loss. Credit losses recognized in the allowance for credit losses are reversed in situations where the estimate of credit losses on those securities has declined. When determining whether an impairment is due to a credit loss or other factors, we determine the extent to which we do not expect to recover the security’s amortized cost and record such amount, if any, as a credit loss. Factors we consider in determining whether the security’s decline in fair value is below amortized cost due to a credit loss include the magnitude of the security’s decline in fair value below its amortized cost, the financial condition, long and near-term prospects for the issuer, industry conditions and trends, rating agency actions, the payment structure of the security, likelihood of the recoverability of principal and interest, and our ability and intent to hold the security for a period of time sufficient to allow for the anticipated recovery of its amortized cost. In assessing our ability and intent to hold the security for a period of time to allow for the anticipated recovery of its amortized cost, we also consider our anticipated sources of cash to fund operating activities and share repurchases. If we do not anticipate recovering a security’s amortized cost basis, we estimate the present value of the security’s expected cash flows and recognize the difference from amortized cost (using fair value as a floor) as a credit loss. Interest income on fixed-maturity securities is recorded when earned by determining the effective yield, which gives consideration to amortization of premiums, accretion of discounts, and any previous credit losses. Dividend income on equity securities is recorded when declared. These amounts are included in net investment income in the accompanying consolidated statements of income. Included within fixed-maturity securities are loan-backed and asset-backed securities. Amortization of the premium or accretion of the discount uses the retrospective method. The effective yield used to determine amortization/accretion is calculated based on actual and historical projected future cash flows and updated quarterly. Cash and Cash Equivalents. Cash and cash equivalents include cash on hand, money market instruments, and all other highly liquid investments purchased with an original or remaining maturity of three months or less at the date of acquisition. Reinsurance. We use reinsurance extensively, utilizing yearly renewable term (“YRT”) and coinsurance agreements. Under YRT agreements, we reinsure only the mortality risk, while under coinsurance, we reinsure a proportionate part of all risks arising under the reinsured policy. Under coinsurance, the reinsurer receives a proportionate part of the premiums, less commission allowances, and is liable for a corresponding part of all benefit payments. All reinsurance contracts in effect for the three-year period ended December 31, 2022 transfer a reasonable possibility of substantial loss to the reinsurer or are accounted for under the deposit method of accounting. Ceded premiums are treated as a reduction to direct premiums and are recognized when due to the assuming company. Ceded claims are treated as a reduction to direct benefits and are recognized when the claim is incurred on a direct basis. Ceded policy reserve changes are also treated as a reduction to benefits and claims expense and are recognized during the applicable financial reporting period. Reinsurance premiums, commissions, expense reimbursements and benefits and reserves related to reinsured long-duration contracts are accounted for over the life of the underlying contracts using assumptions consistent with those used to account for the underlying policies. Amounts recoverable from reinsurers are estimated in a manner consistent with the claim liabilities and future policy benefits associated with reinsured policies. Ceded policy reserves and claims liabilities relating to insurance ceded are shown as reinsurance recoverables on the accompanying consolidated balance sheets. We analyze and monitor the credit-worthiness of each of our reinsurance partners to minimize collection issues. For reinsurance contracts with unauthorized reinsurers, we require collateral such as letters of credit. To the extent we receive ceding allowances to cover policy and claims administration under reinsurance contracts, these allowances are treated as a reduction to insurance commissions and expenses and are recognized when due from the assuming company. To the extent we receive ceding allowances reimbursing commissions that would otherwise be deferred, the amount of commissions deferrable will be reduced. The corresponding DAC balances are reduced on a pro rata basis by the portion of the business reinsured with reinsurance agreements that meet risk transfer provisions. The reduced DAC will result in a corresponding reduction of amortization expense. We estimate and recognize lifetime expected credit losses for reinsurance recoverables. In estimating the allowance for expected credit losses for reinsurance recoverables, we factor in the underlying collateral for reinsurance agreements where available. Specifically, for reinsurers with underlying trust assets, we compare the reinsurance recoverables balance to the underlying trust assets that mitigate the potential exposure to credit losses. We also analyze the financial condition of the reinsurers, as determined by third-party rating agencies, to determine the probability of default for the reinsurers. We then utilize a third-party credit default study to calculate an expected credit loss given default rate or recovery rate. The probability of default and loss given default rates are then applied to the reinsurers’ recoverable balance, while also factoring in any third-party letters of credit that support the reinsurance agreement, in order to calculate our current expected credit loss allowance. DAC. We defer incremental direct costs of successful contract acquisitions that result directly from and are essential to the contract transaction(s) and that would not have been incurred had the contract transaction(s) not occurred. These deferred policy acquisition costs mainly include commissions and policy issue expenses. All other acquisition-related costs, including unsuccessful acquisition and renewal efforts, are charged to expense as incurred. Also, administrative costs, rent, depreciation, occupancy, equipment, and all other general overhead costs are considered indirect costs and are charged to expense as incurred. DAC for term life insurance policies is amortized over the initial premium-paying period of the related policies in proportion to premium revenue. DAC for Canadian segregated funds is amortized over the life of the underlying policies at a constant rate based on the present value of the estimated gross profits expected to be realized over the life of the underlying policies. DAC is subject to recoverability testing annually and when impairment indicators exist. Business Combination . The Company acquired e-TeleQuote on July 1, 2021 and accounts for the acquisition as a business combination in accordance with ASC Topic 805, Business Combinations (“ASC 805”), which requires most identifiable assets and liabilities acquired in a business combination to be recorded at fair value at the acquisition date, subject to certain exceptions. Additionally, ASC 805 requires transaction-related costs to be expensed in the period incurred. The Company allocates the fair value of the purchase consideration of its acquired business to the tangible assets, liabilities assumed, and intangible assets acquired at the acquisition date. The excess of the fair value of purchase consideration over the acquired values of these identifiable assets and liabilities is recorded as goodwill. Transaction-related costs are recognized separately from the business combination and expensed as incurred. Refer to Note 20 (Acquisition) for further details. Goodwill . Goodwill represents the excess of the purchase price over the estimated acquired values of identifiable assets and liabilities acquired in a business combination at the acquisition date. In accordance with U.S. GAAP, goodwill is not amortized. The Company tests goodwill for impairment annually on July 1 and whenever events occur or circumstances change that would indicate the carrying value of goodwill more likely than not exceeds its fair value. All of the Company’s goodwill was obtained from the e-TeleQuote acquisition and the e-TeleQuote business has been designated as a separate operating segment called Senior Health. Therefore, goodwill has been allocated solely to the Senior Health segment and is evaluated for impairment at the Senior Health segment level, which is also defined as the reporting unit. For additional information on the results of the annual goodwill impairment test, see Note 21 (Goodwill) to our consolidated financial statements included elsewhere in this report. Intangible Assets. Intangible assets, which are included in other assets, are amortized over their estimated useful lives. Any intangible asset that was deemed to have an indefinite useful life is not amortized but is subject to an annual impairment test. An impairment exists if the carrying value of the indefinite-lived intangible asset exceeds its fair value. For the other intangible assets, which are subject to amortization, an impairment is recognized if the carrying amount is not recoverable and exceeds the fair value of the intangible asset. The components of intangible assets were as follows: December 31, 2022 2021 Gross carrying amount Accumulated amortization Net carrying amount Gross carrying amount Accumulated amortization Net carrying amount (In thousands) Indefinite-lived intangible asset $ 45,275 n/a $ 45,275 $ 45,275 n/a $ 45,275 Amortizing intangible assets 156,000 ( 15,750 ) 140,250 156,000 ( 5,450 ) 150,550 Total intangible assets $ 201,275 $ ( 15,750 ) $ 185,525 $ 201,275 $ ( 5,450 ) $ 195,825 We have an indefinite-lived intangible asset related to the 1989 purchase of the right to contract with the sales force. This asset represents the core distribution model of our business, which is our primary competitive advantage to profitably distribute term life insurance and investment and savings products on a significant scale, and as such, is considered to have an indefinite life. This indefinite-lived intangible asset is supported by a significant portion of the discounted cash flows of our future business. We assessed this asset for impairment as of October 1, 2022 and determined that no impairment had occurred. There have been no subsequent events requiring further analysis. Intangible assets acquired from the acquisition of e-TeleQuote consist primarily of relationships with health insurance carriers, who are our customers, and are amortized over their estimated useful lives. The Company uses an estimated useful life of 15 years as our relationships with health insurance carriers are not expected to turn over rapidly because these relationships are in-depth, non-exclusive, and pay-for-performance. Intangible asset amortization expense was $ 10.3 million and $ 5.5 million in 2022 and 2021, respectively. Amortization expense is expected to be approximately $ 10.5 million annually for the next five years. Intangible assets subject to amortization are evaluated for impairment in the event factors indicate that the net carrying value may not be recoverable or the asset will not be used throughout its estimated useful life. No events have occurred, and no factors exist as of December 31, 2022 that would indicate that the net carrying value of our amortizing intangible assets may not be recoverable or will not be used throughout their estimated useful life. Property and Equipment. Property and equipment, which are included in other assets, are stated at cost, less accumulated depreciation. Depreciation is recognized on a straight-line basis over the asset’s estimated useful life, which is estimated as follows: Estimated Useful Life Data processing equipment and software 3 to 7 years Leasehold improvements Lesser of 15 years or remaining life of lease Furniture and other equipment 5 to 15 years Depreciation expense is included in other operating expenses in the accompanying consolidated statements of income. Depreciation expense was $ 24.1 million, $ 24.6 million, and $ 18.0 million for the years ended December 31, 2022, 2021, and 2020, respectively. Property and equipment balances were as follows: December 31, 2022 2021 (In thousands) Data processing equipment and software $ 132,596 $ 127,151 Leasehold improvements 18,137 18,631 Other, principally furniture and equipment 35,592 36,460 186,325 182,242 Accumulated depreciation ( 133,668 ) ( 115,220 ) Net property and equipment $ 52,657 $ 67,022 Separate Accounts. The separate accounts are primarily comprised of contracts issued by the Company through its subsidiary, Primerica Life Canada, pursuant to the Insurance Companies Act (Canada). The Insurance Companies Act authorizes Primerica Life Canada to establish the separate accounts. The separate accounts are represented by individual variable insurance contracts. Purchasers of variable insurance contracts issued by Primerica Life Canada have a direct claim to the benefits of the contract that entitles the holder to units in one or more investment funds (the “Funds”) maintained by Primerica Life Canada. The Funds invest in assets that are held for the benefit of the owners of the contracts. The benefits provided vary in amount depending on the fair value of the Funds’ net assets. The Funds’ assets are administered by Primerica Life Canada and are held separate and apart from the general assets of the Company. The liabilities reflect the variable insurance contract holders’ interests in the Funds’ net assets based upon actual investment performance of the respective Funds. Separate account operating results relating to contract holders’ interests are excluded from our consolidated statements of income. Primerica Life Canada’s contract offerings guarantee the maturity value at the date of maturity (or upon death, whichever occurs first) to be equal to 75 % of the sum of all contributions made, net of withdrawals, on a first-in, first-out basis. Otherwise, the maturity value or death benefit will be the accumulated value of units allocated to the contract at the specified valuation date. Renewal Commissions Receivable. Renewal commissions receivable are contract assets that represent the renewal portion of estimated constrained variable consideration recognized in accordance with ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). Renewal commissions receivable primarily consist of the expected value of commissions to be collected by e-TeleQuote from the distribution of Medicare-related health insurance policies where the performance obligation has been satisfied but payment is not due as the underlying policy has not yet renewed. The estimate of renewal commissions requires significant judgment subject to the same assumptions as noted under “Commissions and Fees – Senior Health” below. Cash collections for these receivables are expected to occur over a period of several years. Renewal commissions receivable will be adjusted for differences between actual and expected cash collections as well as for changes in estimates. Under ASC 606, these receivables are not discounted as the timing for collection of payments is dependent on future policyholder renewals and not due to the presence of a significant financing component. Refer to Note 20 (Acquisition) for renewal commissions receivable recognized as part of the acquisition of e-TeleQuote. Policyholder Liabilities. Future policy benefits are accrued over the current and renewal periods of the contracts. Liabilities for future policy benefits on traditional life insurance products are reserves established for death claims and waiver of premium benefits and have been computed using a net level method, using assumptions as to interest rates, mortality, persistency, disability rates and other assumptions based on our experience, modified as necessary to reflect anticipated trends and to include provisions for possible adverse deviation. The underlying mortality tables are the Society of Actuaries (“SOA”) 65-70, SOA 75-80, SOA 85-90, and the 91 Bragg, modified to reflect various underwriting classifications and assumptions. Interest rate reserve assumptions ranged from 2.5 % to 7.0 % at December 31, 2022 and ranged from 2.5 % to 7.0 % at December 31, 2021. For policies issued in 2010 and after, we have been using an increasing interest rate assumption to reflect the historically low interest rate environment. The liability for policy claims and other benefits payable on traditional life insurance products includes estimated unpaid claims that have been reported to us and claims incurred but not yet reported. The future policy benefit reserves we establish are necessarily based on estimates, assumptions and our analysis of historical experience. We do not modify the assumptions used to establish future policy benefit reserves during the policy term unless a premium deficiency is identified. Our results depend significantly upon the extent to which our actual claims experience is consistent with the assumptions we used in determining our future policy benefit reserves and pricing our products. Our future policy benefit reserve assumptions and estimates require significant judgment and, therefore, are inherently uncertain. We cannot determine with precision the ultimate amounts that we will pay for actual claims or the timing of those payments. Unearned and Advance Premiums. Unearned and advance premiums primarily consist of premiums received from policyholders in advance of the premiums due date. Unearned and advance premiums are deferred upon collection and recognized as premiums revenue upon the premium due date. Other Policyholders’ Funds . Other policyholders’ funds primarily represent claim payments left on deposit with us. Litigation. The Company is involved from time-to-time in legal disputes, regulatory inquiries and arbitration proceedings in the normal course of business. Contingent litigation-related losses are recognized when probable and can be reasonably estimated. Legal costs, such as attorneys’ fees and other litigation-related expenses that are incurred in connection with resolving litigation are expensed as incurred. These disputes are subject to uncertainties, including indeterminate amounts sought in certain of these matters and the inherent unpredictability of litigation. Due to the difficulty of estimating costs of litigation, actual costs may be substantially higher or lower than any amounts reserved. Income Taxes . We are subject to the income tax laws of the United States, its states, municipalities, and certain unincorporated territories, as well as foreign jurisdictions, most notably Canada. These tax laws can be complex and subject to different interpretations by the taxpayer and the relevant governmental taxing authorities. In establishing a provision for income tax expense, we must make judgments and interpretations about the applicability of these tax laws. We also must make estimates about the future impact certain items will have on taxable income in the various tax jurisdictions, both domestic and foreign. Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to: (i) differences between the financial statement carrying amounts of acquired assets and liabilities and their respective tax bases and (ii) acquired e-TeleQuote net operating loss and interest deduction carryforwards available for future use. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Deferred tax assets are recognized subject to management’s judgment that realization is more-likely-than-not applicable to the periods in which we expect the temporary difference will reverse. The Company has not recognized any material deferred taxes associated with goodwill as it has not acquired any material goodwill with tax basis. Refer to Note 20 (Acquisition) for deferred income taxes recognized as part of the acquisition of e-TeleQuote. Noncontrolling Interest. In connection with the Company’s acquisition of e-TeleQuote, the Company entered into a shareholders’ agreement with the noncontrolling equity holders of Primerica Health (the “Shareholders’ Agreement”). Under the terms of the Shareholders’ Agreement, the Company agreed to purchase, and the noncontrolling equity holders agreed to sell, the remaining 20 % stake over a period of up to four years through a series of call and put rights. The Shareholders’ Agreement provided for the purchase of the noncontrolling equity holders’ equity interests in Primerica Health at a contractually defined formulaic purchase price (the “Formulaic Price”), which was based on a discounted calculation of selected peer company equity value multiples times the trailing twelve months of adjusted earnings before interest, taxes, depreciation, and amortization (“Adjusted EBITDA”) reduced by the balance of intercompany debt owed by e-TeleQuote to the Parent Company. The noncontrolling equity holders’ interests in Primerica Health was recognized as redeemable noncontrolling interests (“Redeemable NCI”) in the temporary stockholders’ equity section of the consolidated balance sheets. Effective July 1, 2022 , the Company executed its call option to acquire the remaining 20 % of Primerica Health. The Formulaic Price calculation resulted in a purchase price of zero. As such, no further consideration was required to obtain the outstanding 20% stake in Primerica Health and the noncontrolling interest in the Company's consolidated financial statements was redeemed. Prior to redemption, the Company adjusted the Redeemable NCI for net income (loss) attributable to the noncontrolling interests in Primerica Health. Upon redemption, the Redeemable NCI in the temporary stockholders' equity section of the consolidated balance sheets was eliminated through an adjustment to additional paid in capital as no further consideration was required. Premium Revenues . Traditional life insurance products consist principally of those products with fixed and guaranteed premiums and benefits, and are primarily related to term products. Premiums are recognized as revenues when due. Commissions and Fees. We receive commissions and fees revenue from the sale of various non-life insurance products. Commissions revenue is generally received on the sale of mutual funds and annuities. We also receive trail commissions revenue from mutual fund and annuity products based on the net asset value of shares sold by us. We, in turn, pay sales commissions to the sales force. We also receive investment advisory and administrative fees based on the average daily net asset value of client assets held in managed investments programs and contracts related to separate account assets issued by Primerica Life Canada. We, in turn, pay asset-based commissions to the sales force. We earn recordkeeping fees for transfer agent recordkeeping services that we perform on behalf of several of our mutual fund providers and custodial fees for services performed as a non-bank custodian of our clients’ retirement plan accounts. See Note 18 (Revenue from Contracts with Customers) for details related to our commission and fees revenues recognition policies. Commissions and Fees – Senior Health. As a result of the acquisition of e-TeleQuote, the Company distributes Medicare-related insurance policies offered by third-party health insurance carriers to eligible Medicare participants. e-TeleQuote receives initial commissions from health insurance carriers, who are considered its customers, for enrollments in policies it has distributed as well as ongoing renewal commissions that coincide with the period an eligible Medicare participant remains enrolled in a policy after the first policy effective date (collectively, “Lifetime value of commissions” or “LTV”). Revenue is recognized at the point in time e-TeleQuote’s single performance obligation to health insurance carriers is satisfied, which is generally on the date the policy application is approved by the health insurance carrier. The expected commissions represent variable consideration that will not be resolved until after the performance obligation has been satisfied. The Company estimates variable consideration in the transaction price for policies it has distributed as the expected amount of initial and renewal commissions to be received over the life of the enrolled policy. Variable consideration is estimated by using a portfolio approach to policies grouped together by health insurance carrier, Medicare product type, and policy effective date (referred to as a “cohort”). This approach to estimating the initial and renewal commissions expected to be collected involves the evaluation of various factors, including but not limited to, contracted commission rates, disenrollment experience and renewal persistency rates. Upon development of the estimate of expected renewal commissions using the portfolio approach, management applies a constraint so that it is probable that a subsequent change in estimate will not result in a significant revenue reversal. Management judgment is required to determine the inputs to these estimates and the inputs are established primarily based on historical activity. There could be situations where new facts or circumstances, that were not

Other Comprehensive Income

Other Comprehensive Income	12 Months Ended
	Dec. 31, 2022
Equity [Abstract]
Other Comprehensive Income	(2) Other Comprehensive Income The components of other comprehensive income (“OCI”), including the income tax expense or benefit allocated to each component, were as follows: Year ended December 31, 2022 2021 2020 (In thousands) Foreign currency translation adjustments: Change in unrealized foreign currency translation gains (losses) $ ( 20,015 ) $ 7,033 $ 7,343 Income tax expense (benefit) on unrealized foreign currency - - - Change in unrealized foreign currency translation gains $ ( 20,015 ) $ 7,033 $ 7,343 Unrealized gain (losses) on available-for-sale securities: Change in unrealized holding gains (losses) arising during $ ( 385,735 ) $ ( 78,348 ) $ 78,533 Income tax expense (benefit) on unrealized holding gains ( 82,185 ) ( 17,038 ) 17,033 Change in unrealized holding gains (losses) on available-for-sale ( 303,550 ) ( 61,310 ) 61,500 Reclassification from accumulated OCI to net income for (gains) ( 1,387 ) ( 3,849 ) 2,614 Income tax (expense) benefit on (gains) losses reclassified from ( 292 ) ( 808 ) 549 Reclassification from accumulated OCI to net income for (gains) ( 1,095 ) ( 3,041 ) 2,065 Change in unrealized gains (losses) on available-for-sale $ ( 304,645 ) $ ( 64,351 ) $ 63,565

Segment and Geographical Inform

Segment and Geographical Information	12 Months Ended
	Dec. 31, 2022
Segment Reporting [Abstract]
Segment and Geographical Information	(3) Segment and Geographical Information Segments. We have three primary operating segments — Term Life Insurance, Investment and Savings Products and (as of July 1, 2021) Senior Health. The Term Life Insurance segment includes underwriting profits on our in-force book of term life insurance policies, net of reinsurance, which are underwritten by our life insurance company subsidiaries. The Investment and Savings Products segment includes retail and managed mutual funds and annuities distributed through licensed broker-dealer subsidiaries and includes segregated funds, an individual annuity savings product that we underwrite in Canada through Primerica Life Canada. In the United States, we distribute mutual fund and annuity products of several third-party companies. We also earn fees for transfer agent recordkeeping functions and non-bank custodial services that we provide for certain mutual funds products we distribute. In Canada, we primarily offer a suite of mutual fund products, for which we serve as the principal distributor, managed by two well-known mutual fund companies. The Senior Health segment consists of the distribution of Medicare-related insurance products underwritten by third-party health insurance carriers to eligible Medicare participants through e-TeleQuote’s licensed health insurance agents. We also have a Corporate and Other Distributed Products segment, which consists primarily of revenues and expenses related to several discontinued lines of insurance other than our core term life insurance products and the distribution of various other financial products generally underwritten or offered by third-party providers. All of the Company’s net investment income, except for the portion allocated to the Term Life Insurance segment that represents the assumed interest accreted to its U.S. GAAP-measured future policy benefit reserve liability less DAC, is attributed to the Corporate and Other Distributed Products segment. In addition, interest expense incurred by the Company as well as gains and losses on our invested asset portfolio are entirely attributed to the Corporate and Other Distributed Products segment. Notable information included in profit or loss by segment was as follows: Year ended December 31, 2022 2021 2020 (In thousands) Revenues: Term life insurance segment $ 1,687,126 $ 1,575,686 $ 1,382,770 Investment and savings products segment 863,432 941,847 718,867 Senior health segment 62,682 60,440 N/A Corporate and other distributed products segment 106,893 131,759 115,904 Total revenues $ 2,720,133 $ 2,709,732 $ 2,217,541 Net investment income: Term life insurance segment $ 51,160 $ 36,486 $ 27,030 Investment and savings products segment - - - Senior health segment - - N/A Corporate and other distributed products segment 41,905 44,102 56,784 Total net investment income $ 93,065 $ 80,588 $ 83,814 Amortization of DAC: Term life insurance segment $ 342,925 $ 241,451 $ 216,208 Investment and savings products segment 12,141 8,668 7,055 Senior health segment - - N/A Corporate and other distributed products segment 1,077 1,060 1,058 Total amortization of DAC $ 356,143 $ 251,179 $ 224,321 Non-cash share-based compensation expense: Term life insurance segment $ 4,133 $ 4,153 $ 3,612 Investment and savings products segment 3,212 3,206 3,045 Senior health segment 210 - N/A Corporate and other distributed products segment 14,806 9,483 12,370 Total non-cash share-based compensation expense $ 22,361 $ 16,842 $ 19,027 Income (loss) before income taxes: Term life insurance segment $ 448,540 $ 414,619 $ 372,551 Investment and savings products segment 239,330 274,585 202,644 Senior health segment ( 98,673 ) ( 85,050 ) N/A Corporate and other distributed products segment ( 95,448 ) ( 92,983 ) ( 68,465 ) Total income before income taxes $ 493,749 $ 511,171 $ 506,730 Insurance expenses and other operating expenses directly attributable to the Term Life Insurance, Investment and Savings Products, and Senior Health segments are recorded directly to the applicable segment. We allocate certain other revenue and operating expenses that are not directly attributable to a specific operating segment using methods expected to reasonably measure the benefit received by each reporting segment. Such methods include time studies, recorded usage, revenue distribution, and sales force representative distribution. These allocated items include fees charged for access to Primerica Online (“POL”) and costs incurred for technology, sales force support, occupancy and other general and administrative costs. Costs that are not directly charged or allocated to our three primary operating segments are included in the Corporate and Other Distributed Products segment. Total assets by segment were as follows: December 31, 2022 December 31, 2021 December 31, 2020 (In thousands) Assets: Term life insurance segment $ 7,175,746 $ 7,274,820 $ 6,985,086 Investment and savings products segment (1) 2,415,041 2,920,271 2,769,445 Senior health segment 431,993 $ 528,974 N/A Corporate and other distributed products segment 5,326,097 5,399,158 5,150,754 Total assets $ 15,348,877 $ 16,123,223 $ 14,905,285 (1) The Investment and Savings Products segment includes assets held in separate accounts. Excluding separate accounts, the Investment and Savings Products segment assets were $ 109.3 million, $ 120.3 million, and $ 110.0 million as of December 31, 2022, 2021, and 2020 , respectively. Assets specifically related to a segment are held in that segment. All invested assets held by the Company, including the deposit asset recognized in connection with our 10 % coinsurance agreement (the “10% Coinsurance Agreement”) and the held-to-maturity security received in connection with the Vidalia Re Coinsurance Agreement, are reported as assets of the Corporate and Other Distributed Products segment. DAC is recognized in a particular segment based on the product to which it relates. Separate account assets supporting the segregated funds product in Canada are held in the Investment and Savings Products segment. Any remaining unallocated assets are reported in the Corporate and Other Distributed Products segment. Geographical Information. Results of operations by country and long-lived assets — primarily tangible assets reported in other assets in our consolidated balance sheets —were as follows: Year ended December 31, 2022 2021 2020 (In thousands) Revenues by country: United States $ 2,355,139 $ 2,311,051 $ 1,895,708 Canada 364,994 398,681 321,833 Total revenues $ 2,720,133 $ 2,709,732 $ 2,217,541 December 31, 2022 December 31, 2021 December 31, 2020 (In thousands) Long-lived assets by country: United States $ 49,637 $ 62,921 $ 53,281 Canada 2,803 3,871 4,446 Other 217 230 - Total long-lived assets $ 52,657 $ 67,022 $ 57,727

Investments

Investments	12 Months Ended
	Dec. 31, 2022
Investments Debt And Equity Securities [Abstract]
Investments	(4) Investments AFS Securities. The period-end cost or amortized cost, gross unrealized gains and losses, and fair value of AFS fixed-maturity securities were as follows: December 31, 2022 Amortized cost Gross unrealized gains Gross unrealized losses Fair value (In thousands) Securities available-for-sale, carried at fair value: Fixed-maturity securities: U.S. government and agencies $ 31,217 $ 18 $ ( 767 ) $ 30,468 Foreign government 163,725 780 ( 11,590 ) 152,915 States and political subdivisions 142,189 112 ( 20,056 ) 122,245 Corporates 1,665,962 2,439 ( 171,552 ) 1,496,849 Residential mortgage-backed securities 473,309 370 ( 71,949 ) 401,730 Commercial mortgage-backed securities 139,306 3 ( 16,342 ) 122,967 Other asset-backed securities 185,707 108 ( 17,533 ) 168,282 Total fixed-maturity securities $ 2,801,415 $ 3,830 $ ( 309,789 ) $ 2,495,456 Short-term investments 69,393 20 ( 7 ) 69,406 Total fixed-maturity and short-term investments $ 2,870,808 $ 3,850 $ ( 309,796 ) $ 2,564,862 December 31, 2021 Amortized cost Gross unrealized gains Gross unrealized losses Fair value (In thousands) Securities available-for-sale, carried at fair value: Fixed-maturity securities: U.S. government and agencies $ 32,292 $ 187 $ ( 79 ) $ 32,400 Foreign government 147,288 6,283 ( 595 ) 152,976 States and political subdivisions 147,455 6,326 ( 254 ) 153,527 Corporates 1,649,334 72,418 ( 8,068 ) 1,713,684 Residential mortgage-backed securities 373,753 5,108 ( 3,230 ) 375,631 Commercial mortgage-backed securities 142,631 3,314 ( 420 ) 145,525 Other asset-backed securities 128,635 1,409 ( 1,220 ) 128,824 Total fixed-maturity securities $ 2,621,388 $ 95,045 $ ( 13,866 ) $ 2,702,567 Short-term investments 85,246 1 ( 4 ) 85,243 Total fixed-maturity and short-term investments $ 2,706,634 $ 95,046 $ ( 13,870 ) $ 2,787,810 All of our AFS mortgage- and asset-backed securities represent beneficial interests in variable interest entities (“VIEs”). We are not the primary beneficiary of these VIEs because we do not have the power to direct the activities that most significantly impact the entities’ economic performance. The maximum exposure to loss as a result of our involvement in these VIEs equals the carrying value of the securities. The scheduled maturity distribution of the AFS fixed-maturity securities portfolio as of December 31, 2022 was as follows: Amortized cost Fair value (In thousands) Due in one year or less $ 165,117 163,831 Due after one year through five years 783,376 740,167 Due after five years through 10 years 763,273 658,194 Due after 10 years 291,327 240,285 2,003,093 1,802,477 Mortgage- and asset-backed securities 798,322 692,979 Total AFS fixed-maturity securities $ 2,801,415 $ 2,495,456 Expected maturities may differ from scheduled contractual maturities because issuers of securities may have the right to call or prepay obligations with or without call or prepayment penalties. Trading Securities. The costs and fair values of the fixed-maturity securities classified as trading securities were as follows: December 31, 2022 December 31, 2021 Cost Fair value Cost Fair value (In thousands) Fixed-maturity securities $ 4,229 $ 3,698 $ 24,769 $ 24,355 Held-to-maturity Security. Concurrent with the execution of the Vidalia Re Coinsurance Agreement, Vidalia Re entered into a Surplus Note Purchase Agreement (the “Surplus Note Purchase Agreement”) with Hannover Life Reassurance Company of America and certain of its affiliates (collectively, “Hannover Re”) and a newly formed limited liability company (the “LLC”) owned by a third- party service provider. Under the Surplus Note Purchase Agreement, Vidalia Re issued a surplus note (the “Surplus Note”) to the LLC in exchange for a credit enhanced note from the LLC with an equal principal amount (the “LLC Note”). The principal amount of both the LLC Note and the Surplus Note will fluctuate over time to coincide with the amount of reserves contractually supported under the Vidalia Re Coinsurance Agreement. Both the LLC Note and the Surplus Note mature on December 31, 2030 and bear interest at an annual interest rate of 4.50 % . The LLC Note is guaranteed by Hannover Re through a credit enhancement feature in exchange for a fee, which is reflected in interest expense on our consolidated statements of income. The LLC is a VIE as its owner does not have an equity investment at risk that is sufficient to permit the LLC to finance its activities without Vidalia Re or Hannover Re. The Parent Company, Primerica Life, and Vidalia Re share the power to direct the activities of the LLC with Hannover Re, but do not have the obligation to absorb losses or the right to receive any residual returns related to the LLC’s primary risks or sources of variability. Through the credit enhancement feature, Hannover Re is the ultimate risk taker in this transaction and bears the obligation to absorb the LLC’s losses in the event of a Surplus Note default in exchange for the fee. Accordingly, the Company is not the primary beneficiary of the LLC and does not consolidate the LLC within its consolidated financial statements. The LLC Note is classified as a held-to-maturity debt security in the Company’s invested asset portfolio as we have the positive intent and ability to hold the security until maturity. As of December 31, 2022, the LLC Note had an estimated unrealized holding loss of $ 104.7 million based on its amortized cost and estimated fair value. The estimated fair value of the LLC Note is expected to be at least equal to the estimated fair value of the offsetting Surplus Note. See Note 5 (Fair Value of Financial Instruments) for information on the fair value of our financial instruments and see Note 10 (Debt) for more information on the Surplus Note. As of December 31, 2022, no credit losses have been recognized on the LLC Note held-to-maturity security. Investments on Deposit with Governmental Authorities. As required by law, we have investments on deposit with governmental authorities and banks for the protection of policyholders. The fair values of investments on deposit were $ 7.1 million and $ 7.6 million as of December 31, 2022 and 2021, respectively. Securities Lending Transactions. We participate in securities lending transactions with broker-dealers and other financial institutions to increase investment income with minimal risk. We require minimum collateral on securities loaned equal to 102 % of the fair value of the loaned securities. We accept collateral in the form of securities, which we are not able to sell or encumber, and to the extent the collateral declines in value below 100 %, we require additional collateral from the borrower. Any securities collateral received is not reflected on our consolidated balance sheets. We also accept collateral in the form of cash, all of which we reinvest. For loans involving unrestricted cash collateral, the collateral is reported as an asset with a corresponding liability representing our obligation to return the collateral. We continue to carry the loaned securities as invested assets on our consolidated balance sheets during the terms of the loans, and we do not report them as sales. Cash collateral received and reinvested was $ 100.9 million and $ 94.5 million as of December 31, 2022 and 2021, respectively. Investment Income. The components of net investment income were as follows: Year ended December 31, 2022 2021 2020 (In thousands) Fixed-maturity securities (available-for-sale) $ 90,975 $ 80,362 $ 82,805 Fixed-maturity security (held-to-maturity) 63,922 62,207 57,473 Equity securities 1,509 1,632 1,751 Policy loans and other invested assets 1,046 1,019 1,244 Cash, cash equivalent and short-term investments 5,943 456 1,202 Total return on deposit asset underlying 10% coinsurance (1) ( 65 ) 1,875 4,253 Gross investment income 163,330 147,551 148,728 Investment expenses ( 6,343 ) ( 4,756 ) ( 7,441 ) Investment income net of investment expenses 156,987 142,795 141,287 Interest expense on surplus note ( 63,922 ) ( 62,207 ) ( 57,473 ) Net investment income $ 93,065 $ 80,588 $ 83,814 (1) Includes $( 3.8 ) million, $( 2.5 ) million, and $ 2.0 million of net gains (losses) recognized for the change in fair value of the deposit asset underlying the 10 % coinsurance agreement for the years ended December 31, 2022, 2021, and 2020, respectively. The components of investment gains (losses), as well as details on gross realized investment gains (losses) and other investment gains (losses) were as follows: Year ended December 31, 2022 2021 2020 (In thousands) Realized investment gains (losses): Gross gains from sales of available-for-sale fixed maturity securities $ 2,036 $ 7,060 $ 2,595 Gross gains from sales of equity securities - - 12 Gross losses from sales of available-for-sale fixed maturity securities ( 592 ) ( 2,395 ) ( 955 ) Gross losses from sales of equity securities - - ( 293 ) Net realized investment gains (losses): 1,444 4,665 1,359 Other investment gains (losses): Credit losses impairment of available-for-sale securities ( 57 ) ( 816 ) ( 4,254 ) Market gains (losses) recognized in net income during the period on equity securities ( 2,375 ) 2,362 ( 2,154 ) Gains (losses) from bifurcated options - ( 57 ) 57 Gains (losses) on trading securities ( 7 ) ( 282 ) ( 4 ) Other investment gains (losses): ( 2,439 ) 1,207 ( 6,355 ) Investment gains (losses) $ ( 995 ) $ 5,872 $ ( 4,996 ) The proceeds from sales or other redemptions of available-for-sale securities were as follows: Year ended December 31, 2022 2021 2020 (In thousands) Proceeds from sales or other redemptions $ 496,898 $ 676,153 $ 496,907 Accrued Interest. Accrued interest is recorded in accordance with the original interest schedule of the underlying security. In the event of default, the Company’s policy is to no longer accrue interest on these securities and to write off any remaining accrued interest. As a result, the Company has made the policy election to not record an allowance for credit losses on accrued interest. Credit Losses for Available-for-sale Fixed-maturity Securities. The following tables summarizes all AFS securities in an unrealized loss position for which an allowance for credit losses has not been recorded as of December 31, 2022, aggregated by major security type and by length of time such securities have continuously been in an unrealized loss position: December 31, 2022 Less than 12 months 12 months or longer Fair value Unrealized losses Fair value Unrealized losses (Dollars in thousands) Fixed-maturity securities: U.S. government and agencies $ 4,927 $ ( 204 ) $ 25,209 $ ( 563 ) Foreign government 97,094 ( 4,430 ) 38,085 ( 7,160 ) States and political subdivisions 71,131 ( 10,666 ) 44,324 ( 9,390 ) Corporates 974,931 ( 69,726 ) 452,541 ( 101,826 ) Residential mortgage-backed securities 187,158 ( 22,171 ) 201,595 ( 49,778 ) Commercial mortgage-backed securities 65,165 ( 5,069 ) 56,799 ( 11,273 ) Other asset-backed securities 81,907 ( 5,807 ) 72,977 ( 11,726 ) Total fixed-maturity securities 1,482,313 ( 118,073 ) 891,530 ( 191,716 ) Short-term investments: U.S. government and agencies 28,379 ( 5 ) - - Foreign government 1,744 ( 2 ) - - Total Short Term Bonds 30,123 ( 7 ) - - Total fixed-maturity and Short Term securities $ 1,512,436 $ ( 118,080 ) $ 891,530 $ ( 191,716 ) December 31, 2021 Less than 12 months 12 months or longer Fair value Unrealized losses Fair value Unrealized losses (Dollars in thousands) Fixed-maturity securities: U.S. government and agencies $ 24,928 $ ( 45 ) $ 1,557 $ ( 34 ) Foreign government 18,894 ( 384 ) 3,335 ( 211 ) States and political subdivisions 15,909 ( 254 ) - - Corporates 341,963 ( 5,035 ) 59,414 ( 3,033 ) Residential mortgage-backed securities 234,911 ( 3,131 ) 2,707 ( 99 ) Commercial mortgage-backed securities 47,220 ( 419 ) 117 ( 1 ) Other asset-backed securities 80,509 ( 1,037 ) 3,779 ( 183 ) Total fixed-maturity securities $ 764,334 $ ( 10,305 ) $ 70,909 $ ( 3,561 ) Short-term investments: U.S. government and agencies 34,967 * - - Foreign government 4,995 * - - States and political subdivisions 11,394 ( 1 ) - - Corporates 23,891 ( 3 ) - - Total Short Term Bonds 75,247 ( 4 ) - - Total fixed-maturity and Short Term securities $ 839,581 $ ( 10,309 ) $ 70,909 $ ( 3,561 ) * Less than $ 1 thousand The amortized cost of AFS securities with a cost basis in excess of their fair values were $ 2,713.8 million and $ 924.4 million as of December 31, 2022 and 2021, respectively. As of December 31, 2022, we did not recognize credit losses in the consolidated statements of income on available-for-sale securities with unrealized losses that were due to interest rate sensitivity and changes in credit spreads. We believe that fluctuations caused by movement in interest rates and credit spreads generally have little bearing on the recoverability of our investments. For those investments that remain in an unrealized loss position we have the ability to hold these investments until maturity or a market price recovery, and we have no present intention to dispose of them. For the years ended December 31, 2022, 2021, and 2020, we recorded less than $ 0.1 million, $ 0.8 million, and $ 4.3 million respectively, for credit (gains) losses in the consolidated statements of income on available-for-sales securities. We recognized credit losses on securities due to: (i) our intent to sell them; (ii) adverse credit events indicating that we will not receive the security’s contractual cash flows when contractually due, such as news of an impending filing for bankruptcy; (iii) analyses of the issuer’s most recent financial statements or other information indicating that significant liquidity deficiencies, significant losses and large declines in capitalization exist; and (iv) analyses of rating agency information for issuances with severe ratings downgrades indicating a significant increase in the possibility of default. The rollforward of the allowance for credit losses on available-for-sale securities was as follows: Year ended December 31, 2022 2021 2020 (In thousands) Allowance for credit losses, beginning of period $ 816 $ - $ - Additions to the allowance for credit losses on securities for which credit losses were not previously recorded - 821 525 Additional increases (or decreases) to the allowance for credit losses on securities that had an allowance recorded in a previous period ( 81 ) ( 5 ) ( 51 ) Write-offs charged against the allowance, if any ( 735 ) - ( 474 ) Allowance for credit losses, end of period $ - $ 816 $ - Derivatives. We have a deferred loss related to closed forward contracts, which were settled several years ago, that were used to mitigate our exposure to foreign currency exchange rates that resulted from the net investment in our Canadian operations. The amount of deferred loss included in accumulated other comprehensive income (loss) was $ 26.4 million as of December 31, 2022 and 2021 . These deferred losses will not be recognized until such time as we sell or substantially liquidate our Canadian operations, although we have no such intention.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	12 Months Ended
	Dec. 31, 2022
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	(5) Fair Value of Financial Instruments Fair value is the price that would be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Invested assets recorded at fair value are measured and classified in accordance with a three-tier fair value hierarchy based on observable and unobservable inputs. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect our view of market assumptions in the absence of observable market information. We classify and disclose all invested assets carried at fair value in one of the following three levels: • Level 1. Quoted prices for identical instruments in active markets. Level 1 consists of financial instruments whose value is based on quoted market prices in active markets, such as cash, cash equivalents in money market funds, exchange-traded common stocks and actively traded mutual fund investments; • Level 2. Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs are observable in active markets. Level 2 includes those financial instruments that are valued using industry-standard pricing methodologies, models or other valuation methodologies. Various inputs are considered in deriving the fair value of the underlying financial instrument, including interest rate and yield curves, credit spread, and foreign exchange rates. All significant inputs are observable, or derived from observable information in the marketplace or are supported by observable levels at which transactions are executed in the marketplace. Financial instruments in this category primarily include: cash equivalents and short-term investments in U.S. treasury securities; certain public and private corporate fixed-maturity and equity securities; government or agency securities; and certain mortgage- and asset-backed securities; and • Level 3. Valuations derived from valuation techniques in which one or more significant inputs are unobservable. Level 3 consists of financial instruments whose fair value is estimated based on industry-standard pricing methodologies and models using significant inputs not based on, nor corroborated by, readily available market information. Valuations for this category primarily consist of non-binding broker quotes. Financial instruments in this category primarily include less liquid mortgage- and asset-backed securities and equity securities. As of each reporting period, all assets and liabilities recorded at fair value are classified in their entirety based on the lowest level of input (Level 3 being the lowest in the hierarchy) that is significant to the fair value measurement. Significant levels of estimation and judgment are required to determine the fair value of certain of our investments. The factors influencing these estimations and judgments are subject to change in subsequent reporting periods. The estimated fair value and hierarchy classifications for assets and liabilities that are measured at fair value on a recurring basis were as follows: December 31, 2022 Level 1 Level 2 Level 3 Total (In thousands) Fair value assets: Available-for-sale fixed-maturity securities: U.S. government and agencies $ - $ 30,468 $ - $ 30,468 Foreign government - 152,915 - 152,915 States and political subdivisions - 122,245 - 122,245 Corporates 3,586 1,493,263 - 1,496,849 Mortgage-and asset-backed securities: Residential mortgage-backed securities - 401,730 - 401,730 Commercial mortgage-backed securities - 122,967 - 122,967 Other asset-backed securities - 168,282 - 168,282 Total available-for-sale fixed-maturity securities 3,586 2,491,870 - 2,495,456 Short Term Investments - 69,406 - 69,406 Total available-for-sale securities 3,586 2,561,276 - 2,564,862 Equity securities 32,727 967 1,710 35,404 Trading securities - 3,698 - 3,698 Cash and cash equivalents 489,240 - - 489,240 Separate accounts - 2,305,717 - 2,305,717 Total fair value assets $ 525,553 $ 4,871,658 $ 1,710 $ 5,398,921 Fair value liabilities: Separate accounts $ - $ 2,305,717 $ - $ 2,305,717 Total fair value liabilities $ - $ 2,305,717 $ - $ 2,305,717 December 31, 2021 Level 1 Level 2 Level 3 Total (In thousands) Fair value assets: Available-for-sale fixed-maturity securities: U.S. government and agencies $ - $ 32,400 $ - $ 32,400 Foreign government - 152,976 - 152,976 States and political subdivisions - 153,527 - 153,527 Corporates 5,898 1,707,786 - 1,713,684 Mortgage-and asset-backed securities: Residential mortgage-backed securities - 375,604 27 375,631 Commercial mortgage-backed securities - 145,525 - 145,525 Other asset-backed securities - 128,824 - 128,824 Total available-for-sale fixed-maturity securities 5,898 2,696,642 27 2,702,567 Short Term Investments - 85,243 - 85,243 Total available-for-sale securities 5,898 2,781,885 27 2,787,810 Equity securities 37,912 1,070 3,569 42,551 Trading securities - 24,355 - 24,355 Cash and cash equivalents 351,508 40,993 - 392,501 Separate accounts - 2,799,992 - 2,799,992 Total fair value assets $ 395,318 $ 5,648,295 $ 3,596 $ 6,047,209 Fair value liabilities: Separate accounts $ - $ 2,799,992 $ - $ 2,799,992 Total fair value liabilities $ - $ 2,799,992 $ - $ 2,799,992 In estimating fair value of our investments, we use a third-party pricing service for approximately all of our securities that are measured at fair value on a recurring basis. The remaining securities are primarily thinly traded securities, such as private placements, and are valued using models based on observable inputs on public corporate spreads having similar characteristics (e.g., sector, average life and quality rating), liquidity and yield based on quality rating, average life and U.S. Treasury yields. All observable data inputs are corroborated by independent third-party data. We also corroborate pricing information provided by our third-party pricing service by performing a review of selected securities. Our review activities include obtaining detailed information about the assumptions, inputs and methodologies used in pricing the security; documenting this information; and corroborating it by comparison to independently obtained prices and or independently developed pricing methodologies. Furthermore, we perform internal reasonableness assessments on fair value determinations within our portfolio throughout the year and as of year-end, including pricing variance analyses and comparisons to alternative pricing sources and benchmark returns. If a fair value appears unusual relative to these assessments, we will re-examine the inputs and may challenge a fair value assessment made by the pricing service. If there is a known pricing error, we will request a reassessment by the pricing service. If the pricing service is unable to perform the reassessment on a timely basis, we will determine the appropriate price by requesting a reassessment from an alternative pricing service or other qualified source as necessary. We do not adjust quotes or prices except in a rare circumstance to resolve a known error. Because many fixed-maturity securities do not trade on a daily basis, third-party pricing services generally determine fair value using industry-standard methodologies, which vary by asset class. For corporates, governments, and agency securities, these methodologies include developing prices by incorporating available market information such as U.S. Treasury curves, benchmarking of similar securities including new issues, sector groupings, quotes from market participants and matrix pricing. Observable information is compiled and integrates relevant credit information, perceived market movements and sector news. Additionally, security prices are periodically back-tested to validate and/or refine models as conditions warrant. Market indicators and industry and economic events are also monitored as triggers to obtain additional data. For certain structured securities (such as mortgage- and asset-backed securities) with limited trading activity, third-party pricing services generally use industry-standard pricing methodologies that incorporate market information, such as index prices or discounting expected future cash flows based on underlying collateral, and quotes from market participants, to estimate fair value. If one or more of these input measures are not deemed observable for a particular security, the security will be classified as Level 3 in the fair value hierarchy. Where specific market information is unavailable for certain securities, pricing models produce estimates of fair value primarily using Level 2 inputs along with certain Level 3 inputs. These models include matrix pricing. The pricing matrix uses current U.S. Treasury rates and credit spreads received from third-party sources to estimate fair value. The credit spreads incorporate the issuer’s industry- or issuer-specific credit characteristics and the security’s time to maturity, if warranted. Remaining unpriced securities are valued using an estimate of fair value based on indicative market prices that include significant unobservable inputs not based on, nor corroborated by, market information, including the utilization of non-binding broker quotes. The roll-forward of the Level 3 assets measured at fair value on a recurring basis was as follows: Year ended December 31, 2022 2021 (In thousands) Level 3 assets, beginning of period $ 3,596 $ 2,047 Net unrealized gains (losses) included in other ( 1 ) - Realized gains (losses) and accretion (amortization) ( 204 ) ( 493 ) Purchases 1,661 2,067 Sales - - Settlements - ( 25 ) Transfers into Level 3 - - Transfers out of Level 3 ( 3,342 ) - Level 3 assets, end of period $ 1,710 $ 3,596 We obtain independent pricing quotes based on observable inputs as of the end of the reporting period for all securities in Level 2. Those inputs include benchmark yields, reported trades, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, market bids/offers, quoted prices for similar instruments in markets that are not active, and other relevant data. We monitor these inputs for market indicators, industry and economic events. There were no material transfers between Level 1 and Level 3 during the years ended December 31, 2022 and 2021. The carrying values and estimated fair values of our financial instruments were as follows: December 31, 2022 December 31, 2021 Carrying value Estimated fair value Carrying value Estimated fair value (In thousands) Assets: Fixed-maturity securities (available-for-sale) $ 2,495,456 $ 2,495,456 $ 2,702,567 $ 2,702,567 Fixed-maturity security (held-to-maturity) (3) 1,444,920 1,340,265 1,379,100 1,551,113 Short-term investments (available-for-sale) 69,406 69,406 85,243 85,243 Equity securities 35,404 35,404 42,551 42,551 Trading securities 3,698 3,698 24,355 24,355 Policy loans (3) 35,940 35,940 30,612 30,612 Deposit asset underlying 10 % coinsurance agreement (3) 224,371 224,371 231,368 231,368 Separate accounts 2,305,717 2,305,717 2,799,992 2,799,992 Liabilities: Notes payable - Long term (1) (2) 592,905 491,753 592,102 605,667 Surplus note (1) (3) 1,444,469 1,333,047 1,378,585 1,545,854 Separate accounts 2,305,717 2,305,717 2,799,992 2,799,992 (1) Carrying value amounts shown are net of issuance costs. (2) Classified as level 2 fair value measurement. (3) Classified as level 3 fair value measurement. The fair values of financial instruments presented above are estimates of the fair values at a specific point in time using various sources and methods, including market quotations and a complex matrix system that takes into account issuer sector, quality, and spreads in the current marketplace. Financial Instruments Recognized at Fair Value in the Balance Sheet. Estimated fair values of investments in AFS securities are principally a function of current spreads and interest rates that are corroborated by independent third-party data. Therefore, the fair values presented are indicative of amounts we could realize or settle at the respective balance sheet date. We do not necessarily intend to dispose of or liquidate such instruments prior to maturity. Trading securities and equity securities, including common and nonredeemable preferred stocks, are carried at fair value. Segregated funds in separate accounts are carried at the underlying value of the variable insurance contracts, which is fair value. The carrying amounts for cash and cash equivalents, trade receivables, accrued investment income, accounts payable, notes payable – short term, cash collateral and payables for security transactions approximate their fair values due to the short-term nature of these instruments. Consequently, such financial instruments are not included in the above table.

Reinsurance

Reinsurance	12 Months Ended
	Dec. 31, 2022
Reinsurance Disclosures [Abstract]
Reinsurance	(6) Reinsurance We use reinsurance extensively, which has a significant effect on our results of operations. Reinsurance arrangements do not relieve us of our primary obligation to the policyholder. Our reinsurance contracts typically do not have a fixed term. In general, the reinsurers’ ability to terminate coverage for existing cessions is limited to such circumstances as material breach of contract or nonpayment of premiums by the ceding company. Our reinsurance contracts generally contain provisions intended to provide the ceding company with the ability to cede future business on a basis consistent with historical terms. However, either party may terminate any of the contracts with respect to the future business upon appropriate notice to the other party. Generally, the reinsurance contracts do not limit the overall amount of the loss that can be incurred by the reinsurer. Our policy is to limit the amount of life insurance retained on the life of any one person to $ 1 million. To limit our exposure with any one reinsurer, we monitor the concentration of credit risk we have with our reinsurance counterparties, as well as their financial condition. Reinsurance recoverables represents ceded policy reserve balances and ceded claim liabilities. The amounts of ceded claim liabilities included in reinsurance recoverables that we paid and which are recoverable from those reinsurers were $ 7.5 million and $ 26.0 million as of December 31, 2022 and 2021, respectively. Benefits and claims ceded to reinsurers for 2022, 2021, and 2020 were $ 1,570.8 million, $ 2,017.0 million, and $ 1,653.6 million, respectively. In connection with our corporate reorganization that included an initial public offering (“IPO”) of our common stock by Citigroup, Inc. (“Citigroup”), Primerica Life, Primerica Life Canada and NBLIC entered into significant coinsurance transactions (the “IPO coinsurance agreements”) on March 30, 2010 with three insurance companies then affiliated with Citigroup (collectively, the “IPO coinsurers”). Under the IPO coinsurance agreements, we ceded between 80 % and 90 % of the risks and rewards of our term life insurance policies in force at year-end 2009. Because these agreements were part of a business reorganization among entities under common control, they did not generate any deferred gain or loss upon their execution. Concurrent with signing these agreements, we transferred the corresponding account balances in respect of the coinsured policies along with the assets to support the statutory liabilities assumed by the IPO coinsurers. Each of the account balances transferred were at book value with no gain or loss recorded in net income. Beginning in 2017, policies reaching the end of their initial term period are no longer ceded under the IPO coinsurance transactions, but the existing YRT reinsurance already in place prior to the IPO will continue. Three of the IPO coinsurance agreements satisfy U.S. GAAP risk transfer rules. Under these agreements, we ceded between 80% and 90% of our term life future policy benefit reserves, and we transferred a corresponding amount of assets to the IPO coinsurers. These transactions did not impact our future policy benefit reserves. As such, we have recorded an asset for the same amount of risk transferred in reinsurance recoverables. We also reduced DAC by a corresponding amount, which reduces future amortization expenses. In addition, we are transferring between 80% and 90% of all future premiums and benefits and claims associated with these policies to the corresponding reinsurance entities. We receive ongoing ceding allowances, which are reflected as a reduction to insurance expenses, to cover policy and claims administration expenses as well as certain corporate overhead charges under each of these reinsurance contracts. In the 10 % Coinsurance Agreement, we ceded to Prime Reinsurance Company (“Prime Re”), an affiliate of Citigroup, 10 % of our U.S. (except New York) term life insurance business in force at year-end 2009 subject to an experience refund provision. As the 10% Coinsurance Agreement includes an experience refund provision, it does not satisfy U.S. GAAP risk transfer rules. As a result, we have accounted for this contract using deposit method accounting and have recognized a deposit asset in other assets on our consolidated balance sheets for assets backing the economic reserves. The deposit asset held in support of this agreement was $ 224.4 million and $ 231.4 million at December 31, 2022 and 2021 , respectively. We make contributions to the deposit asset during the life of the agreement to fulfill our responsibility of funding the economic reserve. The market return on the deposit asset is reflected in net investment income during the life of the agreement. Prime Re is responsible for ensuring that there are sufficient assets to meet all statutory requirements. The finance charge on the statutory reserves in excess of economic reserves funded by Prime Re in support of the 10% Coinsurance Agreement is 0.5 % per annum and is reflected in interest expense in our consolidated statements of income. The following table represents the Company’s in-force life insurance as of December 31, 2022 and 2021: December 31, 2022 December 31, 2021 (Dollars in thousands) Direct life insurance in-force $ 919,081,738 $ 905,819,671 Amounts ceded to other companies ( 787,907,229 ) ( 777,826,233 ) Net life insurance in-force $ 131,174,509 $ 127,993,438 Percentage of reinsured life insurance in-force 86 % 86 % Reinsurance recoverables include ceded reserve balances and ceded claim liabilities. Reinsurance recoverables and financial strength ratings by reinsurer were as follows: December 31, 2022 December 31, 2021 Reinsurance recoverables A.M. Best rating Reinsurance recoverables A.M. Best rating (In thousands) Swiss Re Life and Health America, Inc. (Novated from Pecan Re Inc.) (1)(2) $ 2,440,274 A+ $ - - Pecan Re Inc. (1) (2) - - 2,567,602 NR SCOR Global Life Reinsurance Companies (3) 394,171 A+ 426,634 A+ Munich Re of Malta (2) (5) 251,078 NR 278,591 NR Swiss Re Life & Health America Inc. (4) 244,056 A+ 259,239 A+ American Health and Life Insurance Company (2) 146,779 B++ 157,837 B++ Munich American Reassurance Company 134,570 A+ 142,705 A+ Korean Reinsurance Company 123,026 A 134,048 A RGA Reinsurance Company 128,443 A+ 140,953 A+ Hannover Life Reassurance Company 47,870 A+ 49,749 A+ TOA Reinsurance Company 35,762 A 38,909 A All other reinsurers 72,816 - 75,094 - Allowance for credit losses ( 2,936 ) ( 2,942 ) Reinsurance recoverables $ 4,015,909 $ 4,268,419 NR – not rated (1) Effective April 1, 2022, the coinsurance agreement with Pecan Re Inc. was novated and replaced by an agreement with Swiss Re Life and Health America, Inc. (2) Reinsurance recoverables include balances ceded under coinsurance transactions of term life insurance policies that were in force as of December 31, 2009. Amounts shown are net of their share of the reinsurance receivable from other reinsurers. Arrangements with these reinsurers include collateral trust agreements held in support of reinsurance recoverables. (3) Includes amounts ceded to Transamerica Reinsurance Companies and fully retroceded to SCOR Global Life Reinsurance Companies. (4) Includes amounts ceded to Lincoln National Life Insurance and fully retroceded to Swiss Re Life & Health America Inc. (5) Entity is rated AA- by S&P. Certain reinsurers with which we do business receive group ratings. Individually, those reinsurers are SCOR Global Life Americas Reinsurance Company, SCOR Global Life U.S.A. Reinsurance Company, SCOR Global Life Re Insurance Company of Delaware, and SCOR Global Life of Canada. The IPO coinsurance agreements include provisions to ensure that Primerica Life, Primerica Life Canada and NBLIC receive full regulatory credit for the reinsurance treaties. Under these agreements, the ceded business can be recaptured with no fee in the event the IPO coinsurers do not comply with the various safeguard provisions in their respective IPO coinsurance agreements. Pecan Re Inc. also has entered into a capital maintenance agreement requiring Swiss Re Life and Health America, Inc. to provide additional funding, if needed, at any point during the term of the agreement up to the maximum as described in the capital maintenance agreement. The rollforward of the allowance for credit losses (“ACL”) on reinsurance recoverables for the years ended December 31, 2022, 2021, and 2020 were as follows: Year ended December 31, 2022 2021 2020 (In thousands) Balance, beginning of period $ 2,942 $ 7,144 $ 3,917 Current period provision for expected credit losses 164 502 3,235 Less: Writeoffs charged against the ACL, if any - ( 4,651 ) - Less: Recoveries of expected credit losses previously recorded ( 170 ) ( 53 ) ( 8 ) Balance, at the end of period $ 2,936 $ 2,942 $ 7,144

Deferred Policy Acquisition Cos

Deferred Policy Acquisition Costs	12 Months Ended
	Dec. 31, 2022
Deferred Policy Acquisition Costs Disclosures [Abstract]
Deferred Policy Acquisition Costs	(7) Deferred Policy Acquisition Costs We defer incremental direct costs of successful contract acquisitions that result directly from and are essential to the contract transaction(s) and that would not have been incurred had the contract transaction(s) not occurred. The amortization of DAC associated with term life insurance policies uses assumptions regarding persistency, expenses, interest rates and mortality consistent with the assumptions used to calculate future policy benefit reserves. These assumptions may not be modified, or unlocked, unless recoverability testing deems them to be inadequate. We update assumptions for new business to reflect the most recent experience. For DAC associated with Canadian segregated funds, the assumptions used in determining amortization expense are evaluated regularly and are updated if actual experience or other evidence suggests revisions to earlier estimates are appropriate. DAC amortization for term life insurance policies is affected by differences between the original assumptions used for persistency, expenses, interest rates and claims and actual results and are recognized in the period in which the change occurs. For policies underlying the Canadian segregated funds, gross profits and the resulting DAC amortization will vary with actual fund returns, redemptions and expenses. Due to the inherent uncertainties in making assumptions about future events, a materially different experience from expected results could result in a material increase or decrease of DAC amortization in a particular period. DAC is subject to recoverability testing annually and when impairment indicators exist. The recoverability of DAC is dependent on the future profitability of the related policies, which, in turn, is dependent principally upon mortality, persistency, investment returns, and the expense of administering the business, as well as upon certain economic variables, such as inflation. The balances and activity in DAC were as follows: Year ended December 31, 2022 2021 2020 (In thousands) DAC balance, beginning of period $ 2,943,782 $ 2,629,644 $ 2,325,750 Capitalization 514,597 562,999 522,705 Amortization ( 356,143 ) ( 251,179 ) ( 224,321 ) Foreign exchange translation and other ( 20,350 ) 2,318 5,510 DAC balance, end of period $ 3,081,886 $ 2,943,782 $ 2,629,644

Separate Accounts

Separate Accounts	12 Months Ended
	Dec. 31, 2022
Separate Accounts Disclosure [Abstract]
Separate Accounts	(8) Separate Accounts The Funds primarily consist of a series of branded investment funds known as the Asset Builder Funds, a registered retirement fund known as the Strategic Retirement Income Fund (“SRIF”), and a money market fund known as the Cash Management Fund. The principal investment objective of the Asset Builder Funds is to achieve long-term growth while preserving capital. The principal objective of the SRIF is to provide a stream of investment income during retirement plus the opportunity for modest capital appreciation. The Asset Builder Funds and the SRIF use diversified portfolios of publicly-traded Canadian stocks, investment-grade corporate bonds, Government of Canada bonds, and foreign equity investments to achieve their objectives. The Cash Management Fund invests in government guaranteed short-term bonds and short-term commercial and bank papers, with the principal investment objective being the provision of interest income while maintaining liquidity and preserving capital. Under these contract offerings, benefit payments to contract holders or their designated beneficiaries are only due upon death of the annuitant or upon reaching a specific maturity date. Benefit payments are based on the value of the contract holder’s units in the portfolio at the payment date, but are guaranteed to be no less than 75 % of the contract holder’s contribution, adjusted for withdrawals. Account values are not guaranteed for withdrawn units if contract holders make withdrawals prior to the maturity dates. Maturity dates for contracts investing in the Asset Builder Funds and Cash Management Fund vary by contract and range from 10 years from the contract issuance date to December 31, 2070 . Contracts investing in the SRIF mature when the policyholder reaches age 100, which is a minimum of 20 years after issue. The SRIF is designed to provide periodic retirement income payments and as such, regular withdrawals, subject to legislated minimums, are anticipated. The cumulative effects of the periodic withdrawals are expected to substantially reduce both account and minimum guaranteed values prior to maturity. Both the asset and the liability for the separate accounts reflect the net value of the underlying assets in the portfolio as of the reporting date. Primerica Life Canada’s exposure to losses under the guarantee at the time of account maturity is limited to contract holder accounts that have declined in value more than 25 %, adjusted for withdrawals, since the contribution date prior to maturity. Because maturity dates are of a long-term nature, the likelihood guarantee payments are required at any given point is very small. Additionally, the portfolios consist of a very large number of individual contracts, further spreading the risk related to the guarantee being exercised upon death. The length of the contract terms provides significant opportunity for the underlying portfolios to recover any short-term losses prior to maturities or deaths of the contract holders. Furthermore, the Funds’ investment allocations are aligned with the maturity risks of the related contracts and include investments in Government Strip Bonds and floating-rate notes. We periodically assess the exposure related to these contracts to determine whether any additional liability should be recorded. As of December 31, 2022 and 2021, an additional liability for these contracts was deemed to be unnecessary. The following table represents the fair value of assets supporting separate accounts by major investment category: Year ended December 31, 2022 2021 (In thousands) Fixed-income securities $ 796,384 $ 1,172,425 Equity securities 1,340,541 1,534,993 Cash and cash equivalents 181,162 92,648 Due to/from funds ( 12,399 ) ( 112 ) Other 29 38 Total separate accounts assets $ 2,305,717 $ 2,799,992

Policy Claims and Other Benefit

Policy Claims and Other Benefits Payable	12 Months Ended
	Dec. 31, 2022
Liability For Future Policy Benefits And Unpaid Claims And Claims Adjustment Expense [Abstract]
Policy Claims and Other Benefits Payable	(9) Policy Claims and Other Benefits Payable Changes in policy claims and other benefits payable were as follows: Year ended December 31, 2022 2021 2020 (In thousands) Policy claims and other benefits payable, beginning of period $ 585,382 $ 519,711 $ 339,954 Less reinsured policy claims and other benefits payable 637,139 545,030 388,797 Net balance, beginning of period ( 51,757 ) ( 25,319 ) ( 48,843 ) Incurred related to current year 248,127 284,719 236,157 Incurred related to prior years (1) ( 4,363 ) ( 216 ) ( 4,033 ) Total incurred 243,764 284,503 232,124 Claims paid related to current year, net of reinsured policy claims received ( 263,114 ) ( 345,130 ) ( 268,914 ) Reinsured policy claims received related to prior years, net of claims paid 67,267 34,128 60,144 Total paid ( 195,847 ) ( 311,002 ) ( 208,770 ) Foreign currency translation ( 531 ) 61 170 Net balance, end of period ( 4,371 ) ( 51,757 ) ( 25,319 ) Add reinsured policy claims and other benefits payable 542,621 637,139 545,030 Balance, end of period $ 538,250 $ 585,382 $ 519,711 (1) Includes the difference between our estimate of claims incurred but not yet reported at year end and the actual incurred claims reported after year end. See Note 1 (Description of Business, Basis of Presentation, and Summary of Significant Accounting Policies) for details regarding the accounting for policyholder liabilities.

Debt

Debt	12 Months Ended
	Dec. 31, 2022
Debt Disclosure [Abstract]
Debt	(10) Debt Notes Payable – Long Term. Notes payable consisted of the following: December 31, 2022 December 31, 2021 (In thousands) 2.80 % Senior Notes, due November 19, 2031 $ 600,000 $ 600,000 Unamortized issuance discount on notes payable ( 2,385 ) ( 2,655 ) Total notes payable $ 597,615 $ 597,345 As of December 31, 2022, we had outstanding $ 600.0 million in principal amount of publicly-traded, senior unsecured notes (the “Senior Notes”). The Senior Notes were issued in November 2021 at a price of 99.550 % of the principal amount with an annual interest rate of 2.80 % , payable semi-annually in arrears on May 19 and November 19, and are scheduled to mature on November 19, 2031 . As of December 31, 2022, we were in compliance with the covenants of the Senior Notes. No events of default occurred on the Senior Notes during the year ended December 31, 2022. As unsecured senior obligations, the Senior Notes rank equally in right of payment with all existing and future unsubordinated indebtedness and senior to all existing and future subordinated indebtedness of the Parent Company. The Senior Notes are structurally subordinated in right of payment to all existing and future liabilities of our subsidiaries. In addition, the Senior Notes contain covenants that restrict our ability to, among other things, create or incur any indebtedness that is secured by a lien on the capital stock of certain of our subsidiaries, and merge, consolidate or sell all or substantially all of our properties and assets. Notes Payable – Short term. On July 1, 2021, as part of the acquisition of e-TeleQuote, Primerica Health issued a $ 15.0 million unsecured, subordinated note, guaranteed by the Parent Company, to Etelequote Limited’s (“Etelequote Bermuda”) majority shareholder. This note was retired during the year ended December 31, 2022. Surplus Note. As of December 31, 2022, the principal amount outstanding on the Surplus Note issued by Vidalia Re was $ 1.4 billion, which is equal to the principal amount of the LLC Note. The principal amount of both the Surplus Note and the LLC Note will fluctuate over time to coincide with the amount of policy reserves being contractually supported under the Vidalia Re Coinsurance Agreement. Both the LLC Note and the Surplus Note mature on December 31, 2030 and bear interest at an annual interest rate of 4.50 %. Based on the estimated reserves for policies issued in 2011 through 2017 that have been ceded under the Vidalia Re Coinsurance Agreement, the maximum scheduled principal amounts of the Surplus Note and the LLC Note are expected to reach $ 1.5 billion each. This financing arrangement is non-recourse to the Parent Company and Primerica Life, meaning that neither of these companies has guaranteed the Surplus Note or is otherwise liable for reimbursement for any payments triggered by the LLC Note’s credit enhancement feature. The Parent Company has agreed to support Vidalia Re’s obligation to pay the credit enhancement fee incurred on the LLC Note. See Note 4 (Investments) for more information on the LLC Note. Revolving Credit Facility. On June 22, 2021, we amended and restated our unsecured $ 200.0 million revolving credit facility (“Revolving Credit Facility”) with a syndicate of commercial banks. The Revolving Credit Facility has a scheduled termination date of June 22, 2026 . Amounts outstanding under the Revolving Credit Facility are borrowed, at our discretion, on the basis of either a LIBOR rate loan, or a base rate loan. LIBOR rate loans bear interest at a periodic rate equal to one-, three-, six-, or 12-month LIBOR, plus an applicable margin. Base rate loans bear interest at the highest of (a) the Prime Rate, (b) the Federal Funds Rate plus 0.50% and (c) one-month LIBOR plus 1.00%, plus an applicable margin. The Revolving Credit Facility contains language providing for a benchmark replacement in the event that LIBOR is no longer available. The Revolving Credit Facility also permits the issuance of letters of credit. The applicable margins are based on our debt rating with such margins for LIBOR rate loans and letters of credit ranging from 1.00 % to 1.625 % per annum and for base rate loans ranging from 0.00 % to 0.625 % per annum. Under the Revolving Credit Facility, we incur a commitment fee that is payable quarterly in arrears and is determined by our debt rating. This commitment fee ranges from 0.10 % to 0.225 % per annum of the aggregate amount of the $ 200.0 million commitment of the lenders under the Revolving Credit Facility that remains undrawn. During the year ended December 31, 2022, no amounts were drawn under the Revolving Credit Facility. As of December 31, 2022, we were in compliance with the covenants of the Revolving Credit Facility. Furthermore, no events of default occurred under the Revolving Credit Facility during the year ended December 31, 2022 .

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Income Taxes	(11) Income Taxes Income tax expense. Income tax expense (benefit) consists of the following: Current Deferred Total (In thousands) Year ended December 31, 2022 Federal $ 149,034 $ ( 49,683 ) $ 99,351 Foreign 51,692 ( 27,163 ) 24,529 State and local 5,029 ( 3,134 ) 1,895 Total tax expense $ 205,755 $ ( 79,980 ) $ 125,775 Year ended December 31, 2021 Federal $ 115,657 $ ( 10,589 ) $ 105,068 Foreign 43,687 ( 13,890 ) 29,797 State and local 5,440 ( 1,114 ) 4,326 Total tax expense $ 164,784 $ ( 25,593 ) $ 139,191 Year ended December 31, 2020 Federal $ 88,837 $ 853 $ 89,690 Foreign 26,749 ( 547 ) $ 26,202 State and local 4,714 ( 40 ) $ 4,674 Total tax expense $ 120,300 $ 266 $ 120,566 Income before income taxes. Income before income taxes by domestic and foreign were as follows: Year ended December 31, 2022 2021 2020 (In thousands) Income before income taxes by domestic and foreign Domestic $ 394,773 $ 399,149 $ 411,751 Foreign 98,976 112,022 94,979 Total income before income taxes $ 493,749 $ 511,171 $ 506,730 Effective tax rate reconciliation. Total income tax expense is different from the amount determined by multiplying income before income taxes by the U.S. statutory federal tax rate of 21 % for the years ended December 31, 2022 and 2021 and 2020 . The reconciliation for such difference follows: Year ended December 31, 2022 2021 2020 Amount Percentage Amount Percentage Amount Percentage (Dollars in thousands) Computed tax expense $ 103,687 21.0 % $ 107,346 21.0 % $ 106,413 21.0 % Goodwill impairment loss 12,600 2.6 % 15,960 3.1 % - 0.0 % Difference between foreign statutory 5,571 1.1 % 5,871 1.1 % 5,075 1.0 % Other 3,917 0.8 % 10,014 2.0 % 9,078 1.8 % Total tax expense / $ 125,775 25.5 % $ 139,191 27.2 % $ 120,566 23.8 % Deferred tax assets and liabilities. The main components of deferred income tax assets and liabilities were as follows: December 31, 2022 2021 (In thousands) Deferred tax assets: Future policy benefit reserves and unpaid policy claims $ 428,438 $ 353,677 Net operating loss and interest carryforwards 28,675 36,343 Investments 59,085 - Future deductible liabilities 23,217 20,883 Foreign tax credits 36,424 46,455 Other 23,809 27,610 Total deferred tax assets before valuation allowance 599,648 484,968 Valuation allowance ( 36,511 ) ( 46,542 ) Total deferred tax assets after valuation allowance $ 563,137 $ 438,426 Deferred tax liabilities: Deferred policy acquisition costs ( 385,351 ) ( 383,163 ) Renewal commissions receivable ( 53,874 ) ( 60,782 ) Intangibles ( 47,806 ) ( 50,310 ) Investments - ( 17,952 ) Reinsurance deposit asset ( 47,118 ) ( 48,587 ) Other ( 19,112 ) ( 21,833 ) Total deferred tax liabilities ( 553,261 ) ( 582,627 ) Net deferred tax liabilities $ 9,876 $ ( 144,201 ) The majority of total deferred tax assets are attributable to future policy benefit reserves and unpaid policy claims, which represents the difference between the financial statement carrying value and tax basis for liabilities related to future policy benefits. The tax basis for future policy benefit reserves and unpaid policy claims is actuarially determined in accordance with guidelines set forth in the respective jurisdictional tax codes in the U.S. and Canada. The majority of total deferred tax liabilities are attributable to DAC, which represents the difference between the policy acquisition costs capitalized for U.S. GAAP purposes and those capitalized for tax purposes, as well as the difference in the resulting amortization methods. The Company has federal net operating losses resulting in a deferred tax asset of $ 11.8 million as of December 31, 2022. The federal net operating losses as of December 31, 2022 have an indefinite life. The Company has state net operating losses and interest carryforwards resulting in a net deferred tax asset of $ 16.8 million, of which approximately half are available for use through 2037 and approximately half with an indefinite life. The Company has no other material net operating loss or credit carryforwards other than foreign tax credit carryforwards. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income, carryback and carryforward periods, and tax planning strategies in making this assessment. As of December 31, 2022, management identified excess foreign tax credits of approximately $ 36.4 million that could not be used to offset the mandatory deemed repatriation of foreign earnings tax stipulated by the Tax Cuts and Jobs Act of 2017 and believes it will not be able to utilize these foreign tax credits in the future. Therefore, the Company established a deferred tax asset for these foreign tax credits with a corresponding full valuation allowance. These foreign tax credits are available for use through 2027 with some beginning to expire in 2023. With the exception of these foreign tax credits, management believes that it is more likely than not that the results of future operations will generate sufficient taxable income to realize its deferred tax assets. Therefore, there were no other significant deferred tax asset valuation allowances as of December 31, 2022 or 2021. Controlled foreign corporations . The Company has direct ownership of a group of controlled foreign corporations. The tax effects of controlled foreign corporations other than in Canada were not material. We have not made a permanent reinvestment assertion for any unremitted earnings in Canada; therefore, we have recorded a deferred tax liability to account for Canadian withholding taxes that will occur upon repatriation of such earnings and we continue to record deferred tax liabilities to account for Canadian withholding taxes as earnings are recognized. The Company has no intentions to sell or substantially liquidate our Canadian operations and, therefore, has not provided for any additional outside basis difference for the amount of book basis in excess of tax basis in its Canadian subsidiaries. In addition, it is not practicable to determine the amount of the unrecognized deferred tax liability related to any additional outside basis difference in these entities. Unrecognized tax benefits. The total amount of unrecognized benefits on uncertain tax positions that, if recognized, would affect our effective tax rate was approximately $ 18.8 million and $ 17.9 million as of December 31, 2022 and 2021, respectively. We recognize interest expense related to unrecognized tax benefits in tax expense net of federal income tax. The total amount of accrued interest and penalties in the consolidated balance sheets was $ 3.4 million and $ 3.1 million as of December 31, 2022 and 2021, respectively. Additionally, we recognized less than $ 0.3 million of interest expense related to unrecognized tax benefits in the consolidated statements of income for the years ended December 31, 2022, 2021, and 2020. A reconciliation of the change in the unrecognized income tax benefit for the years ended December 31, 2022 and 2021 is as follows: December 31, 2022 2021 2020 (In thousands) Unrecognized tax benefits, beginning of period $ 19,224 $ 17,104 $ 15,805 Change in prior period unrecognized tax benefits ( 944 ) ( 103 ) 40 Change in current period unrecognized tax benefits 3,993 3,777 3,296 Reductions as a result of a lapse in statute of limitations ( 2,093 ) ( 1,554 ) ( 2,037 ) Unrecognized tax benefits, end of period $ 20,180 $ 19,224 $ 17,104 We have an immaterial amount of penalties included in calculating our provision for income taxes. There is no significant change that is reasonably possible to occur within twelve months of the reporting date. The major tax jurisdictions in which we operate are the United States and Canada. We are currently open to tax audit by the Internal Revenue Service for the year ended December 31, 2019 and thereafter for federal income tax purposes. We are currently open to audit in Canada for tax years ended December 31, 2018 and thereafter for federal and provincial income tax purposes. Qualified affordable housing projects. We have investments in various limited partnerships that sponsor qualified affordable housing projects, which meet the definition of a VIE. We are not the primary beneficiary of these VIEs because we do not have the power to direct the activities that most significantly impact the entities’ economic performance. The maximum exposure to loss as a result of our involvement in these VIEs equals the carrying value of the investments. The primary economic purpose of these investments is to achieve a satisfactory return on capital through the receipt of tax credits. Our qualified affordable housing project investments are accounted for using the proportional amortization method of accounting. During the year ended December 31, 2022 and 2021, the amount of income tax benefits recognized from these investments was insignificant. Our investment in qualified affordable housing projects was $ 12.8 million and $ 3.5 million as of December 31, 2022, and 2021, respectively, and is included within policy loans and other invested assets on our consolidated balance sheets. Additionally, unfunded commitments to provide additional capital to investees in qualified affordable housing projects was $ 9.7 million as of December 31, 2022 and are included within other liabilities on our consolidated balance sheets. Substantially all of the unfunded commitments as of December 31, 2022 are expected to be paid out within the next five years. There were no unfunded commitments as of December 31, 2021.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2022
Stockholders Equity Note [Abstract]
Stockholders' Equity	(12) Stockholders’ Equity A reconciliation of the number of shares of our common stock follows: Year ended December 31, 2022 2021 2020 (In thousands) Common stock, beginning of period 39,368 39,306 41,207 Shares issued for stock options exercised - 10 - Shares of common stock issued upon lapse of sales restrictions on RSUs 236 225 335 Common stock retired ( 2,780 ) ( 173 ) ( 2,236 ) Common stock, end of period 36,824 39,368 39,306 The above reconciliation excludes RSUs and PSUs, which do not have voting rights. As sales restrictions on RSUs lapse and PSUs are earned, we issue common shares with voting rights. As of December 31, 2022, we had a total of 297,583 RSUs and 74,054 PSUs outstanding. The PSU outstanding balance is based on the number of PSUs granted pursuant to the award agreement; however, the actual number of common shares earned could be higher or lower based on actual versus targeted performance. See Note 14 (Share-Based Transactions) for a discussion of the PSU award structure. On November 17, 2021 our Board of Directors authorized a Share Repurchase Program for up to $ 275.0 million of our outstanding common stock for purchases through December 31, 2022. On February 14, 2022, our Board of Directors authorized an increase of $ 50.0 million to the Share Repurchase Program. On August 11, 2022, our Board of Directors authorized an additional increase of $ 50.0 million to the Share Repurchase Program bringing the authorized share repurchases to $ 375.0 million of our outstanding common stock through December 31, 2022. Under the Share Repurchase Program, we repurchased 2,864,394 shares of our common stock in the open market for an aggregate purchase price of $ 375.0 million through December 31, 2022. There is no remaining authority under the Share Repurchase Program as of December 31, 2022. On November 17, 2022, our Board of Directors authorized a new $ 375.0 million share repurchase program to occur from January 1, 2023 through December 31, 2023.

Earnings Per Share

Earnings Per Share	12 Months Ended
	Dec. 31, 2022
Earnings Per Share [Abstract]
Earnings Per Share	(13) Earnings Per Share The Company has outstanding common stock and equity awards that consist of RSUs, PSUs and stock options. The RSUs maintain non-forfeitable dividend rights that result in dividend payment obligations on a one-to-one ratio with common shares for any future dividend declarations. Unvested RSUs are deemed participating securities for purposes of calculating EPS as they maintain dividend rights. We calculate EPS using the two-class method. Under the two-class method, we allocate earnings to common shares and vested RSUs outstanding for the period. Earnings attributable to unvested participating securities, along with the corresponding share counts, are excluded from EPS as reflected in our consolidated statements of income. In calculating basic EPS, we deduct from net income any dividends and undistributed earnings allocated to unvested RSUs and then divide the result by the weighted-average number of common shares and vested RSUs outstanding for the period. We determine the potential dilutive effect of PSUs and stock options outstanding (“contingently-issuable shares”) on EPS using the treasury-stock method. Under this method, we determine the proceeds that would be received from the issuance of the contingently- issuable shares if the end of the reporting period were the end of the contingency period. The proceeds from the contingently-issuable shares include the remaining unrecognized compensation expense of the awards and the cash received for the exercise price on stock options. We then use the average market price of our common shares during the period the contingently-issuable shares were outstanding to determine how many shares we could repurchase with the proceeds raised from the issuance of the contingently-issuable shares. The net incremental share count issued represents the potential dilutive securities. We then reallocate earnings to common shares and vested RSUs by incorporating the increased fully-diluted share count to determine diluted EPS. The calculation of basic and diluted EPS was as follows: Year ended December 31, 2022 2021 2020 (In thousands, except per-share amounts) Basic EPS: Numerator: Net income attributable to Primerica, Inc. $ 373,012 $ 373,357 $ 386,164 Income attributable to unvested participating securities ( 1,684 ) ( 1,533 ) ( 1,671 ) Net income used in calculating basic EPS $ 371,328 $ 371,824 $ 384,493 Denominator: Weighted-average vested shares 37,997 39,530 40,065 Basic EPS $ 9.77 $ 9.41 $ 9.60 Diluted EPS: Numerator: Net income attributable to Primerica, Inc. $ 373,012 $ 373,357 $ 386,164 Income attributable to unvested participating securities ( 1,680 ) ( 1,529 ) ( 1,667 ) Net income used in calculating diluted EPS $ 371,332 $ 371,828 $ 384,497 Denominator: Weighted-average vested shares 37,997 39,530 40,065 Dilutive effect of incremental shares to be issued for 109 122 120 Weighted-average shares used in calculating diluted EPS 38,106 39,652 40,185 Diluted EPS $ 9.74 $ 9.38 $ 9.57

Share-Based Transactions

Share-Based Transactions	12 Months Ended
	Dec. 31, 2022
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Share-Based Transactions	(14) Share-Based Transactions The Company has outstanding equity awards under the Primerica, Inc. Second Amended and Restated 2010 Omnibus Incentive Plan (“2010 OIP”), which expired in 2020 in accordance with its terms and under which no future awards will be made, and the Primerica, Inc. 2020 Omnibus Incentive Plan (the “2020 OIP”, and together with the 2010 OIP, the “OIP”), which was approved by the Company’s stockholders on May 13, 2020. The OIP provides for the issuance of equity awards, including stock options, stock appreciation rights, restricted stock, deferred stock, RSUs, PSUs, and stock payment awards, as well as cash-based awards. In addition to time-based vesting requirements, awards granted under the OIP may also be subject to specified performance criteria. Under the OIP, the Company issues equity awards to our management (officers and other key employees), non-employees who served on our Board of Directors, and sales force leaders. As of December 31, 2022, we had 1.4 million shares available for future grants under the 2020 OIP. Employee and Director Share-Based Compensation. As of December 31, 2022, the Company had outstanding RSUs, PSUs, and stock options issued to our management (officers and other key employees), as well as RSUs issued to our directors, under the OIP. RSUs. • RSUs granted to management generally have time-based vesting requirements with equal and annual graded vesting over approximately three years subsequent to the grant date, but also generally vest upon voluntary termination of employment by any employee who is “retirement eligible” as of his or her termination date. In order to be retirement eligible, an employee must be at least 55 years old and his or her age plus years of service with the Company must equal at least 75. • RSUs granted to directors have time-based vesting requirements with equal and quarterly graded vesting over four quarters subsequent to the grant date. • In addition, certain directors elected to defer their cash and/or equity retainers into deferred RSUs, which vest immediately (for cash deferrals) or, if applicable, on the dates the RSUs would have vested. All of our outstanding employee and director RSU awards are eligible for dividend equivalents regardless of vesting status. We recognized expense and tax benefit offsets as follows for employee and director RSU share-based compensation: Year ended December 31, 2022 2021 2020 (In thousands) Total equity awards expense recognized $ 12,626 $ 11,779 $ 11,218 Tax benefit associated with total employee and director 1,642 1,638 1,455 The following table summarizes employee and director RSU activity during the years ended December 31, 2022, 2021, and 2020. Shares Weighted-average measurement-date fair value per share (Shares in thousands) Unvested employee and director RSUs, December 31, 2019 180 $ 107.59 Granted 94 119.03 Forfeited - (1) 121.42 Vested ( 108 ) 101.75 Unvested employee and director RSUs, December 31, 2020 166 117.87 Granted 84 144.95 Forfeited ( 4 ) 147.23 Vested ( 93 ) 116.55 Unvested employee and director RSUs, December 31, 2021 153 132.85 Granted 113 117.06 Forfeited ( 3 ) 123.38 Vested ( 90 ) 129.89 Unvested employee and director RSUs, December 31, 2022 173 131.78 (1) Less than 1,000 shares As of December 31, 2022, total compensation cost not yet recognized in our consolidated financial statements related to employee and director RSU awards with time-based vesting conditions yet to be reached was $ 5.7 million, and the weighted-average period over which cost will be recognized was 0.9 years. PSUs. The Company issued PSUs to certain of its executive officers under the OIP as part of their annual equity compensation. To date, PSU awards have included a performance target of a specified average annual Return on Adjusted Equity (“ROAE”) and EPS growth (starting with the 2020 award) for the Company over a three-year performance period, as well as a threshold ROAE and EPS growth below which no shares would be earned and an ROAE and EPS growth metric at which the maximum number of shares can be earned. Awards are earned two months after the performance period ends. Depending on the ROAE and EPS growth, if applicable, achieved within the specified range, recipients may receive shares of common stock equal to between 0 % and 150 % of the number of PSUs granted. In addition, PSUs accrue forfeitable dividend equivalents, which are also paid out based on the number of shares earned. PSU awards provide for vesting upon the voluntary termination of employment by any employee who is “retirement eligible” as of his or her termination date. The number of shares that will be earned for a retirement-eligible employee is equal to the amount calculated using the Company’s actual performance metrics for the entire performance period, even if that employee retires prior to the completion of the performance period. In connection with our granting of PSU awards, we recognized expense and tax benefit offsets as follows: Year ended December 31, 2022 2021 2020 (In thousands) Total employee PSU award expense $ 2,092 $ 3,494 $ 4,179 Tax benefit associated with total employee PSU award expense - - - The following table summarizes PSU activity during the years ended December 31, 2022, 2021, and 2020. Shares Weighted-average measurement-date fair value per share (Shares in thousands) Unvested employee PSUs, December 31, 2019 (1) 91 $ 98.79 Granted 26 121.42 Forfeited - - Performance Adjustment 5 80.45 Vested ( 41 ) 80.45 Unvested employee PSUs, December 31, 2020 (1) 81 113.99 Granted 22 143.04 Forfeited - - Performance Adjustment 3 100.55 Vested ( 33 ) 100.55 Unvested employee PSUs, December 31, 2021 (1) 73 128.30 Granted 27 130.30 Forfeited - - Performance Adjustment 2 122.62 Vested ( 28 ) 122.62 Unvested employee PSUs, December 31, 2022 (1) 74 130.97 (1) The 2020 PSU awards outstanding are based on the actual performance. As a result of the performance achieved during the performance period, recipients will receive an aggregate of 20,559 shares of common stock on the vesting date of March 1, 2023, reflecting a payout rate of 79.9 %. The 2021 PSU awards outstanding are based on target. Depending upon the performance achieved during the performance period, recipients may receive between 0 and 32,768 shares of common stock. The 2022 PSU awards outstanding are based on target. Depending upon the performance achieved during the performance period, recipients may receive between 0 and 39,713 shares of common stock. As of December 31, 2022 the Company did no t have any unrecognized compensation related PSU awards. Stock Options. From 2013 to 2016, the Company issued stock options to certain of its executive officers under the OIP as part of their annual equity compensation. Stock options were granted with an exercise price equal to the fair market value of our common stock on the grant date, and they expire 10 years from the date of grant. These options had time-based restrictions with equal and annual graded vesting over a three-year period and are all fully vested. Upon retirement, employees have the lesser of three years or the remaining option term to exercise any vested options. We did no t issue any stock options in 2022, 2021 or 2020. Compensation expense and related tax benefits recognized for stock option awards were as follows: Year ended December 31, 2022 2021 2020 (In thousands) Expense recognized for stock option awards $ - $ - $ - Tax benefit recognized for stock option awards - - - The following table summarizes activity related to stock options outstanding and exercisable during the years ended December 31, 2022, 2021, and 2020: Outstanding Exercisable Number of shares Weighted average exercise price Number of shares Weighted average exercise price (Shares in thousands) Outstanding at December 31, 2019 70 $ 44.23 70 $ 44.23 Granted - - Exercised - - Outstanding at December 31, 2020 70 44.23 70 44.23 Granted - - Exercised ( 10 ) 41.88 Outstanding at December 31, 2021 60 44.62 60 44.62 Granted - - Exercised - - Outstanding at December 31, 2022 60 44.62 60 44.62 Range of granted option exercise prices outstanding at December 31, 2022 $ 41.20 (average term remaining - 1.1 years) 3 $ 41.20 3 $ 41.20 $ 53.50 (average term remaining - 2.2 years) 14 53.50 14 53.50 $ 41.88 (average term remaining - 3.2 years) 42 41.88 42 41.88 The aggregate intrinsic value represents the difference between the exercise price of our stock options and the quoted closing price of our common stock. The aggregate intrinsic value of exercisable stock options was $ 5.8 million as of December 31, 2022, which represents the aggregate intrinsic value of stock options outstanding. The intrinsic value, tax benefit realized and value of shares withheld related to option exercise activity are summarized as follows: Year ended December 31, 2022 2021 2020 (In thousands) Intrinsic value of options exercised $ - $ 1,156 $ - Tax benefit realized from the options exercised - - - Value of issued shares withheld to satisfy option - 419 - As of December 31, 2022 , there was no unrecognized compensation cost related to outstanding options. Non-Employee Share-Based Compensation. Non-employee share-based transactions relate to the granting of RSUs to members of the sales force (“agent equity awards”). Agent equity awards are generally granted as a part of quarterly contests for successful life insurance policy acquisitions and for sales of investment and savings products for which the grant and the service period occur within the same quarterly reporting period. The following table summarizes non-employee RSU activity during the years ended December 31, 2022, 2021, and 2020. Shares Weighted-average measurement-date fair value per share (Shares in thousands) Unvested non-employee RSUs, December 31, 2019 24 $ 132.68 Granted 128 106.65 Vested ( 126 ) 105.71 Unvested non-employee RSUs, December 31, 2020 26 134.75 Granted 99 150.72 Vested ( 94 ) 145.03 Unvested non-employee RSUs, December 31, 2021 31 154.59 Granted 118 129.99 Vested ( 117 ) 133.25 Unvested non-employee RSUs, December 31, 2022 32 141.60 Agent equity awards are measured using the fair market value at the grant date and vest during the service period, which occur within the same quarterly reporting period. To the extent that these awards are an incremental direct cost of successful acquisitions of life insurance policies that result directly from and are essential to the policy acquisition(s) and would not have been incurred had the policy acquisition(s) not occurred, we defer and amortize the fair value of the awards in the same manner as other deferred policy acquisition costs. All agent equity awards that are not directly related to the acquisition of life insurance policies are recognized as expense in the quarter granted and earned. Details on the granting and valuation of these awards were as follows: Year ended December 31, 2022 2021 2020 (In thousands) Quarterly incentive awards expense recognized currently $ 4,060 $ 4,036 $ 3,630 Quarterly incentive awards expense deferred 11,260 10,807 10,071 Tax benefit associated with incentive awards 3,056 2,904 2,692 As of December 31, 2022 , all agent equity awards were fully vested with the exception of approximately 31,819 shares that vested on January 1, 2023.

Statutory Accounting and Divide

Statutory Accounting and Dividend Restrictions	12 Months Ended
	Dec. 31, 2022
Insurance [Abstract]
Statutory Accounting and Dividend Restrictions	(15) Statutory Accounting and Dividend Restrictions U.S. Insurance Subsidiaries. Our two underwriting U.S. insurance subsidiaries are Primerica Life and NBLIC. Primerica Life wholly owns Peach Re and Vidalia Re, and ceded to each in separate coinsurance arrangements certain level-premium term life insurance policies. Our U.S. insurance subsidiaries are required to report their results of operations and financial position to state authorities on the basis of statutory accounting practices prescribed or permitted by such authorities and the National Association of Insurance Commissioners (“NAIC”), which is a comprehensive basis of accounting other than U.S. GAAP. Prescribed statutory accounting practices include a variety of publications of the NAIC, as well as state laws, regulations and general administrative rules. Permitted statutory accounting practices encompass all accounting practices not so prescribed. The Company’s principal life insurance company, Primerica Life, prepares its statutory financial statements on the basis of accounting practices prescribed or permitted by the NAIC and the Tennessee Department of Commerce and Insurance (“Tennessee DOCI”) and includes the statutory financial statements of its wholly owned insurance subsidiaries, NBLIC, Peach Re, and Vidalia Re. NBLIC’s statutory financial statements are prepared on the basis of accounting practices prescribed or permitted by the NAIC or the New York State Department of Financial Services, while the statutory financial statements of Peach Re and Vidalia Re are prepared on the basis of accounting practices prescribed or permitted by the NAIC or the Vermont Department of Financial Regulation (“Vermont DOI”). Our U.S. insurance subsidiaries’ ability to pay dividends to their parent is subject to and limited by the various laws and regulations of their respective states. There are no regulatory restrictions on the ability of the Parent Company to pay dividends (other than limitations under the Delaware General Corporation Law that provide that dividends on common stock shall be declared by the Board of Directors out of surplus or, if there is no surplus, out of net profits for the fiscal year in which the dividend is declared and/or the preceding prior fiscal year). Primerica Life’s statutory ordinary dividend capacity is based on the greater of: (1) the previous year’s statutory net gain from operations (excluding pro rata distributions of any class of the insurer’s own securities) or (2) 10% of the previous year-end statutory surplus (net of capital stock). Dividends that, together with the amount of other distributions or dividends made within the preceding 12 months, exceed this statutory limitation are referred to as extraordinary dividends and require advance notice to the Tennessee DOCI, and are subject to potential disapproval. Dividends paid from other than statutory unassigned surplus require approval of the commissioner of the Tennessee DOCI. Primerica Life’s statutory capital and surplus as of December 31, 2022 and 2021 were as follows: December 31, 2022 December 31, 2021 (In thousands) Statutory capital and surplus $ 834,565 $ 779,620 Primerica Life’s statutory net gain from operations was $ 446.1 million, $ 257.3 million, and $ 395.4 million for 2022, 2021, and 2020, respectively. Primerica Life made no pro rata distributions of any class of its own securities during 2022. During 2022, Primerica Life paid ordinary dividends of $ 255.0 million to the Parent Company. As of January 1, 2023, the amount of dividends Primerica Life could pay from statutory unassigned surplus without prior approval of the commissioner of the Tennessee DOCI was $ 336.8 million, which is limited by the amount of statutory unassigned surplus on that date. Primerica Life’s investment basis in NBLIC, Peach Re, and Vidalia Re reflect their statutory capital and surplus amounts recorded in accordance with statutory accounting practices prescribed or permitted by the NAIC and/or each subsidiary’s state of domicile; New York and Vermont. Peach Re was formed as a special-purpose financial captive insurance company and, with the explicit permission of the Vermont DOI, has included the value of a letter of credit serving as collateral for its policy reserves as an admitted asset in its statutory capital and surplus. This permitted accounting practice was critical to the organization and operational plans of Peach Re and explicitly included in the licensing order issued by the Vermont DOI. The impact of this permitted practice as of December 31, 2022 was $ 90.8 million on Peach Re’s statutory capital and surplus. As of December 31, 2022, even if Peach Re had not been permitted to include the letter of credit as an admitted asset, Primerica Life would not have been below the minimum statutory capital and surplus level that triggers a regulatory action event. There are no other permitted accounting practices that are not encompassed in prescribed statutory accounting practices. Canadian Insurance Subsidiary. Primerica Life Canada is incorporated under the provisions of the Canada Business Corporations Act and is a domiciled Canadian Company subject to regulation under the Insurance Companies Act (Canada) by the Office of the Superintendent of Financial Institutions in Canada (“OSFI”) and by Provincial Superintendents of Financial Institutions/Insurance in those provinces in which Primerica Life Canada is licensed. The statutory financial statements of Primerica Life Canada reported to OSFI are prepared in accordance with International Financial Reporting Standards (“IFRS”). Primerica Life Canada’s capacity to pay ordinary dividends to its parent is limited by OSFI regulations to the extent that its capital exceeds internal capital targets. OSFI requires companies to set internal target levels of capital sufficient to provide for all the risks of the insurer, including risks specified in OSFI’s capital guidelines. As of December 31, 2022 and 2021, Primerica Life Canada’s statutory capital and surplus satisfied regulatory requirements and was $ 511.4 million and $ 417.7 million, respectively. In Canada, dividends can typically be paid subject to the paying insurance company continuing to have adequate capital and forms of liquidity as defined by OSFI following the dividend payment and upon 15 days minimum notice to OSFI. Primerica Life Canada’s dividend capacity at January 1, 2023 was estimated to be $ 65.7 million, which was calculated based on satisfying the Company’s internal capital targets. During 2022, Primerica Life Canada paid ordinary dividends of $ 23.1 million to its parent company.

Commitments and Contingent Liab

Commitments and Contingent Liabilities	12 Months Ended
	Dec. 31, 2022
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingent Liabilities	(1 6) Commitments and Contingent Liabilities Letter of Credit. Peach Re maintains a Credit Facility Agreement with Deutsche Bank (the “Credit Facility Agreement”) to support certain obligations for a portion of the reserves (commonly referred to as Regulation XXX reserves) related to level premium term life insurance policies ceded to Peach Re from Primerica Life under the Peach Re Coinsurance Agreement. Under the Credit Facility Agreement, Deutsche Bank issued a letter of credit in the initial amount of $ 450.0 million with a term expiring on December 31, 2025 (the “LOC”) for the benefit of Primerica Life, the direct parent of Peach Re. Subject to certain conditions, the amount of the LOC periodically increased up to a maximum amount of approximately $ 507.0 million, which was reached in 2014. As of December 31, 2022, the amount outstanding under the LOC was $ 90.8 million. This amount will continue to decline over the remaining term of the LOC to correspond with declines in the Regulation XXX reserve. Pursuant to the terms of the Credit Facility Agreement, in the event amounts are drawn under the LOC by Primerica Life, Peach Re will be obligated, subject to certain limited conditions, to reimburse Deutsche Bank for the amount of any draws and interest thereon. Peach Re has collateralized its obligations to Deutsche Bank by granting it a security interest in all of its assets with the exception of amounts held in a special account established to meet minimum asset thresholds required by state regulatory authorities. As of December 31, 2022, the Company was in compliance with all financial covenants under the Credit Facility Agreement. Contingent Liabilities. The Company is involved from time-to-time in legal disputes, regulatory inquiries and arbitration proceedings in the normal course of business. These disputes are subject to uncertainties, including the large and/or indeterminate amounts sought in certain of these matters and the inherent unpredictability of litigation. As such, the Company is unable to estimate the possible loss or range of loss that may result from these matters unless otherwise indicated.

Benefit Plan

Benefit Plan	12 Months Ended
	Dec. 31, 2022
Compensation And Retirement Disclosure [Abstract]
Benefit Plans	(17) Benefit Plans We sponsor defined contribution plans for the benefit of our employees. The expense associated with these plans was approximately $ 10.5 million, $ 10.5 million, and $ 10.0 million in 2022, 2021, and 2020 , respectively.

Revenue from Contracts with Cus

Revenue from Contracts with Customers	12 Months Ended
	Dec. 31, 2022
Revenue From Contract With Customer [Abstract]
Revenue from Contract with Customers	(18) Revenue from Contracts with Customers Our revenues from contracts with customers primarily include: • Commissions and fees earned for the marketing and distribution of investment and savings products underwritten by mutual fund companies and annuity providers. For purposes of revenue recognition, mutual fund companies and annuity providers are considered the customers in marketing and distribution arrangements; • Fees earned for investment advisory and administrative services within our managed investments program and shareholder service fees earned in Canada for mutual funds for which we serve as principal distributor; • Account-based fees for transfer agent recordkeeping functions and non-bank custodial services; • Commissions and fees earned from the distribution of Medicare-related insurance products on behalf of health insurance carriers, including tail revenue adjustments; • Marketing development revenues earned for selling Medicare-related insurance products on behalf of health insurance carriers, which is recorded in Other, net revenue; • Fees associated with mortgage distribution and the distribution of other third-party financial products; and • Other revenue from the sale of miscellaneous products and services including monthly subscription fees from the sales representatives for access to Primerica Online (“POL”), our primary sales force support tool. Premiums from insurance contracts we underwrite, fees received from segregated funds insurance contracts, and income earned on our invested assets are excluded from the definition of revenues from contracts with customers in accordance with U.S. GAAP. The disaggregation of our revenues from contracts with customers were as follows: Year ended December 31, 2022 2021 2020 (In thousands) Term Life Insurance segment revenues: Other, net $ 50,320 $ 48,970 $ 46,079 Total segment revenues from contracts with customers 50,320 48,970 46,079 Revenues from sources other than contracts with customers 1,636,806 1,526,716 1,336,691 Total Term Life Insurance segment revenues $ 1,687,126 $ 1,575,686 $ 1,382,770 Investment and Savings Products segment revenues: Commissions and fees: Sales-based revenues $ 326,378 $ 401,508 $ 284,651 Asset-based revenues 375,502 376,751 282,080 Account-based revenues 90,391 86,939 83,041 Other, net 12,610 12,097 11,271 Total segment revenues from contracts with customers 804,881 877,295 661,043 Revenues from sources other than contracts 58,551 64,552 57,824 Total Investment and Savings Products segment revenues $ 863,432 $ 941,847 $ 718,867 Senior Health segment revenues: Commissions and fees $ 47,420 $ 50,903 N/A Other, net 15,262 9,537 N/A Total Senior Health segment revenues 62,682 60,440 N/A Corporate and Other Distributed Products segment revenues: Commissions and fees $ 46,434 $ 62,160 $ 43,675 Other, net 4,967 3,971 3,719 Total segment revenues from contracts with customers 51,401 66,131 47,394 Revenues from sources other than contracts with customers 55,492 65,628 68,510 Total Corporate and Other Distributed Products segment revenues $ 106,893 $ 131,759 $ 115,904 We recognize revenue upon the satisfaction of the related performance obligation, unless the transaction price includes variable consideration that is constrained; in such case, we recognize revenue when the uncertainty associated with the constrained amount is subsequently resolved. Variable consideration is not treated as constrained to the extent it is probable that no significant reversal in the amount of cumulative revenue recognized will occur when the uncertainty associated with the variable consideration is resolved. We have no material obligations for refunds of commission and fees on contracts with customers subsequent to completion of our performance obligation. Investment and Savings Products Marketing and Distribution Services. We receive commissions and fees from mutual fund companies and annuity providers for the marketing and distribution by the licensed sales representatives of investment and savings products underwritten by such companies and providers. We recognize the sales-based marketing and distribution revenue received from such companies and providers at the point in time our performance obligation to them is satisfied, which is the trade date. The sales-based commissions from mutual fund companies and annuity providers are known and are due at the same time our performance obligation to such mutual fund companies and annuity providers is satisfied. We also receive ongoing asset-based commissions from mutual fund companies and annuity providers each reporting period based on client asset values. We do not recognize revenue for asset-based marketing and distribution commissions until the end of each subsequent reporting period when the amount becomes known and due from mutual fund companies or annuity providers as this revenue represents variable consideration that is fully constrained at the point in time our distinct performance obligation to mutual fund companies and annuity providers is satisfied. We consider variable consideration in the form of asset-based marketing and distribution commissions to be fully constrained as the amounts we will be entitled to collect are highly uncertain and susceptible to factors outside of our control. Such factors include the market values of assets under management and the length of time investors hold their accounts. Asset-based marketing and distribution commissions recognized during the current period are almost exclusively attributable to distinct performance obligations satisfied to mutual fund companies and annuity providers in previous periods. Investment Advisory and Administrative Services. We provide investment advisory and administrative services over time to investors in the managed investments program we offer. We recognize revenue as our performance obligation is satisfied over time for daily investment advisory and administrative services that are substantially the same and have the same pattern of delivery. Fees for these services, which are based on a percentage of client assets in the managed investments program, become known and are charged to investors during the same reporting period in which the daily investment advisory and administrative services are performed. Shareholder Services. We provide shareholder services over time to investors in the mutual funds in which we serve as the principal distributor in Canada. We recognize revenue as our performance obligation is satisfied over time for shareholder services that are substantially the same and have the same pattern of delivery. Fees for these services, which are based on a percentage of client assets in the mutual funds, become known and are charged to investors during the same reporting period in which the shareholder services are performed. Account-based Services. We provide distinct transfer agent recordkeeping services for certain mutual funds we distribute and non-bank custodial services to investors purchasing investment products we distribute through qualified retirement accounts in the United States. Fees charged for these account-based services consist primarily of a stated fee for each investment position or each qualified retirement account. Generally, our performance obligation for each account-based service arrangement is satisfied over time and is substantially the same with the same pattern of delivery. We recognize revenue to which we are entitled for each investment position or each qualified account over time based on the time-based pro-rata amount earned each reporting period. Distribution of Medicare-Related Insurance Products on Behalf of Health Insurance Carriers. As a result of the acquisition of e-TeleQuote, the Company distributes Medicare-related insurance policies to eligible Medicare participants offered by third-party health insurance carriers. e-TeleQuote receives initial commissions and renewal commissions from health insurance carriers for enrollments in policies it has distributed. The Company recognizes commission revenue in accordance with the following five steps outlined in ASC 606 discussed in further detail below: • identification of the contract, or contracts, with a customer; • identification of the performance obligations in the contract; • determination of the transaction price; • allocation of the transaction price to the performance obligations in the contract; and • recognition of revenue when, or as, the Company satisfies a performance obligation. The Company’s customers are the health insurance carriers that it contracts with to distribute Medicare-related insurance policies on their behalf. The Company reviews each contract with customers to determine what promises the Company must deliver and which of these promises are capable of being distinct in the context of the contract. The identification and delivery of new policyholders to the health insurance carriers is the only material promise specified within the contracts. After a policy is approved by the health insurance carrier, the Company has no material additional or recurring obligations to the policyholder or the health insurance carrier. The Company’s performance obligation is complete when a health insurance carrier has received and approved an insurance application. The Company’s contracts do not include downstream policyholder activities such as claims support or payment collection services. The transaction price is identified as the first-year commission due upon the initial approval of a policy as well as an estimate of renewal commission, which we define collectively as the Lifetime value of commissions. Commissions earned are determined based on the health insurance carrier, where the insured is based, and the month in which the policy becomes effective. The commissions are based on contractually agreed upon rate cards for which guidance and ranges are set by the regulatory body – Centers for Medicare and Medicaid Services (“CMS”). To estimate LTV, the Company utilizes the expected value approach. This approach incorporates historical lapse experience and effective commission rates, an estimate of chargebacks for paid policies that are disenrolled in the first policy year, and forecasted renewal commissions. The estimate of initial and renewal commissions is considered variable consideration and requires significant judgment in determining the number of approved policies that will become disenrolled and the number of periods in which policyholders will remain enrolled. We apply a constraint on our estimate of renewal commissions based on historical experience so that it is probable that a significant reversal in the amount of cumulative revenue will not occur. The uncertainty associated with the variable consideration is subsequently resolved each period the policy remains enrolled or renews. The Company recognizes the expected Lifetime value of commission revenue by applying the use of a portfolio approach to policies grouped together by the health insurance carrier, Medicare product type, and period the policy was approved by the health insurance carrier (referred to as a “cohort”). This approach to estimating the commissions expected to be collected for each cohort involves the evaluation of various factors, including but not limited to, contracted commission rates, disenrollment experience and renewal persistency rates. We recognize revenue for approved applications during the period by applying the latest estimated constrained LTV. We recognize adjustments to revenue for approved applications in prior periods when our cash collections are, or are expected to be, different from the estimated constrained LTVs, which we refer to as tail adjustments. Tail adjustments to revenue occur when actual cash collections or communicated rate increases have indicated a trend that is different from the estimated constrained LTV. Tail adjustments to revenue can be positive or negative and we recognize positive adjustments to revenue when we do not believe it is probable that a significant reversal of cumulative revenue will occur. Marketing Development Revenues. As a result of the acquisition of e-TeleQuote, the Company earns marketing development revenues for selling Medicare-related insurance products on behalf of health insurance carriers, which is recorded in Other, net revenue. Distribution of Other Third-party Financial Products. We distribute various other financial products on behalf of third parties to consumers. We receive upfront commissions and/or renewal commissions from product providers for sales of other financial product sales we have arranged. We recognize revenue at the point in time our performance obligation to product providers is satisfied, which is generally on the date the financial product is purchased by the consumer from the product provider. For certain financial products, most notably prepaid legal subscriptions and auto and homeowners’ insurance referrals, we receive ongoing renewal commissions that coincide with recurring payments received by product providers from active subscribers or policyholders. Ongoing renewal commissions represent variable consideration that will not be resolved until after the reporting period in which our performance obligation has been satisfied. We estimate variable consideration in the transaction price for these financial products (with the exception of miscellaneous products for which we expect nominal ongoing commissions) as the expected amount of commissions to be received over the life of the subscription or referred policy and apply a constraint so that it is probable that a subsequent change in estimate will not result in a significant revenue reversal. Management judgment primarily is required to determine the average life of a subscription or referred policy, which we establish based on historical information. We recognize variable consideration in excess of the amount constrained in subsequent reporting periods when the uncertainty is resolved and the excess amounts are due from the product providers. Revenue for Other Services. We recognize revenue from the sale of other miscellaneous products and services, including monthly subscription fees from the sales representatives for access to POL, upon the transfer of the promised product or service. For POL subscriptions, we satisfy our performance obligation by providing subscribers access to the promised services over time during each monthly subscription period. Revenue recognized from the sale of other miscellaneous products and services becomes known and charged at the same time we satisfy the corresponding performance obligation. Renewal Commissions Receivable. For revenue associated with ongoing renewal commissions in the Senior Health and Corporate and Other Distributed Products segments, we record a renewal commission receivable asset for the amount of ongoing renewal commissions we anticipate collecting in reporting periods subsequent to the satisfaction of the performance obligation, less amounts that are constrained in the accompanying consolidated balance sheets. Activity in the Renewal commissions receivable account was as follows: December 31, 2022 December 31, 2021 (In thousands) Senior Health segment: Balance, beginning of period $ 172,308 $ - Contract balances acquired as part of business combination - 199,575 Measurement period adjustment ( 11,863 ) ( 46,128 ) Commissions revenue 42,628 37,225 Less: collections ( 40,740 ) ( 13,442 ) Tail revenue adjustment from change in estimate ( 22,934 ) ( 4,922 ) Balance, at the end of period $ 139,399 $ 172,308 Corporate and Other Distributed Products segment: Balance, beginning of period $ 59,443 $ 54,845 Commissions revenue 25,325 27,618 Less: collections ( 24,124 ) ( 23,020 ) Balance, at the end of period $ 60,644 $ 59,443 Incremental costs to obtain or fulfill contracts, most notably sales commissions to the sales representatives, are not incurred prior to the recognition of the related revenue. Therefore, we have no assets recognized for incremental costs to obtain or fulfill contracts.

Leases

Leases	12 Months Ended
	Dec. 31, 2022
Lessee Disclosure [Abstract]
Leases	(19) Leases We have operating leases for our executive office operations and other real estate leases of office space and finance leases for certain office equipment. Our leases have remaining lease terms of 1 year to 8 years, some of which include options to extend the leases for up to 10 years, and some of which include options to terminate the leases within 1 year, exercisable at the Company’s discretion. Operating lease right-of-use assets and operating lease liabilities are presented separately in our consolidated balance sheets. As of December 31, 2022 and December 31, 2021 , finance lease right-of-use assets of $ 0.7 million and $ 1.0 million, respectively, and finance lease liabilities of $ 0.8 million and $ 1.0 million, respectively, were recorded within Other assets and Other liabilities within our consolidated balance sheets. The Company determines its lease liabilities, which are measured at the present value of future lease payments, using the Company’s incremental secured borrowing rate that is commensurate with the term of the underlying lease or the rate implicit in the lease if readily determinable. The components of lease expense were as follows: Year ended December 31, 2022 2021 2020 (In thousands) Operating lease cost Operating lease cost $ 9,686 $ 8,620 $ 7,638 Variable lease cost (includes taxes, common area maintenance and insurance) 1,099 980 725 Finance lease cost Depreciation of finance lease assets 271 280 280 Interest on lease liabilities 55 60 56 Total lease cost $ 11,111 $ 9,940 $ 8,699 Other information related to leases was as follows: December 31, 2022 December 31, 2021 December 31, 2020 (In thousands) Supplemental Cash Flows Information Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows used in operating leases (1) $ 9,960 $ 8,878 $ 7,737 Operating cash flows used in finance leases (1) 55 60 56 Financing cash flows used in finance leases 262 264 274 (1) Included in change in other operating assets and liabilities, net in the accompanying consolidated statements of cash flows. December 31, 2022 December 31, 2021 (In thousands) Weighted Average Remaining Lease Term Operating leases 6 years 6 years Finance leases 3 years 4 years Weighted Average Discount Rate Operating leases 4.2 % 4.1 % Finance leases 6.0 % 6.2 % Future minimum lease payments under non-cancellable leases were as follows: Operating Leases Finance Leases Year Ended December 31, (In thousands) 2023 $ 10,009 $ 302 2024 9,745 269 2025 8,446 192 2026 8,199 78 2027 8,098 - Thereafter 7,290 - Total minimum rental commitments for operating leases 51,787 841 Less imputed interest 5,792 66 Total lease liabilities $ 45,995 $ 775

Acquisition

Acquisition	12 Months Ended
	Dec. 31, 2022
Business Combinations [Abstract]
Acquisition	(20) Acquisition On July 1, 2021 , the Company acquired an 80 % interest, as described in the next paragraph, in the operating subsidiaries of Etelequote Bermuda, including e-TeleQuote, a Florida corporation that is a senior health insurance distributor of Medicare-related insurance policies in all 50 states and Puerto Rico (the “Acquisition”). The Company’s subsidiary, Primerica Health, purchased from the shareholders of Etelequote Bermuda 100 % of the issued and outstanding capital stock of e-TeleQuote and its subsidiaries for consideration of (i) approximately $ 350 million in cash, (ii) replacement of e-TeleQuote’s debt as of the closing date of $ 146 million with intercompany funding provided by the Parent Company, (iii) a $ 15 million majority shareholder note and (iv) common shares of Primerica Health constituting 20 % of the total issued and outstanding shares of capital stock of Primerica Health that were issued to Etelequote Bermuda’s minority shareholders, most of which included or were beneficially owned by e-TeleQuote’s management (“noncontrolling equity holders”). The cash consideration provided was subsequently reduced by $ 3.9 million as a result of the final purchase price agreed upon with the sellers following finalization of the closing statement. In connection with the Company’s acquisition of 80% of e-TeleQuote on July 1, 2021 (the “Acquisition Date”), the Company entered into a Shareholders’ Agreement with the noncontrolling equity holders of Primerica Health. Under the terms of the Shareholders’ Agreement, the Company agreed to purchase, and the noncontrolling equity holders agreed to sell, the remaining 20 % stake over a period of up to four years through a series of call and put rights. The Shareholders’ Agreement provided for the purchase of the noncontrolling equity holders’ equity interests in Primerica Health at a contractually defined Formulaic Price, which was based on a discounted calculation of selected peer company equity value multiples times the trailing twelve months of Adjusted EBITDA reduced by the balance of intercompany debt owed by e-TeleQuote to the Parent Company. Effective July 1, 2022 , the Company executed its call option to acquire the remaining 20 % of Primerica Health. The Formulaic Price calculation resulted in a purchase price of zero . As such, no further consideration was required to obtain the outstanding 20% stake in Primerica Health and the noncontrolling interest in the Company's consolidated financial statements was redeemed. The following table presents the preliminary purchase price allocation recorded in the Company’s consolidated balance sheets as of the Acquisition Date, adjustments made during the measurement period that ended June 30, 2022, and the final purchase price allocation: Preliminary Purchase Price Allocation 2021 Measurement Period Adjustments 2022 Measurement Period Adjustments Revised Preliminary Purchase Price Allocation (In thousands) Assets: Cash and cash equivalent $ 1,080 $ - $ - $ 1,080 Accounts receivables 692 ( 389 ) - 303 Renewal commissions receivable 199,575 ( 46,128 ) ( 11,863 ) 141,584 Other assets 15,705 - - 15,705 Intangible assets 162,000 ( 6,000 ) - 156,000 Goodwill 224,180 30,973 8,553 263,706 Total assets $ 603,232 $ ( 21,544 ) $ ( 3,310 ) $ 578,378 Liabilities: Accounts payable and accrued expenses 8,785 ( 4,195 ) (1) - 4,590 Deferred tax liability 65,425 ( 13,482 ) ( 3,310 ) 48,633 Other liabilities 10,046 - - 10,046 Total liabilities 84,256 ( 17,677 ) ( 3,310 ) 63,269 Net assets acquired $ 518,976 $ ( 3,867 ) $ - $ 515,109 Temporary Stockholders' Equity: Redeemable noncontrolling interests $ 8,437 $ - $ - $ 8,437 Total temporary stockholders' equity $ 8,437 $ - $ - $ 8,437 (1) The Company also recognized an adjustment during the measurement period to reclassify certain amounts from a payable to a reduction in the renewal commissions receivable. Renewal commissions receivable from the acquired business was recognized in accordance with Accounting Standards Codification Topic 606, Revenue from Contracts with Customers (“ASC 606” ) as the Company adopted Accounting Standards Update No. 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (“ASU 2021-08”). ASU 2021-08 requires contract assets arising from revenue contracts with customers to be accounted for in accordance with ASC 606 instead of at fair value. During the measurement period, the Company made two adjustments to renewal commissions receivable as of the Acquisition Date. The adjustments, which were booked in 2021 and 2022, resulted from the Company’s reassessment of the estimates made by e-TeleQuote for the variable consideration expected for approved policies as of the Acquisition Date. The reassessment of estimates involved the implementation of an enhanced algorithmic model for processing historical lapse data and forecasting future policy duration curves. In addition, the Company revised the estimate for renewal commission rate escalation assumptions in accordance with its accounting policy for determining constraints of variable consideration. As a result, the Company recognized a purchase price allocation adjustment to decrease renewal commissions receivable and deferred tax liability with a corresponding increase to goodwill. Intangible assets identified in the acquisition of the business are capitalized separately from goodwill if the fair value can be measured reliably on initial recognition (transaction date). The primary intangible assets identified were customer relationships with health insurance carriers of $ 153.0 million with an estimated useful life of 15 years. The Company will amortize the intangible assets acquired on a straight-line basis over their estimated useful lives. During the measurement period, the Company revised long-term growth rates used in the cash flow projections that support the intangibles valuation. As a result, the Company recognized a purchase price allocation adjustment to decrease intangible assets and deferred tax liability with a corresponding increase to goodwill. Goodwill is calculated as the difference between the acquisition date fair value of the total consideration transferred and the aggregate values assigned to the assets acquired and liabilities assumed. The amount of goodwill calculated as of the Acquisition Date determined by the final purchase price allocation was $ 263.7 million. The goodwill created in the acquisition is not deductible for tax purposes. Refer to Note 21 (Goodwill) for more information regarding the valuation of goodwill. Transaction costs related to the e-TeleQuote acquisition included within Other operating expenses on the consolidated statements of income was $( 2.0 ) million and $ 12.9 million for the years ended December 31, 2022 and 2021, respectively. The following unaudited pro forma consolidated financial information combines the audited results of the Company for the years ended December 31, 2021 and 2020 and the unaudited results of e-TeleQuote for the year ended December 31, 2021 and 2020, and assumes that the Acquisition, which closed on July 1, 2021, was completed on January 1, 2020 (the first day of fiscal year 2020). The pro forma consolidated financial information has been calculated after applying adjustments for amortization expense of acquired intangible assets and the consequential tax effect. These pro forma results have been prepared for comparative purpose only and do not purport to be indicative of the operating results of the Company that would have been achieved had the e-TeleQuote acquisition actually taken place on January 1, 2020. Year ended December 31, 2021 2020 (in thousands) Revenue $ 2,774,991 $ 2,369,811 Net income (loss) 361,783 391,527

Goodwill

Goodwill	12 Months Ended
	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	(21) Goodwill During the annual impairment test as of July 1, 2022, the Company performed a quantitative impairment analysis using the income approach by preparing a discounted cash flow analysis to determine the reporting unit’s fair value. The discounted cash flow analysis included key assumptions such as the weighted average cost of capital (“WACC ” ), long-term growth rate and projected operating results such as approved policies, lifetime value of commissions, contract acquisition costs, operating expenses, collections of renewal commissions receivable, and utilization of net operating losses for income tax purposes. We did not utilize a market approach as part of the quantitative impairment analysis as we believe management’s expectations of the cash flow generated by the reporting unit were more relevant in determining fair value given inherent limitations in the credibility of available peer company data. The measurement of the reporting unit’s fair value is classified as a Level 3 fair value measurement given the significance of the unobservable inputs such as forecasted operating results and discount rates. After the fair value of the reporting unit was determined, the Company calculated its carrying value by taking the reporting unit’s assets minus its liabilities. The carrying value of the reporting unit was then compared to its fair value to determine the extent of any goodwill impairment. Based on this analysis, we recognized a non-cash goodwill impairment charge of $ 60.0 million during 2022, which represents the excess of the Senior Health reporting unit’s carrying value over its estimated fair value at July 1, 2022. The goodwill impairment charge recognized did not impact the Company’s income tax expense as the goodwill acquired from the Acquisition does not have any tax basis. The decline in the reporting unit's fair value below its carrying value was primarily attributable to an increase in the market-based WACC used to discount the forecasted cash flows. The increase in the WACC was driven by recent increases in the equity market risk premium and higher interest rates. The determination of whether the carrying value of the reporting unit exceeds its fair value involves a high degree of estimation and can be affected by a number of industry and company-specific risk factors that are subject to change over time. At December 31, 2022, the Company had goodwill of $ 127.7 million in its Senior Health reporting unit after accumulated goodwill impairment charges since the Acquisition Date of $ 136.0 million.

Schedule I Summary of Investmen

Schedule I Summary of Investments - Other Than Investments in Related Party	12 Months Ended
	Dec. 31, 2022
Debt Securities [Abstract]
Consolidated Summary of Investments-Other than Investments in Related Parties	Sc hedule I Consolidated Summary of Investments — Other Than Investments in Related Parties PRIMERICA, INC. December 31, 2022 Type of Investment Cost Fair value Amount at which shown in the balance sheet (In thousands) Fixed maturities: Bonds (1) : United States government and government agencies and authorities $ 111,419 $ 105,841 $ 105,841 States, municipalities, and political subdivisions 142,189 122,245 122,245 Foreign governments 163,725 152,915 152,915 All other corporate bonds (1) 3,828,276 3,454,656 3,559,311 Certificates of deposit 176 176 176 Redeemable preferred stocks 4,248 3,586 3,586 Total fixed maturities 4,250,033 3,839,419 3,944,074 Equity securities: Common stocks: Public utilities 6,469 9,719 9,719 Banks, trusts and insurance companies 13,934 13,979 13,979 Industrial, miscellaneous and all other 7,189 10,739 10,739 Nonredeemable preferred stocks 1,838 967 967 Total equity securities 29,430 35,404 35,404 Policy loans and other invested assets 48,713 48,713 48,713 Short-term investments 69,393 69,406 69,406 Total investments $ 4,397,569 $ 3,992,942 $ 4,097,597 (1) The amount shown on the consolidated balance sheet does not match the amortized cost or cost or fair value for “All other corporate bonds” due to our held-to-maturity security, which is carried at cost on the consolidated balance sheet and all other fixed maturities are carried at fair value. See the report of independent registered public accounting firm.

Schedule II - Condensed Financi

Schedule II - Condensed Financial Information Of Registrant	12 Months Ended
	Dec. 31, 2022
Condensed Financial Information Of Parent Company Only Disclosure [Abstract]
Condensed Financial Information of Registrant	Sc hedule II Condensed Financial Information of Registrant PRIMERICA, INC. (Parent Only) Condensed Balance Sheets December 31, 2022 2021 (In thousands) Assets Investments: Fixed-maturity securities available-for-sale, at fair value (amortized cost: 112,052 in 2022 and $ 107,969 in 2021) $ 107,538 $ 109,547 Short-term investments available-for-sale, at fair value (amortized cost: $ 39,270 in 85,246 in 2021) 39,285 85,243 Equity securities, at fair value (historical cost: $ 2,517 in 2022 and $ 2,486 in 2021) 2,572 3,059 Total investments 149,395 197,849 Cash and cash equivalents 157,462 97,513 Due from affiliates* 9,825 184,733 Other receivables 785 4,348 Income tax receivable 493 4,330 Deferred income taxes 6,902 8,475 Investment in subsidiaries* 1,994,309 2,190,437 Other assets 946 1,005 Total assets $ 2,320,117 $ 2,688,690 Liabilities and Stockholders’ Equity Liabilities: Notes payable 592,905 592,102 Deferred income taxes 2,434 2,482 Interest payable 1,913 1,913 Other liabilities 1,366 2,410 Commitments and contingent liabilities (see Note F) Total liabilities 598,618 598,907 Temporary Stockholders' Equity Redeemable noncontrolling interests in consolidated entities - 7,271 Permanent Stockholders' Equity Equity attributable to Primerica, Inc.: Common stock ($ 0.01 par value; authorized 500,000 in 2022 and 2021; issued and 36,824 shares in 2022 and 39,368 shares in 2021) 368 394 Paid-in capital - 5,224 Retained earnings 1,973,403 2,004,506 Accumulated other comprehensive income, net of income tax ( 252,272 ) 72,388 Total permanent stockholders’ equity 1,721,499 2,082,512 Total liabilities and temporary and permanent stockholders’ equity $ 2,320,117 $ 2,688,690 * Eliminated in consolidation. See the accompanying notes to condensed financial statements. See the report of independent registered public accounting firm. Schedule II Condensed Financial Information of Registrant PRIMERICA, INC. (Parent Only) Condensed Statements of Income Year ended December 31, 2022 2021 2020 (In thousands) Revenues: Dividends from subsidiaries* $ 450,929 $ 387,355 $ 378,063 Net investment income 3,916 1,503 3,670 Realized investment gains (losses) 872 115 112 Other investment gains (losses) ( 519 ) 259 63 Investment gains (losses), including credit losses 353 374 175 Total revenues 455,198 389,232 381,908 Expenses: Interest expense, net 11,066 15,675 18,673 Loss on extinguishment of debt - 8,927 - Other operating expenses 13,358 26,421 13,903 Total expenses 24,424 51,023 32,576 Income before income taxes 430,774 338,209 349,332 Income taxes ( 1,504 ) ( 5,786 ) ( 3,540 ) Income before equity in undistributed earnings of subsidiaries 432,278 343,995 352,872 Equity in undistributed earnings of subsidiaries* ( 59,266 ) 29,362 33,292 Net income $ 373,012 $ 373,357 $ 386,164 * Eliminated in consolidation. See the accompanying notes to condensed financial statements. See the report of independent registered public accounting firm. Schedule II Condensed Financial Information of Registrant PRIMERICA, INC. (Parent Only) Condensed Statements of Comprehensive Income Year ended December 31, 2022 2021 2020 (In thousands) Net income $ 373,012 $ 373,357 $ 386,164 Other comprehensive income (loss) before income taxes: Unrealized investment gains (losses): Equity in unrealized holding gains (losses) on investment securities ( 299,847 ) ( 63,089 ) 62,618 Change in unrealized holding gains (losses) on investment securities ( 5,201 ) ( 1,483 ) 1,372 Reclassification adjustment for realized investment (gains) losses ( 872 ) ( 115 ) ( 175 ) Foreign currency translation adjustments: Equity in unrealized foreign currency translation gains (losses) of subsidiaries ( 20,015 ) 7,033 7,343 Total other comprehensive income (loss) before income taxes ( 325,935 ) ( 57,654 ) 71,158 Income tax expense (benefit) related to items of other comprehensive ( 1,275 ) ( 336 ) 250 Other comprehensive income (loss), net of income taxes ( 324,660 ) ( 57,318 ) 70,908 Total comprehensive income $ 48,352 $ 316,039 $ 457,072 See the accompanying notes to condensed financial statements. See the report of independent registered public accounting firm. Schedule II Condensed Financial Information of Registrant PRIMERICA, INC. (Parent Only) Condensed Statements of Cash Flows Year ended December 31, 2022 2021 2020 (In thousands) Cash flows from operating activities: Net income $ 373,012 $ 373,357 $ 386,164 Adjustments to reconcile net income to cash provided by (used in) operating activities: Equity in undistributed earnings of subsidiaries* (1) 29,960 ( 283 ) ( 42,030 ) Deferred tax provision 2,800 ( 3,751 ) 2,553 Change in income taxes 3,837 ( 1,696 ) ( 1,607 ) Investment (gains) losses ( 353 ) ( 374 ) ( 175 ) Accretion and amortization of investments 205 1,448 1,777 Share-based compensation 1,592 1,559 1,447 Change in due to/from affiliates* (2) 4,458 ( 34,886 ) ( 2,580 ) Trading securities sold, matured, or called (acquired), net - - ( 6 ) Change in other operating assets and liabilities, net 1,967 ( 9,519 ) 3,030 Loss on extinguishment of debt - 8,927 - Net cash provided by (used in) operating activities 417,478 334,782 348,573 Cash flows from investing activities: Available-for-sale investments sold, matured or called: Fixed maturity securities — sold 409 - 26,256 Fixed-maturity securities — matured or called 94,960 91,710 131,894 Short-term investments —sold - 50,065 - Short-term investments — matured or called 85,302 40,000 - Equity securities — sold 16 718 212 Available-for-sale investments acquired: Fixed-maturity securities (1) ( 57,762 ) ( 84,564 ) ( 36,190 ) Short-term investments ( 39,090 ) ( 176,125 ) - Equity securities acquired ( 7 ) ( 1,155 ) ( 76 ) Purchase of business, net of cash acquired 3,867 ( 494,459 ) - Net cash provided by (used in) investing activities 87,695 ( 573,810 ) 122,096 Cash flows from financing activities: Dividends paid ( 83,783 ) ( 74,636 ) ( 64,346 ) Common stock repurchased ( 356,306 ) ( 18,751 ) ( 231,431 ) Proceeds from revolving credit facility - 125,000 - Repayment of revolving credit facility - ( 125,000 ) - Proceeds from issuance of debt - 597,300 - Debt issuance costs - ( 5,332 ) - Repayment of debt - ( 383,691 ) - Tax withholdings on share-based compensation ( 5,135 ) ( 6,652 ) ( 5,739 ) Net cash provided by (used) in financing activities ( 445,224 ) 108,238 ( 301,516 ) Change in cash and cash equivalents 59,949 ( 130,790 ) 169,153 Cash and cash equivalents, beginning of period 97,513 228,303 59,150 Cash and cash equivalents, end of period $ 157,462 $ 97,513 $ 228,303 Supplement disclosures: Interest paid $ 17,053 $ 20,150 $ 18,118 * Eliminated in consolidation. (1) Does not include $ 41.3 million and $ 33.6 million of fixed-maturity securities transferred from subsidiaries in the form of noncash dividend for the years ended December 31, 2022 and 2020, respectively. There were no fixed-maturity securities transferred from subsidiaries in the form of noncash dividends for the year ended December 31, 2021. (2) Does not include $ 170.5 million reduction in due from affiliates for the conversion of a subsidiary note to an equity contribution in that subsidiary during the year ended December 31, 2022. See the accompanying notes to condensed financial statements. See the report of independent registered public accounting firm. Schedule II Condensed Financial Information of Registrant PRIMERICA, INC. (Parent Only) Notes to Condensed Financial Statements (A) Description of Business Primerica, Inc. (“we”, “us” or the “Company”) is a holding company with our primary asset being the capital stock of our wholly owned operating subsidiaries, and our primary liability being $ 600.0 million in principal amount of senior unsecured notes issued in a public offering in 2021 (the “Senior Notes”). Our subsidiaries assist clients in meeting their needs for term life insurance, which our insurance subsidiaries underwrite, and mutual funds, annuities, managed investments and other financial products, which our subsidiaries distribute primarily on behalf of third parties. We acquired 80 % of e-TeleQuote Insurance, Inc. and subsidiaries (collectively, “e-TeleQuote”) through our subsidiary, Primerica Health, Inc. on July 1, 2021 and the remaining 20 % of e-TeleQuote on July 1, 2022 . e-TeleQuote markets Medicare-related insurance products underwritten by third-party health insurance carriers to eligible Medicare participants through its licensed health insurance agents. Our primary subsidiaries include the following entities: Primerica Financial Services, LLC, a general agency and marketing company; Primerica Life Insurance Company (“Primerica Life”), our principal life insurance company; PFS Investments Inc., an investment products company and broker-dealer; and Primerica Financial Services (Canada) Ltd., a holding company for our Canadian operations, which includes Primerica Life Insurance Company of Canada and PFSL Investments Canada Ltd. Primerica Life, domiciled in Tennessee, owns National Benefit Life Insurance Company, a New York insurance company. In addition, we established Peach Re, Inc. (“Peach Re”) and Vidalia Re, Inc. (“Vidalia Re”) as special purpose financial captive insurance companies domiciled in Vermont and wholly owned subsidiaries of Primerica Life. (B) Basis of Presentation These condensed financial statements reflect the results of operations, financial position and cash flows for the Company. We prepare our financial statements in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). These principles are established primarily by the Financial Accounting Standards Board. The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect financial statement balances, revenues and expenses and cash flows, as well as the disclosure of contingent assets and liabilities. Management considers available facts and knowledge of existing circumstances when establishing the estimates included in our financial statements. The most significant item that involves a greater degree of accounting estimates subject to change in the future is the determination of our investments in subsidiaries. Estimates for this and other items are subject to change and are reassessed by management in accordance with U.S. GAAP. Actual results could differ from those estimates. The accompanying condensed financial statements should be read in conjunction with the consolidated financial statements and notes thereto of Primerica, Inc. and subsidiaries included in Part II, Item 8 of this report. (C) Note Payable Notes Payable – Long term. As of December 31, 2022, we had $ 600.0 million in principal amount of publicly-traded, senior unsecured notes (the “Senior Notes”). The Senior Notes were issued in November 2021 at a price of 99.550 % of the principal amount with an annual interest rate of 2.80 %, payable semi-annually in arrears on May 19 and November 19, and are scheduled to mature on November 19, 2031 . As of December 31, 2022, we were in compliance with the covenants of the Senior Notes. No events of default occurred on the Senior Notes during the year ended December 31, 2022. As unsecured senior obligations, the Senior Notes rank equally in right of payment with all existing and future unsubordinated indebtedness and senior to all existing and future subordinated indebtedness of the Company. The Senior Notes are structurally subordinated in right of payment to all existing and future liabilities of our subsidiaries. In addition, the Senior Notes contain covenants that restrict our ability to, among other things, create or incur any indebtedness that is secured by a lien on the capital stock of certain of our subsidiaries, and merge, consolidate or sell all or substantially all of our properties and assets. (D) Revolving Credit Facility On June 22, 2021, we amended and restated our unsecured $ 200.0 million revolving credit facility (“Revolving Credit Facility”) with a syndicate of commercial banks. The Revolving Credit Facility has a scheduled termination date of June 22, 2026. Amounts outstanding under the Revolving Credit Facility are borrowed, at our discretion, on the basis of either a LIBOR rate loan, or a base rate loan. LIBOR rate loans bear interest at a periodic rate equal to one-, three-, six-, or 12-month LIBOR, plus an applicable margin. Base rate loans bear interest at the highest of (a) the Prime Rate, (b) the Federal Funds Rate plus 0.50% and (c) one-month LIBOR plus 1.00%, plus an applicable margin. The Revolving Credit Facility contains language providing for a benchmark replacement in the event that LIBOR is no longer available. The Revolving Credit Facility also permits the issuance of letters of credit. The applicable margins are based on our debt rating with such margins for LIBOR rate loans and letters of credit ranging from 1.00 % to 1.625 % per annum and for base rate loans ranging from 0.00 % to 0.625 % per annum. Under the Revolving Credit Facility, we incur a commitment fee that is payable quarterly in arrears and is determined by our debt rating. This commitment fee ranges from 0.10 % to 0.225 % per annum of the aggregate amount of the $ 200.0 million commitment of the lenders under the Revolving Credit Facility that remains undrawn. During the year ended December 31, 2022, no amounts were drawn under the Revolving Credit Facility. As of December 31, 2022, we were in compliance with the covenants of the Revolving Credit Facility. Furthermore, no events of default occurred under the Revolving Credit Facility during the year ended December 31, 2022. (E) Dividends For the years ended December 31, 2022, 2021, and 2020, the Company received dividends from our non-life insurance subsidiaries of $ 173.0 million, $ 217.1 million, and $ 185.5 million, respectively. For the years ended December 31, 2022, 2021, and 2020, the Company received dividends from our life insurance subsidiaries of $ 277.9 million, $ 170.2 million, and $ 192.5 million, respectively. (F) Commitments and Contingent Liabilities Peach Re and Vidalia Re have each entered into separate coinsurance agreements with Primerica Life whereby Primerica Life has ceded certain level-premium term life insurance policies to Peach Re and Vidalia Re. In conjunction with these coinsurance agreements, we have capital maintenance agreements with both Peach Re and Vidalia Re. Each capital maintenance agreement may require us at times to make capital contributions to Peach Re and Vidalia Re to ensure that their regulatory accounts, as defined in the coinsurance agreements with Primerica Life, will not be less than $ 20.0 million for each financial captive insurance company. For Peach Re, the regulatory account will only be used to satisfy obligations under its coinsurance agreement after all other available assets have been used, including a letter of credit issued by Deutsche Bank for the benefit of Primerica Life. For Vidalia Re, the regulatory account will only be used to satisfy obligations under its coinsurance agreement after all other available assets have been used, including its held-to-maturity security ultimately guaranteed by Hannover Life Reassurance Company of America. The Company is involved from time-to-time in legal disputes, regulatory inquiries and arbitration proceedings in the normal course of business. These disputes are subject to uncertainties, including large and/or indeterminate amounts sought in certain of these matters and the inherent unpredictability of litigation. As such, the Company is unable to estimate the possible loss or range of loss that may result from these matters.

Schedule III - Supplementary In

Schedule III - Supplementary Insurance Information	12 Months Ended
	Dec. 31, 2022
Supplementary Insurance Information [Abstract]
Supplementary Insurance Information	Schedu le III Supplementary Insurance Information PRIMERICA, INC. Deferred policy acquisition costs Future policy benefits Unearned and advance premiums Policy claims and other benefits payable Separate account liabilities (In thousands) December 31, 2022 Term Life Insurance $ 3,008,330 $ 7,181,525 $ 14,992 $ 525,877 $ - Investment and Savings Products 53,127 - - - 2,305,688 Senior Health - - - - - Corporate and Other Distributed Products 20,429 209,275 430 12,373 29 Total $ 3,081,886 $ 7,390,800 $ 15,422 $ 538,250 $ 2,305,717 December 31, 2021 Term Life Insurance $ 2,859,758 $ 6,927,789 $ 15,982 $ 573,316 $ - Investment and Savings Products 62,278 - - - 2,799,954 Senior Health - - - - - Corporate and Other Distributed Products 21,746 210,860 455 12,066 38 Total $ 2,943,782 $ 7,138,649 $ 16,437 $ 585,382 $ 2,799,992 Premium revenue Net investment income Benefits and claims Amortization of deferred policy acquisition costs Other operating expenses Premiums written (In thousands) Year ended December 31, 2022 Term Life Insurance $ 1,585,646 $ 51,160 $ 649,530 $ 342,925 $ 246,131 $ - Investment and Savings Products - - - 12,141 611,961 - Senior Health - - - - 161,355 - Corporate and Other Distributed Products 14,582 41,905 16,219 1,077 185,045 602 Total $ 1,600,228 $ 93,065 $ 665,749 $ 356,143 $ 1,204,492 $ 602 Year ended December 31, 2021 Term Life Insurance $ 1,490,230 $ 36,486 $ 703,897 $ 241,451 $ 215,719 $ - Investment and Savings Products - - - 8,668 658,595 - Senior Health - - - - 145,490 - Corporate and Other Distributed Products 15,654 44,102 18,856 1,060 204,825 670 Total $ 1,505,884 $ 80,588 $ 722,753 $ 251,179 $ 1,224,629 $ 670 Year ended December 31, 2020 Term Life Insurance $ 1,309,661 $ 27,030 $ 593,948 $ 216,208 $ 200,063 $ - Investment and Savings Products - - - 7,055 509,167 - Corporate and Other Distributed Products 16,722 56,784 21,621 1,058 161,691 701 Total $ 1,326,383 $ 83,814 $ 615,569 $ 224,321 $ 870,921 $ 701 See the report of independent registered public accounting firm.

Schedule IV - Reinsurance

Schedule IV - Reinsurance	12 Months Ended
	Dec. 31, 2022
Schedule Iv Reinsurance [Abstract]
Reinsurance	S chedule IV Reinsurance PRIMERICA, INC. Year ended December 31, 2022 Gross amount Ceded to other companies Assumed from other companies Net amount Percentage of amount assumed to net (Dollars in thousands) Life insurance in force $ 919,081,738 $ 787,907,229 $ - $ 131,174,509 — % Premiums: Life insurance $ 3,229,229 $ 1,629,634 $ - $ 1,599,595 — % Accident and health insurance 891 258 - 633 — % Total premiums $ 3,230,120 $ 1,629,892 $ - $ 1,600,228 — % Year ended December 31, 2021 Gross amount Ceded to other companies Assumed from other companies Net amount Percentage of amount assumed to net (Dollars in thousands) Life insurance in force $ 905,819,671 $ 777,826,233 $ - $ 127,993,438 — % Premiums: Life insurance $ 3,121,167 $ 1,615,966 $ - $ 1,505,201 — % Accident and health insurance 981 298 - 683 — % Total premiums $ 3,122,148 $ 1,616,264 $ - $ 1,505,884 — % Year ended December 31, 2020 Gross amount Ceded to other companies Assumed from other companies Net amount Percentage of amount assumed to net (Dollars in thousands) Life insurance in force $ 861,392,223 $ 742,356,917 $ - $ 119,035,306 — % Premiums: Life insurance $ 2,906,083 $ 1,580,427 $ - $ 1,325,656 — % Accident and health insurance 1,066 339 - 727 — % Total premiums $ 2,907,149 $ 1,580,766 $ - $ 1,326,383 — %

Description of Business, Basi_2

Description of Business, Basis of Presentation, and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2022
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation. We prepare our financial statements in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). These principles are established primarily by the Financial Accounting Standards Board (“FASB”).
Use of Estimates	Use of Estimates. The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect financial statement balances, revenues and expenses and cash flows, as well as the disclosure of contingent assets and liabilities. Management considers available facts and knowledge of existing circumstances when establishing the estimates included in our financial statements. The most significant items that involve a greater degree of accounting estimates and actuarial determinations subject to change in the future are the valuation of investments, deferred policy acquisition costs (“DAC”), future policy benefit reserves and corresponding amounts recoverable from reinsurers, renewal commissions receivable, income taxes, and valuation of intangible assets and goodwill. Estimates for these and other items are subject to change and are reassessed by management in accordance with U.S. GAAP. Actual results could differ from those estimates.
Consolidation	Consolidation. The accompanying consolidated financial statements include the accounts of the Company and those entities required to be consolidated under U.S. GAAP. All material intercompany profits, transactions, and balances among the consolidated entities have been eliminated.
Reclassifications	Reclassifications. Certain reclassifications have been made to prior-period amounts to conform to current-period reporting classifications. These reclassifications had no impact on net income or total stockholders’ equity.
Foreign Currency Translation	Foreign Currency Translation. Assets and liabilities of our Canadian subsidiaries are translated into U.S. dollars using year-end exchange rates, and the translation adjustments are reported in other comprehensive income (loss). Revenues and expenses of our Canadian subsidiaries are translated monthly at amounts that approximate weighted-average exchange rates.
Investments	Investments. Investments are reported on the following bases: • Available-for-sale (“AFS”) fixed-maturity securities, including bonds and redeemable preferred stocks, are carried at fair value. • Our held-to-maturity fixed-maturity security is carried at amortized cost. • Equity securities, including common and nonredeemable preferred stocks, are carried at fair value. Changes in fair value of equity securities are included in realized investment gains (losses) in the period in which the change occurred. • Trading securities, which primarily consist of bonds held by PFS Investments, are carried at fair value. Changes in fair value of trading securities are included in realized investment gains (losses) in the period in which the change occurred. • Policy loans are carried at unpaid principal balances, which approximate fair value. Investment transactions are recorded on a trade-date basis. We use the specific-identification method to determine the realized gains or losses from securities transactions and report the investment gains or losses in the accompanying consolidated statements of income. Unrealized gains and losses on AFS securities are included as a separate component of other comprehensive income (loss), except for credit loss impairment discussed below, in the accompanying consolidated statements of comprehensive income. For an AFS security with an amortized cost that exceeds its fair value, we first determine if we intend to sell or will more-likely-than-not be required to sell the security before the expected recovery of its amortized cost. If we intend to sell or will more-likely-than-not be required to sell the security, then we recognize the impairment as a credit loss in our consolidated statements of income by writing down the security’s amortized cost to its fair value. If we do not intend to sell or it is not more-likely-than-not that we will be required to sell the security before the expected recovery of its amortized cost, we recognize the portion of the impairment that is due to a credit loss, if any, in our consolidated statement of income through an allowance. The portion of the impairment that is due to factors other than a credit loss is recognized in other comprehensive income in the consolidated statement of comprehensive income as an unrealized loss. Credit losses recognized in the allowance for credit losses are reversed in situations where the estimate of credit losses on those securities has declined. When determining whether an impairment is due to a credit loss or other factors, we determine the extent to which we do not expect to recover the security’s amortized cost and record such amount, if any, as a credit loss. Factors we consider in determining whether the security’s decline in fair value is below amortized cost due to a credit loss include the magnitude of the security’s decline in fair value below its amortized cost, the financial condition, long and near-term prospects for the issuer, industry conditions and trends, rating agency actions, the payment structure of the security, likelihood of the recoverability of principal and interest, and our ability and intent to hold the security for a period of time sufficient to allow for the anticipated recovery of its amortized cost. In assessing our ability and intent to hold the security for a period of time to allow for the anticipated recovery of its amortized cost, we also consider our anticipated sources of cash to fund operating activities and share repurchases. If we do not anticipate recovering a security’s amortized cost basis, we estimate the present value of the security’s expected cash flows and recognize the difference from amortized cost (using fair value as a floor) as a credit loss. Interest income on fixed-maturity securities is recorded when earned by determining the effective yield, which gives consideration to amortization of premiums, accretion of discounts, and any previous credit losses. Dividend income on equity securities is recorded when declared. These amounts are included in net investment income in the accompanying consolidated statements of income. Included within fixed-maturity securities are loan-backed and asset-backed securities. Amortization of the premium or accretion of the discount uses the retrospective method. The effective yield used to determine amortization/accretion is calculated based on actual and historical projected future cash flows and updated quarterly.
Cash and Cash Equivalents	Cash and Cash Equivalents. Cash and cash equivalents include cash on hand, money market instruments, and all other highly liquid investments purchased with an original or remaining maturity of three months or less at the date of acquisition.
Reinsurance	Reinsurance. We use reinsurance extensively, utilizing yearly renewable term (“YRT”) and coinsurance agreements. Under YRT agreements, we reinsure only the mortality risk, while under coinsurance, we reinsure a proportionate part of all risks arising under the reinsured policy. Under coinsurance, the reinsurer receives a proportionate part of the premiums, less commission allowances, and is liable for a corresponding part of all benefit payments. All reinsurance contracts in effect for the three-year period ended December 31, 2022 transfer a reasonable possibility of substantial loss to the reinsurer or are accounted for under the deposit method of accounting. Ceded premiums are treated as a reduction to direct premiums and are recognized when due to the assuming company. Ceded claims are treated as a reduction to direct benefits and are recognized when the claim is incurred on a direct basis. Ceded policy reserve changes are also treated as a reduction to benefits and claims expense and are recognized during the applicable financial reporting period. Reinsurance premiums, commissions, expense reimbursements and benefits and reserves related to reinsured long-duration contracts are accounted for over the life of the underlying contracts using assumptions consistent with those used to account for the underlying policies. Amounts recoverable from reinsurers are estimated in a manner consistent with the claim liabilities and future policy benefits associated with reinsured policies. Ceded policy reserves and claims liabilities relating to insurance ceded are shown as reinsurance recoverables on the accompanying consolidated balance sheets. We analyze and monitor the credit-worthiness of each of our reinsurance partners to minimize collection issues. For reinsurance contracts with unauthorized reinsurers, we require collateral such as letters of credit. To the extent we receive ceding allowances to cover policy and claims administration under reinsurance contracts, these allowances are treated as a reduction to insurance commissions and expenses and are recognized when due from the assuming company. To the extent we receive ceding allowances reimbursing commissions that would otherwise be deferred, the amount of commissions deferrable will be reduced. The corresponding DAC balances are reduced on a pro rata basis by the portion of the business reinsured with reinsurance agreements that meet risk transfer provisions. The reduced DAC will result in a corresponding reduction of amortization expense. We estimate and recognize lifetime expected credit losses for reinsurance recoverables. In estimating the allowance for expected credit losses for reinsurance recoverables, we factor in the underlying collateral for reinsurance agreements where available. Specifically, for reinsurers with underlying trust assets, we compare the reinsurance recoverables balance to the underlying trust assets that mitigate the potential exposure to credit losses. We also analyze the financial condition of the reinsurers, as determined by third-party rating agencies, to determine the probability of default for the reinsurers. We then utilize a third-party credit default study to calculate an expected credit loss given default rate or recovery rate. The probability of default and loss given default rates are then applied to the reinsurers’ recoverable balance, while also factoring in any third-party letters of credit that support the reinsurance agreement, in order to calculate our current expected credit loss allowance.
Deferred Policy Acquisition Costs	DAC. We defer incremental direct costs of successful contract acquisitions that result directly from and are essential to the contract transaction(s) and that would not have been incurred had the contract transaction(s) not occurred. These deferred policy acquisition costs mainly include commissions and policy issue expenses. All other acquisition-related costs, including unsuccessful acquisition and renewal efforts, are charged to expense as incurred. Also, administrative costs, rent, depreciation, occupancy, equipment, and all other general overhead costs are considered indirect costs and are charged to expense as incurred. DAC for term life insurance policies is amortized over the initial premium-paying period of the related policies in proportion to premium revenue. DAC for Canadian segregated funds is amortized over the life of the underlying policies at a constant rate based on the present value of the estimated gross profits expected to be realized over the life of the underlying policies. DAC is subject to recoverability testing annually and when impairment indicators exist.
Business Combination	Business Combination . The Company acquired e-TeleQuote on July 1, 2021 and accounts for the acquisition as a business combination in accordance with ASC Topic 805, Business Combinations (“ASC 805”), which requires most identifiable assets and liabilities acquired in a business combination to be recorded at fair value at the acquisition date, subject to certain exceptions. Additionally, ASC 805 requires transaction-related costs to be expensed in the period incurred. The Company allocates the fair value of the purchase consideration of its acquired business to the tangible assets, liabilities assumed, and intangible assets acquired at the acquisition date. The excess of the fair value of purchase consideration over the acquired values of these identifiable assets and liabilities is recorded as goodwill. Transaction-related costs are recognized separately from the business combination and expensed as incurred. Refer to Note 20 (Acquisition) for further details.
Goodwill	Goodwill . Goodwill represents the excess of the purchase price over the estimated acquired values of identifiable assets and liabilities acquired in a business combination at the acquisition date. In accordance with U.S. GAAP, goodwill is not amortized. The Company tests goodwill for impairment annually on July 1 and whenever events occur or circumstances change that would indicate the carrying value of goodwill more likely than not exceeds its fair value. All of the Company’s goodwill was obtained from the e-TeleQuote acquisition and the e-TeleQuote business has been designated as a separate operating segment called Senior Health. Therefore, goodwill has been allocated solely to the Senior Health segment and is evaluated for impairment at the Senior Health segment level, which is also defined as the reporting unit. For additional information on the results of the annual goodwill impairment test, see Note 21 (Goodwill) to our consolidated financial statements included elsewhere in this report.
Intangible Assets	Intangible Assets. Intangible assets, which are included in other assets, are amortized over their estimated useful lives. Any intangible asset that was deemed to have an indefinite useful life is not amortized but is subject to an annual impairment test. An impairment exists if the carrying value of the indefinite-lived intangible asset exceeds its fair value. For the other intangible assets, which are subject to amortization, an impairment is recognized if the carrying amount is not recoverable and exceeds the fair value of the intangible asset. The components of intangible assets were as follows: December 31, 2022 2021 Gross carrying amount Accumulated amortization Net carrying amount Gross carrying amount Accumulated amortization Net carrying amount (In thousands) Indefinite-lived intangible asset $ 45,275 n/a $ 45,275 $ 45,275 n/a $ 45,275 Amortizing intangible assets 156,000 ( 15,750 ) 140,250 156,000 ( 5,450 ) 150,550 Total intangible assets $ 201,275 $ ( 15,750 ) $ 185,525 $ 201,275 $ ( 5,450 ) $ 195,825 We have an indefinite-lived intangible asset related to the 1989 purchase of the right to contract with the sales force. This asset represents the core distribution model of our business, which is our primary competitive advantage to profitably distribute term life insurance and investment and savings products on a significant scale, and as such, is considered to have an indefinite life. This indefinite-lived intangible asset is supported by a significant portion of the discounted cash flows of our future business. We assessed this asset for impairment as of October 1, 2022 and determined that no impairment had occurred. There have been no subsequent events requiring further analysis. Intangible assets acquired from the acquisition of e-TeleQuote consist primarily of relationships with health insurance carriers, who are our customers, and are amortized over their estimated useful lives. The Company uses an estimated useful life of 15 years as our relationships with health insurance carriers are not expected to turn over rapidly because these relationships are in-depth, non-exclusive, and pay-for-performance. Intangible asset amortization expense was $ 10.3 million and $ 5.5 million in 2022 and 2021, respectively. Amortization expense is expected to be approximately $ 10.5 million annually for the next five years. Intangible assets subject to amortization are evaluated for impairment in the event factors indicate that the net carrying value may not be recoverable or the asset will not be used throughout its estimated useful life. No events have occurred, and no factors exist as of December 31, 2022 that would indicate that the net carrying value of our amortizing intangible assets may not be recoverable or will not be used throughout their estimated useful life.
Property and Equipment	Property and Equipment. Property and equipment, which are included in other assets, are stated at cost, less accumulated depreciation. Depreciation is recognized on a straight-line basis over the asset’s estimated useful life, which is estimated as follows: Estimated Useful Life Data processing equipment and software 3 to 7 years Leasehold improvements Lesser of 15 years or remaining life of lease Furniture and other equipment 5 to 15 years Depreciation expense is included in other operating expenses in the accompanying consolidated statements of income. Depreciation expense was $ 24.1 million, $ 24.6 million, and $ 18.0 million for the years ended December 31, 2022, 2021, and 2020, respectively. Property and equipment balances were as follows: December 31, 2022 2021 (In thousands) Data processing equipment and software $ 132,596 $ 127,151 Leasehold improvements 18,137 18,631 Other, principally furniture and equipment 35,592 36,460 186,325 182,242 Accumulated depreciation ( 133,668 ) ( 115,220 ) Net property and equipment $ 52,657 $ 67,022
Separate Accounts	Separate Accounts. The separate accounts are primarily comprised of contracts issued by the Company through its subsidiary, Primerica Life Canada, pursuant to the Insurance Companies Act (Canada). The Insurance Companies Act authorizes Primerica Life Canada to establish the separate accounts. The separate accounts are represented by individual variable insurance contracts. Purchasers of variable insurance contracts issued by Primerica Life Canada have a direct claim to the benefits of the contract that entitles the holder to units in one or more investment funds (the “Funds”) maintained by Primerica Life Canada. The Funds invest in assets that are held for the benefit of the owners of the contracts. The benefits provided vary in amount depending on the fair value of the Funds’ net assets. The Funds’ assets are administered by Primerica Life Canada and are held separate and apart from the general assets of the Company. The liabilities reflect the variable insurance contract holders’ interests in the Funds’ net assets based upon actual investment performance of the respective Funds. Separate account operating results relating to contract holders’ interests are excluded from our consolidated statements of income. Primerica Life Canada’s contract offerings guarantee the maturity value at the date of maturity (or upon death, whichever occurs first) to be equal to 75 % of the sum of all contributions made, net of withdrawals, on a first-in, first-out basis. Otherwise, the maturity value or death benefit will be the accumulated value of units allocated to the contract at the specified valuation date.
Renewal Commissions Receivable	Renewal Commissions Receivable. Renewal commissions receivable are contract assets that represent the renewal portion of estimated constrained variable consideration recognized in accordance with ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). Renewal commissions receivable primarily consist of the expected value of commissions to be collected by e-TeleQuote from the distribution of Medicare-related health insurance policies where the performance obligation has been satisfied but payment is not due as the underlying policy has not yet renewed. The estimate of renewal commissions requires significant judgment subject to the same assumptions as noted under “Commissions and Fees – Senior Health” below. Cash collections for these receivables are expected to occur over a period of several years. Renewal commissions receivable will be adjusted for differences between actual and expected cash collections as well as for changes in estimates. Under ASC 606, these receivables are not discounted as the timing for collection of payments is dependent on future policyholder renewals and not due to the presence of a significant financing component. Refer to Note 20 (Acquisition) for renewal commissions receivable recognized as part of the acquisition of e-TeleQuote.
Future Policy Benefits Liability	Policyholder Liabilities. Future policy benefits are accrued over the current and renewal periods of the contracts. Liabilities for future policy benefits on traditional life insurance products are reserves established for death claims and waiver of premium benefits and have been computed using a net level method, using assumptions as to interest rates, mortality, persistency, disability rates and other assumptions based on our experience, modified as necessary to reflect anticipated trends and to include provisions for possible adverse deviation. The underlying mortality tables are the Society of Actuaries (“SOA”) 65-70, SOA 75-80, SOA 85-90, and the 91 Bragg, modified to reflect various underwriting classifications and assumptions. Interest rate reserve assumptions ranged from 2.5 % to 7.0 % at December 31, 2022 and ranged from 2.5 % to 7.0 % at December 31, 2021. For policies issued in 2010 and after, we have been using an increasing interest rate assumption to reflect the historically low interest rate environment. The liability for policy claims and other benefits payable on traditional life insurance products includes estimated unpaid claims that have been reported to us and claims incurred but not yet reported. The future policy benefit reserves we establish are necessarily based on estimates, assumptions and our analysis of historical experience. We do not modify the assumptions used to establish future policy benefit reserves during the policy term unless a premium deficiency is identified. Our results depend significantly upon the extent to which our actual claims experience is consistent with the assumptions we used in determining our future policy benefit reserves and pricing our products. Our future policy benefit reserve assumptions and estimates require significant judgment and, therefore, are inherently uncertain. We cannot determine with precision the ultimate amounts that we will pay for actual claims or the timing of those payments. Other Policyholders’ Funds . Other policyholders’ funds primarily represent claim payments left on deposit with us.
Unearned and Advance Premiums	Unearned and Advance Premiums. Unearned and advance premiums primarily consist of premiums received from policyholders in advance of the premiums due date. Unearned and advance premiums are deferred upon collection and recognized as premiums revenue upon the premium due date.
Litigation	Litigation. The Company is involved from time-to-time in legal disputes, regulatory inquiries and arbitration proceedings in the normal course of business. Contingent litigation-related losses are recognized when probable and can be reasonably estimated. Legal costs, such as attorneys’ fees and other litigation-related expenses that are incurred in connection with resolving litigation are expensed as incurred. These disputes are subject to uncertainties, including indeterminate amounts sought in certain of these matters and the inherent unpredictability of litigation. Due to the difficulty of estimating costs of litigation, actual costs may be substantially higher or lower than any amounts reserved.
Income Taxes	Income Taxes . We are subject to the income tax laws of the United States, its states, municipalities, and certain unincorporated territories, as well as foreign jurisdictions, most notably Canada. These tax laws can be complex and subject to different interpretations by the taxpayer and the relevant governmental taxing authorities. In establishing a provision for income tax expense, we must make judgments and interpretations about the applicability of these tax laws. We also must make estimates about the future impact certain items will have on taxable income in the various tax jurisdictions, both domestic and foreign. Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to: (i) differences between the financial statement carrying amounts of acquired assets and liabilities and their respective tax bases and (ii) acquired e-TeleQuote net operating loss and interest deduction carryforwards available for future use. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Deferred tax assets are recognized subject to management’s judgment that realization is more-likely-than-not applicable to the periods in which we expect the temporary difference will reverse. The Company has not recognized any material deferred taxes associated with goodwill as it has not acquired any material goodwill with tax basis. Refer to Note 20 (Acquisition) for deferred income taxes recognized as part of the acquisition of e-TeleQuote.
Noncontrolling Interest	Noncontrolling Interest. In connection with the Company’s acquisition of e-TeleQuote, the Company entered into a shareholders’ agreement with the noncontrolling equity holders of Primerica Health (the “Shareholders’ Agreement”). Under the terms of the Shareholders’ Agreement, the Company agreed to purchase, and the noncontrolling equity holders agreed to sell, the remaining 20 % stake over a period of up to four years through a series of call and put rights. The Shareholders’ Agreement provided for the purchase of the noncontrolling equity holders’ equity interests in Primerica Health at a contractually defined formulaic purchase price (the “Formulaic Price”), which was based on a discounted calculation of selected peer company equity value multiples times the trailing twelve months of adjusted earnings before interest, taxes, depreciation, and amortization (“Adjusted EBITDA”) reduced by the balance of intercompany debt owed by e-TeleQuote to the Parent Company. The noncontrolling equity holders’ interests in Primerica Health was recognized as redeemable noncontrolling interests (“Redeemable NCI”) in the temporary stockholders’ equity section of the consolidated balance sheets. Effective July 1, 2022 , the Company executed its call option to acquire the remaining 20 % of Primerica Health. The Formulaic Price calculation resulted in a purchase price of zero. As such, no further consideration was required to obtain the outstanding 20% stake in Primerica Health and the noncontrolling interest in the Company's consolidated financial statements was redeemed. Prior to redemption, the Company adjusted the Redeemable NCI for net income (loss) attributable to the noncontrolling interests in Primerica Health. Upon redemption, the Redeemable NCI in the temporary stockholders' equity section of the consolidated balance sheets was eliminated through an adjustment to additional paid in capital as no further consideration was required.
Premium Revenues	Premium Revenues . Traditional life insurance products consist principally of those products with fixed and guaranteed premiums and benefits, and are primarily related to term products. Premiums are recognized as revenues when due.
Commissions and Fees	Commissions and Fees. We receive commissions and fees revenue from the sale of various non-life insurance products. Commissions revenue is generally received on the sale of mutual funds and annuities. We also receive trail commissions revenue from mutual fund and annuity products based on the net asset value of shares sold by us. We, in turn, pay sales commissions to the sales force. We also receive investment advisory and administrative fees based on the average daily net asset value of client assets held in managed investments programs and contracts related to separate account assets issued by Primerica Life Canada. We, in turn, pay asset-based commissions to the sales force. We earn recordkeeping fees for transfer agent recordkeeping services that we perform on behalf of several of our mutual fund providers and custodial fees for services performed as a non-bank custodian of our clients’ retirement plan accounts. See Note 18 (Revenue from Contracts with Customers) for details related to our commission and fees revenues recognition policies.
Commissions and Fees ? Senior Health	Commissions and Fees – Senior Health. As a result of the acquisition of e-TeleQuote, the Company distributes Medicare-related insurance policies offered by third-party health insurance carriers to eligible Medicare participants. e-TeleQuote receives initial commissions from health insurance carriers, who are considered its customers, for enrollments in policies it has distributed as well as ongoing renewal commissions that coincide with the period an eligible Medicare participant remains enrolled in a policy after the first policy effective date (collectively, “Lifetime value of commissions” or “LTV”). Revenue is recognized at the point in time e-TeleQuote’s single performance obligation to health insurance carriers is satisfied, which is generally on the date the policy application is approved by the health insurance carrier. The expected commissions represent variable consideration that will not be resolved until after the performance obligation has been satisfied. The Company estimates variable consideration in the transaction price for policies it has distributed as the expected amount of initial and renewal commissions to be received over the life of the enrolled policy. Variable consideration is estimated by using a portfolio approach to policies grouped together by health insurance carrier, Medicare product type, and policy effective date (referred to as a “cohort”). This approach to estimating the initial and renewal commissions expected to be collected involves the evaluation of various factors, including but not limited to, contracted commission rates, disenrollment experience and renewal persistency rates. Upon development of the estimate of expected renewal commissions using the portfolio approach, management applies a constraint so that it is probable that a subsequent change in estimate will not result in a significant revenue reversal. Management judgment is required to determine the inputs to these estimates and the inputs are established primarily based on historical activity. There could be situations where new facts or circumstances, that were not available at the time of the initial estimate, may indicate that the expected renewal commissions are higher or lower than our renewal commissions receivable. In those situations, the expected renewal commissions receivable will be written down or up to its revised expected value by adjustments to revenue, which we refer to as tail revenue adjustments. Refer to Note 18 (Revenue from Contracts with Customers) for detail related to commissions and fees revenues recognized by e-TeleQuote.
Benefits and Expenses	Benefits and Expenses . Benefit and expense items are charged to income in the period in which they are incurred. Both the change in policyholder liabilities, which is included in benefits and claims, and the amortization of deferred policy acquisition costs will vary with policyholder persistency.
Share-Based Transactions	Share-Based Transactions. For employee and director share-based compensation awards, we determine a grant date fair value based on the price of our publicly-traded common stock and recognize the related compensation expense, adjusted for actual forfeitures, in the consolidated statements of income on a straight-line basis over the requisite service period for the entire award. For non-employee share-based compensation, we recognize the impact during the period of performance, and the fair value of the award is measured as of the grant date, which occurs in the same quarter as the service period. To the extent non-employee share-based compensation is an incremental direct cost of successful acquisitions or renewals of life insurance policies that result directly from and are essential to the policy acquisition(s) and would not have been incurred had the policy acquisition(s) not occurred, we defer and amortize the fair value of the awards in the same manner as other deferred policy acquisition costs.
Earnings Per Share	Earnings Per Share (“EPS”). The Company has outstanding equity awards that consist of restricted stock units (“RSUs”), performance-based stock units (“PSUs”), and stock options. The RSUs maintain non-forfeitable dividend rights that result in dividend payment obligations on a one-to-one ratio with common shares for any future dividend declarations. Unvested RSUs are deemed participating securities for purposes of calculating EPS as they maintain dividend rights. See Note 13 (Earnings Per Share) for details related to the calculations of our basic and diluted EPS using the two-class method.
New Accounting Principles	Future Application of Accounting Standards. In August 2018, the FASB issued Accounting Standards Update No. 2018-12 , Financial Services—Insurance (Topic 944) — Targeted Improvements to the Accounting for Long-Duration Contracts (“ASU 2018-12” or “LDTI”). The amendments in this update change accounting guidance for insurance companies that issue long-duration contracts, including term life insurance . ASU 2018-12 requires companies that issue long-duration insurance contracts to update assumptions used in measuring future policy benefits and DAC, including mortality, disability, and persistency, at least annually instead of locking those assumptions at contract inception and reflecting differences in assumptions and actual performance as the experience occurs. ASU 2018-12 also changes how insurance companies that issue long-duration contracts amortize DAC and determine and update the discount rate assumptions used in measuring future policy benefits reserves while increasing the level of financial statement disclosures required. The guidance in ASU 2018-12 will be applied to the earliest period presented in the consolidated financial statements beginning on the effective date of January 1, 2023. The adoption of ASU 2018-12 will have an impact on our consolidated financial statements and related disclosures and will require changes to certain of our processes, systems, and controls. We will continue to evaluate the impact the adoption will have on our business until we issue our condensed consolidated financial statements as of and for the three months ending March 31, 2023. We continue to work on model refinement and model governance, finalizing actuarial assumptions and documenting our control process. Below is a list of topics relevant to the adoption of ASU 2018-12 and the expected impact on the Company. Topic Description Planned Approach Transition Approach LDTI guidance can be applied using either: • the retrospective method, which applies the provisions of the standard from the original policy inception; or The Company will elect to adopt the standard using the modified retrospective method for both future policy benefits reserves and amortization of DAC. The Company will adopt the standard effective January 1, 2023, which corresponds with the issuance of our condensed consolidated • the modified retrospective method, which applies the provisions of the standard by pivoting off the historical December 31, 2020 future policy benefits reserve (“Pre-transition Reserve”) and DAC balances just prior to January 1, 2021 (the “Transition Date”). financial statements for the three months ended March 31, 2023. Cohort Definition Cohorts refer to the level of policy grouping used in the calculation of the future policy benefits reserve (“FPBR”) and amortization of DAC. Under LDTI, cohorts must vary by policy issue year and may be set more granularly to reflect additional policy characteristics. The net premium ratio for each policy cohort is used to calculate FPBR. At the Transition Date, the Net Premium Ratio is defined as the present value of future benefits and claim settlement expenses less the Pre-transition Reserve divided by the present value of the gross premiums. The present value of both the future benefits and gross premiums use best estimate cash flow assumptions at the locked-in discount rate (discount rate at the Transition Date). Under LDTI, a cohort’s Net Premium Ratio is capped at 100 %. This concept replaces the need for loss recognition analysis under current GAAP. Any adjustments necessary at the Transition Date to cap the Net Premium Ratio for a cohort at 100 % are recognized in retained earnings. After the Transition Date, the Net Premium Ratio will be updated each quarter as projected benefits and premiums are replaced with actual amounts. The Company will define the Term Life Insurance segment cohorts based on the legal entity that issued the policy and the year the policy was issued. The Company expects the impact to retained earnings as of the Transition Date of capping the Net Premium Ratio at 100 % to be less than $ 50.0 million. The identified impact from capping the Net Premium Ratio at 100 % is primarily attributable to a limited amount of older policy year cohorts. Discount Rates LDTI requires entities to use market observable rates, based on an upper-medium grade fixed income instrument yield, to measure future policy benefits reserves each period. The difference between the FPBR calculated using market observable rates and the Pre-transition Reserve is recognized as part of accumulated other comprehensive income (“AOCI”) at the Transition Date. After the Transition Date, the impact of changes in market observable rates each quarter will be recorded to AOCI and may add volatility to our reported equity. The Company will use discount rates applied by geography to align with local currency cash flows. Discount rates will consist of yield curves that will be developed using Bloomberg’s Evaluated Pricing Product (BVAL) based on senior unsecured fixed rate bonds ratings of A+, A or A-. Given how low market observable rates were at the Transition Date, we expect that the amount recorded in AOCI as of the Transition Date will reduce our AOCI and equity balances by approximately $ 1.2 billion to $ 1.5 billion, net of income tax. As of December 31, 2022, market observable rates have increased relative to the Transition Date, which will significantly reduce the AOCI impact in equity on our current balance sheet. If we were to apply market observable rates as of December 31, 2022 to the FPBR as of the Transition Date, the impact on AOCI would be between a $ 150 million increase and a $ 150 million decrease on an after-tax basis. Cash Flow Assumptions LDTI requires entities to use their best estimates for cash flow assumptions with no provision for adverse deviation. Cash flow assumptions are to be reviewed at least annually at the same time each year, or more frequently if experience suggests. Forecasted cash flow assumptions must be replaced with actual cash flows in FPBR at least annually. The Company expects to formally review cash flow assumptions during the third quarter each year and update these assumptions as necessary. The Company will replace forecasted cash flow assumptions with actual cash flows in FPBR each quarter. The impact of assumption changes and experience variances will be partly reflected in the current period and partly spread to future periods, based on the remaining duration of the impacted cohort(s), by unlocking the Net Premium Ratio in FPBR. DAC Amortization LDTI requires DAC to be amortized on a constant-level basis over the expected term of the contracts using an appropriate unit of measure. Companies can amortize DAC either at an individual contract level on a straight-line basis or at a cohort level that approximates a straight-line basis. Under current GAAP, DAC is amortized using amortization models linked to revenue or profit. Also, interest is accrued on unamortized DAC under current GAAP while LDTI disallows the accrual of interest. The Company anticipates it will use current face amount as a unit of measure to amortize DAC for its term life insurance products and policy count as a unit of measure to amortize DAC for its Canadian segregated funds products. In addition, the Company expects to group contracts by cohort to amortize DAC. For term life insurance products, we expect DAC to be amortized more slowly under LDTI as compared with current GAAP. For Canadian segregated funds, we expect DAC amortization to be less volatile than under current GAAP as it will no longer be based on the present value of gross profits, which are subject to changes in the market value of assets under management. Market Risk Benefits (“MRBs”) MRBs are benefits that protect policyholders from capital market risk. Under LDTI, MRBs are measured at fair value. The Company has MRBs from limited guaranteed benefits provided as part of our Canadian segregated funds products. We currently anticipate that the fair value of MRBs associated with this product will be immaterial when LDTI is adopted. Recently-issued accounting guidance not discussed above is not applicable, is immaterial to our consolidated financial statements, or did not or is not expected to have a material impact on our business.

Description of Business, Basi_3

Description of Business, Basis of Presentation, and Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2022
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Schedule of Intangible Assets	The components of intangible assets were as follows: December 31, 2022 2021 Gross carrying amount Accumulated amortization Net carrying amount Gross carrying amount Accumulated amortization Net carrying amount (In thousands) Indefinite-lived intangible asset $ 45,275 n/a $ 45,275 $ 45,275 n/a $ 45,275 Amortizing intangible assets 156,000 ( 15,750 ) 140,250 156,000 ( 5,450 ) 150,550 Total intangible assets $ 201,275 $ ( 15,750 ) $ 185,525 $ 201,275 $ ( 5,450 ) $ 195,825
Schedule of Assets Estimated Useful Life	Depreciation is recognized on a straight-line basis over the asset’s estimated useful life, which is estimated as follows: Estimated Useful Life Data processing equipment and software 3 to 7 years Leasehold improvements Lesser of 15 years or remaining life of lease Furniture and other equipment 5 to 15 years
Property and Equipment	Property and equipment balances were as follows: December 31, 2022 2021 (In thousands) Data processing equipment and software $ 132,596 $ 127,151 Leasehold improvements 18,137 18,631 Other, principally furniture and equipment 35,592 36,460 186,325 182,242 Accumulated depreciation ( 133,668 ) ( 115,220 ) Net property and equipment $ 52,657 $ 67,022

Other Comprehensive Income (Tab

Other Comprehensive Income (Tables)	12 Months Ended
	Dec. 31, 2022
Equity [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss)	The components of other comprehensive income (“OCI”), including the income tax expense or benefit allocated to each component, were as follows: Year ended December 31, 2022 2021 2020 (In thousands) Foreign currency translation adjustments: Change in unrealized foreign currency translation gains (losses) $ ( 20,015 ) $ 7,033 $ 7,343 Income tax expense (benefit) on unrealized foreign currency - - - Change in unrealized foreign currency translation gains $ ( 20,015 ) $ 7,033 $ 7,343 Unrealized gain (losses) on available-for-sale securities: Change in unrealized holding gains (losses) arising during $ ( 385,735 ) $ ( 78,348 ) $ 78,533 Income tax expense (benefit) on unrealized holding gains ( 82,185 ) ( 17,038 ) 17,033 Change in unrealized holding gains (losses) on available-for-sale ( 303,550 ) ( 61,310 ) 61,500 Reclassification from accumulated OCI to net income for (gains) ( 1,387 ) ( 3,849 ) 2,614 Income tax (expense) benefit on (gains) losses reclassified from ( 292 ) ( 808 ) 549 Reclassification from accumulated OCI to net income for (gains) ( 1,095 ) ( 3,041 ) 2,065 Change in unrealized gains (losses) on available-for-sale $ ( 304,645 ) $ ( 64,351 ) $ 63,565

Segment and Geographical Info_2

Segment and Geographical Information (Tables)	12 Months Ended
	Dec. 31, 2022
Segment Reporting [Abstract]
Summary of Assets and Profit or Loss by Segment	Notable information included in profit or loss by segment was as follows: Year ended December 31, 2022 2021 2020 (In thousands) Revenues: Term life insurance segment $ 1,687,126 $ 1,575,686 $ 1,382,770 Investment and savings products segment 863,432 941,847 718,867 Senior health segment 62,682 60,440 N/A Corporate and other distributed products segment 106,893 131,759 115,904 Total revenues $ 2,720,133 $ 2,709,732 $ 2,217,541 Net investment income: Term life insurance segment $ 51,160 $ 36,486 $ 27,030 Investment and savings products segment - - - Senior health segment - - N/A Corporate and other distributed products segment 41,905 44,102 56,784 Total net investment income $ 93,065 $ 80,588 $ 83,814 Amortization of DAC: Term life insurance segment $ 342,925 $ 241,451 $ 216,208 Investment and savings products segment 12,141 8,668 7,055 Senior health segment - - N/A Corporate and other distributed products segment 1,077 1,060 1,058 Total amortization of DAC $ 356,143 $ 251,179 $ 224,321 Non-cash share-based compensation expense: Term life insurance segment $ 4,133 $ 4,153 $ 3,612 Investment and savings products segment 3,212 3,206 3,045 Senior health segment 210 - N/A Corporate and other distributed products segment 14,806 9,483 12,370 Total non-cash share-based compensation expense $ 22,361 $ 16,842 $ 19,027 Income (loss) before income taxes: Term life insurance segment $ 448,540 $ 414,619 $ 372,551 Investment and savings products segment 239,330 274,585 202,644 Senior health segment ( 98,673 ) ( 85,050 ) N/A Corporate and other distributed products segment ( 95,448 ) ( 92,983 ) ( 68,465 ) Total income before income taxes $ 493,749 $ 511,171 $ 506,730
Total Assets by Segment	Total assets by segment were as follows: December 31, 2022 December 31, 2021 December 31, 2020 (In thousands) Assets: Term life insurance segment $ 7,175,746 $ 7,274,820 $ 6,985,086 Investment and savings products segment (1) 2,415,041 2,920,271 2,769,445 Senior health segment 431,993 $ 528,974 N/A Corporate and other distributed products segment 5,326,097 5,399,158 5,150,754 Total assets $ 15,348,877 $ 16,123,223 $ 14,905,285 (1) The Investment and Savings Products segment includes assets held in separate accounts. Excluding separate accounts, the Investment and Savings Products segment assets were $ 109.3 million, $ 120.3 million, and $ 110.0 million as of December 31, 2022, 2021, and 2020 , respectively.
Long Lived Assets and Continuing Operations by Country	Geographical Information. Results of operations by country and long-lived assets — primarily tangible assets reported in other assets in our consolidated balance sheets —were as follows: Year ended December 31, 2022 2021 2020 (In thousands) Revenues by country: United States $ 2,355,139 $ 2,311,051 $ 1,895,708 Canada 364,994 398,681 321,833 Total revenues $ 2,720,133 $ 2,709,732 $ 2,217,541 December 31, 2022 December 31, 2021 December 31, 2020 (In thousands) Long-lived assets by country: United States $ 49,637 $ 62,921 $ 53,281 Canada 2,803 3,871 4,446 Other 217 230 - Total long-lived assets $ 52,657 $ 67,022 $ 57,727

Investments (Tables)

Investments (Tables)	12 Months Ended
	Dec. 31, 2022
Investments Debt And Equity Securities [Abstract]
Schedule of AFS Securities Reconciliation	The period-end cost or amortized cost, gross unrealized gains and losses, and fair value of AFS fixed-maturity securities were as follows: December 31, 2022 Amortized cost Gross unrealized gains Gross unrealized losses Fair value (In thousands) Securities available-for-sale, carried at fair value: Fixed-maturity securities: U.S. government and agencies $ 31,217 $ 18 $ ( 767 ) $ 30,468 Foreign government 163,725 780 ( 11,590 ) 152,915 States and political subdivisions 142,189 112 ( 20,056 ) 122,245 Corporates 1,665,962 2,439 ( 171,552 ) 1,496,849 Residential mortgage-backed securities 473,309 370 ( 71,949 ) 401,730 Commercial mortgage-backed securities 139,306 3 ( 16,342 ) 122,967 Other asset-backed securities 185,707 108 ( 17,533 ) 168,282 Total fixed-maturity securities $ 2,801,415 $ 3,830 $ ( 309,789 ) $ 2,495,456 Short-term investments 69,393 20 ( 7 ) 69,406 Total fixed-maturity and short-term investments $ 2,870,808 $ 3,850 $ ( 309,796 ) $ 2,564,862 December 31, 2021 Amortized cost Gross unrealized gains Gross unrealized losses Fair value (In thousands) Securities available-for-sale, carried at fair value: Fixed-maturity securities: U.S. government and agencies $ 32,292 $ 187 $ ( 79 ) $ 32,400 Foreign government 147,288 6,283 ( 595 ) 152,976 States and political subdivisions 147,455 6,326 ( 254 ) 153,527 Corporates 1,649,334 72,418 ( 8,068 ) 1,713,684 Residential mortgage-backed securities 373,753 5,108 ( 3,230 ) 375,631 Commercial mortgage-backed securities 142,631 3,314 ( 420 ) 145,525 Other asset-backed securities 128,635 1,409 ( 1,220 ) 128,824 Total fixed-maturity securities $ 2,621,388 $ 95,045 $ ( 13,866 ) $ 2,702,567 Short-term investments 85,246 1 ( 4 ) 85,243 Total fixed-maturity and short-term investments $ 2,706,634 $ 95,046 $ ( 13,870 ) $ 2,787,810
Fixed-maturity Securities Classified by Contractual Maturity Securities Date	The scheduled maturity distribution of the AFS fixed-maturity securities portfolio as of December 31, 2022 was as follows: Amortized cost Fair value (In thousands) Due in one year or less $ 165,117 163,831 Due after one year through five years 783,376 740,167 Due after five years through 10 years 763,273 658,194 Due after 10 years 291,327 240,285 2,003,093 1,802,477 Mortgage- and asset-backed securities 798,322 692,979 Total AFS fixed-maturity securities $ 2,801,415 $ 2,495,456
Costs and Fair Values of Fixed-Maturity Securities Classified as Trading Securities	The costs and fair values of the fixed-maturity securities classified as trading securities were as follows: December 31, 2022 December 31, 2021 Cost Fair value Cost Fair value (In thousands) Fixed-maturity securities $ 4,229 $ 3,698 $ 24,769 $ 24,355
Net Investment Income	The components of net investment income were as follows: Year ended December 31, 2022 2021 2020 (In thousands) Fixed-maturity securities (available-for-sale) $ 90,975 $ 80,362 $ 82,805 Fixed-maturity security (held-to-maturity) 63,922 62,207 57,473 Equity securities 1,509 1,632 1,751 Policy loans and other invested assets 1,046 1,019 1,244 Cash, cash equivalent and short-term investments 5,943 456 1,202 Total return on deposit asset underlying 10% coinsurance (1) ( 65 ) 1,875 4,253 Gross investment income 163,330 147,551 148,728 Investment expenses ( 6,343 ) ( 4,756 ) ( 7,441 ) Investment income net of investment expenses 156,987 142,795 141,287 Interest expense on surplus note ( 63,922 ) ( 62,207 ) ( 57,473 ) Net investment income $ 93,065 $ 80,588 $ 83,814 (1) Includes $( 3.8 ) million, $( 2.5 ) million, and $ 2.0 million of net gains (losses) recognized for the change in fair value of the deposit asset underlying the 10 % coinsurance agreement for the years ended December 31, 2022, 2021, and 2020, respectively.
Schedule of Investment Gains and Losses	The components of investment gains (losses), as well as details on gross realized investment gains (losses) and other investment gains (losses) were as follows: Year ended December 31, 2022 2021 2020 (In thousands) Realized investment gains (losses): Gross gains from sales of available-for-sale fixed maturity securities $ 2,036 $ 7,060 $ 2,595 Gross gains from sales of equity securities - - 12 Gross losses from sales of available-for-sale fixed maturity securities ( 592 ) ( 2,395 ) ( 955 ) Gross losses from sales of equity securities - - ( 293 ) Net realized investment gains (losses): 1,444 4,665 1,359 Other investment gains (losses): Credit losses impairment of available-for-sale securities ( 57 ) ( 816 ) ( 4,254 ) Market gains (losses) recognized in net income during the period on equity securities ( 2,375 ) 2,362 ( 2,154 ) Gains (losses) from bifurcated options - ( 57 ) 57 Gains (losses) on trading securities ( 7 ) ( 282 ) ( 4 ) Other investment gains (losses): ( 2,439 ) 1,207 ( 6,355 ) Investment gains (losses) $ ( 995 ) $ 5,872 $ ( 4,996 )
Schedule of Proceeds from Sales or Other Redemptions of Available-for-Sale Securities	The proceeds from sales or other redemptions of available-for-sale securities were as follows: Year ended December 31, 2022 2021 2020 (In thousands) Proceeds from sales or other redemptions $ 496,898 $ 676,153 $ 496,907
Schedule of Securities in Unrealized Loss Position	The following tables summarizes all AFS securities in an unrealized loss position for which an allowance for credit losses has not been recorded as of December 31, 2022, aggregated by major security type and by length of time such securities have continuously been in an unrealized loss position: December 31, 2022 Less than 12 months 12 months or longer Fair value Unrealized losses Fair value Unrealized losses (Dollars in thousands) Fixed-maturity securities: U.S. government and agencies $ 4,927 $ ( 204 ) $ 25,209 $ ( 563 ) Foreign government 97,094 ( 4,430 ) 38,085 ( 7,160 ) States and political subdivisions 71,131 ( 10,666 ) 44,324 ( 9,390 ) Corporates 974,931 ( 69,726 ) 452,541 ( 101,826 ) Residential mortgage-backed securities 187,158 ( 22,171 ) 201,595 ( 49,778 ) Commercial mortgage-backed securities 65,165 ( 5,069 ) 56,799 ( 11,273 ) Other asset-backed securities 81,907 ( 5,807 ) 72,977 ( 11,726 ) Total fixed-maturity securities 1,482,313 ( 118,073 ) 891,530 ( 191,716 ) Short-term investments: U.S. government and agencies 28,379 ( 5 ) - - Foreign government 1,744 ( 2 ) - - Total Short Term Bonds 30,123 ( 7 ) - - Total fixed-maturity and Short Term securities $ 1,512,436 $ ( 118,080 ) $ 891,530 $ ( 191,716 ) December 31, 2021 Less than 12 months 12 months or longer Fair value Unrealized losses Fair value Unrealized losses (Dollars in thousands) Fixed-maturity securities: U.S. government and agencies $ 24,928 $ ( 45 ) $ 1,557 $ ( 34 ) Foreign government 18,894 ( 384 ) 3,335 ( 211 ) States and political subdivisions 15,909 ( 254 ) - - Corporates 341,963 ( 5,035 ) 59,414 ( 3,033 ) Residential mortgage-backed securities 234,911 ( 3,131 ) 2,707 ( 99 ) Commercial mortgage-backed securities 47,220 ( 419 ) 117 ( 1 ) Other asset-backed securities 80,509 ( 1,037 ) 3,779 ( 183 ) Total fixed-maturity securities $ 764,334 $ ( 10,305 ) $ 70,909 $ ( 3,561 ) Short-term investments: U.S. government and agencies 34,967 * - - Foreign government 4,995 * - - States and political subdivisions 11,394 ( 1 ) - - Corporates 23,891 ( 3 ) - - Total Short Term Bonds 75,247 ( 4 ) - - Total fixed-maturity and Short Term securities $ 839,581 $ ( 10,309 ) $ 70,909 $ ( 3,561 ) * Less than $ 1 thousand
Rollforward of Allowance for Credit Losses on Available-for-sale Securities	The rollforward of the allowance for credit losses on available-for-sale securities was as follows: Year ended December 31, 2022 2021 2020 (In thousands) Allowance for credit losses, beginning of period $ 816 $ - $ - Additions to the allowance for credit losses on securities for which credit losses were not previously recorded - 821 525 Additional increases (or decreases) to the allowance for credit losses on securities that had an allowance recorded in a previous period ( 81 ) ( 5 ) ( 51 ) Write-offs charged against the allowance, if any ( 735 ) - ( 474 ) Allowance for credit losses, end of period $ - $ 816 $ -

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2022
Fair Value Disclosures [Abstract]
Schedule of Fair Value Assets and Liabilities Measured on Recurring Basis	The estimated fair value and hierarchy classifications for assets and liabilities that are measured at fair value on a recurring basis were as follows: December 31, 2022 Level 1 Level 2 Level 3 Total (In thousands) Fair value assets: Available-for-sale fixed-maturity securities: U.S. government and agencies $ - $ 30,468 $ - $ 30,468 Foreign government - 152,915 - 152,915 States and political subdivisions - 122,245 - 122,245 Corporates 3,586 1,493,263 - 1,496,849 Mortgage-and asset-backed securities: Residential mortgage-backed securities - 401,730 - 401,730 Commercial mortgage-backed securities - 122,967 - 122,967 Other asset-backed securities - 168,282 - 168,282 Total available-for-sale fixed-maturity securities 3,586 2,491,870 - 2,495,456 Short Term Investments - 69,406 - 69,406 Total available-for-sale securities 3,586 2,561,276 - 2,564,862 Equity securities 32,727 967 1,710 35,404 Trading securities - 3,698 - 3,698 Cash and cash equivalents 489,240 - - 489,240 Separate accounts - 2,305,717 - 2,305,717 Total fair value assets $ 525,553 $ 4,871,658 $ 1,710 $ 5,398,921 Fair value liabilities: Separate accounts $ - $ 2,305,717 $ - $ 2,305,717 Total fair value liabilities $ - $ 2,305,717 $ - $ 2,305,717 December 31, 2021 Level 1 Level 2 Level 3 Total (In thousands) Fair value assets: Available-for-sale fixed-maturity securities: U.S. government and agencies $ - $ 32,400 $ - $ 32,400 Foreign government - 152,976 - 152,976 States and political subdivisions - 153,527 - 153,527 Corporates 5,898 1,707,786 - 1,713,684 Mortgage-and asset-backed securities: Residential mortgage-backed securities - 375,604 27 375,631 Commercial mortgage-backed securities - 145,525 - 145,525 Other asset-backed securities - 128,824 - 128,824 Total available-for-sale fixed-maturity securities 5,898 2,696,642 27 2,702,567 Short Term Investments - 85,243 - 85,243 Total available-for-sale securities 5,898 2,781,885 27 2,787,810 Equity securities 37,912 1,070 3,569 42,551 Trading securities - 24,355 - 24,355 Cash and cash equivalents 351,508 40,993 - 392,501 Separate accounts - 2,799,992 - 2,799,992 Total fair value assets $ 395,318 $ 5,648,295 $ 3,596 $ 6,047,209 Fair value liabilities: Separate accounts $ - $ 2,799,992 $ - $ 2,799,992 Total fair value liabilities $ - $ 2,799,992 $ - $ 2,799,992
Roll forward of Level 3 Assets Measured on Recurring Basis	The roll-forward of the Level 3 assets measured at fair value on a recurring basis was as follows: Year ended December 31, 2022 2021 (In thousands) Level 3 assets, beginning of period $ 3,596 $ 2,047 Net unrealized gains (losses) included in other ( 1 ) - Realized gains (losses) and accretion (amortization) ( 204 ) ( 493 ) Purchases 1,661 2,067 Sales - - Settlements - ( 25 ) Transfers into Level 3 - - Transfers out of Level 3 ( 3,342 ) - Level 3 assets, end of period $ 1,710 $ 3,596
Carrying Values and Estimated Fair Values of Financial Instruments	The carrying values and estimated fair values of our financial instruments were as follows: December 31, 2022 December 31, 2021 Carrying value Estimated fair value Carrying value Estimated fair value (In thousands) Assets: Fixed-maturity securities (available-for-sale) $ 2,495,456 $ 2,495,456 $ 2,702,567 $ 2,702,567 Fixed-maturity security (held-to-maturity) (3) 1,444,920 1,340,265 1,379,100 1,551,113 Short-term investments (available-for-sale) 69,406 69,406 85,243 85,243 Equity securities 35,404 35,404 42,551 42,551 Trading securities 3,698 3,698 24,355 24,355 Policy loans (3) 35,940 35,940 30,612 30,612 Deposit asset underlying 10 % coinsurance agreement (3) 224,371 224,371 231,368 231,368 Separate accounts 2,305,717 2,305,717 2,799,992 2,799,992 Liabilities: Notes payable - Long term (1) (2) 592,905 491,753 592,102 605,667 Surplus note (1) (3) 1,444,469 1,333,047 1,378,585 1,545,854 Separate accounts 2,305,717 2,305,717 2,799,992 2,799,992 (1) Carrying value amounts shown are net of issuance costs. (2) Classified as level 2 fair value measurement. (3) Classified as level 3 fair value measurement.

Reinsurance (Tables)

Reinsurance (Tables)	12 Months Ended
	Dec. 31, 2022
Reinsurance Disclosures [Abstract]
In-force Life Insurance	The following table represents the Company’s in-force life insurance as of December 31, 2022 and 2021: December 31, 2022 December 31, 2021 (Dollars in thousands) Direct life insurance in-force $ 919,081,738 $ 905,819,671 Amounts ceded to other companies ( 787,907,229 ) ( 777,826,233 ) Net life insurance in-force $ 131,174,509 $ 127,993,438 Percentage of reinsured life insurance in-force 86 % 86 %
Reinsurance Recoverables and Financial Strength Ratings by Reinsurer	Reinsurance recoverables include ceded reserve balances and ceded claim liabilities. Reinsurance recoverables and financial strength ratings by reinsurer were as follows: December 31, 2022 December 31, 2021 Reinsurance recoverables A.M. Best rating Reinsurance recoverables A.M. Best rating (In thousands) Swiss Re Life and Health America, Inc. (Novated from Pecan Re Inc.) (1)(2) $ 2,440,274 A+ $ - - Pecan Re Inc. (1) (2) - - 2,567,602 NR SCOR Global Life Reinsurance Companies (3) 394,171 A+ 426,634 A+ Munich Re of Malta (2) (5) 251,078 NR 278,591 NR Swiss Re Life & Health America Inc. (4) 244,056 A+ 259,239 A+ American Health and Life Insurance Company (2) 146,779 B++ 157,837 B++ Munich American Reassurance Company 134,570 A+ 142,705 A+ Korean Reinsurance Company 123,026 A 134,048 A RGA Reinsurance Company 128,443 A+ 140,953 A+ Hannover Life Reassurance Company 47,870 A+ 49,749 A+ TOA Reinsurance Company 35,762 A 38,909 A All other reinsurers 72,816 - 75,094 - Allowance for credit losses ( 2,936 ) ( 2,942 ) Reinsurance recoverables $ 4,015,909 $ 4,268,419 NR – not rated (1) Effective April 1, 2022, the coinsurance agreement with Pecan Re Inc. was novated and replaced by an agreement with Swiss Re Life and Health America, Inc. (2) Reinsurance recoverables include balances ceded under coinsurance transactions of term life insurance policies that were in force as of December 31, 2009. Amounts shown are net of their share of the reinsurance receivable from other reinsurers. Arrangements with these reinsurers include collateral trust agreements held in support of reinsurance recoverables. (3) Includes amounts ceded to Transamerica Reinsurance Companies and fully retroceded to SCOR Global Life Reinsurance Companies. (4) Includes amounts ceded to Lincoln National Life Insurance and fully retroceded to Swiss Re Life & Health America Inc. (5) Entity is rated AA- by S&P.
Allowance for Credit Loss on Reinsurance Recoverable	The rollforward of the allowance for credit losses (“ACL”) on reinsurance recoverables for the years ended December 31, 2022, 2021, and 2020 were as follows: Year ended December 31, 2022 2021 2020 (In thousands) Balance, beginning of period $ 2,942 $ 7,144 $ 3,917 Current period provision for expected credit losses 164 502 3,235 Less: Writeoffs charged against the ACL, if any - ( 4,651 ) - Less: Recoveries of expected credit losses previously recorded ( 170 ) ( 53 ) ( 8 ) Balance, at the end of period $ 2,936 $ 2,942 $ 7,144

Deferred Policy Acquisition C_2

Deferred Policy Acquisition Costs (Tables)	12 Months Ended
	Dec. 31, 2022
Deferred Policy Acquisition Costs Disclosures [Abstract]
Deferred Policy Acquisition Costs Balance Roll Forward	The balances and activity in DAC were as follows: Year ended December 31, 2022 2021 2020 (In thousands) DAC balance, beginning of period $ 2,943,782 $ 2,629,644 $ 2,325,750 Capitalization 514,597 562,999 522,705 Amortization ( 356,143 ) ( 251,179 ) ( 224,321 ) Foreign exchange translation and other ( 20,350 ) 2,318 5,510 DAC balance, end of period $ 3,081,886 $ 2,943,782 $ 2,629,644

Separate Accounts (Tables)

Separate Accounts (Tables)	12 Months Ended
	Dec. 31, 2022
Separate Accounts Disclosure [Abstract]
Schedule of Fair Value of Separate Accounts by Major Category of Investment	The following table represents the fair value of assets supporting separate accounts by major investment category: Year ended December 31, 2022 2021 (In thousands) Fixed-income securities $ 796,384 $ 1,172,425 Equity securities 1,340,541 1,534,993 Cash and cash equivalents 181,162 92,648 Due to/from funds ( 12,399 ) ( 112 ) Other 29 38 Total separate accounts assets $ 2,305,717 $ 2,799,992

Policy Claims and Other Benef_2

Policy Claims and Other Benefits Payable (Tables)	12 Months Ended
	Dec. 31, 2022
Liability For Future Policy Benefits And Unpaid Claims And Claims Adjustment Expense [Abstract]
Schedule of Liability For Future Policy Benefits and Unpaid Claims	Changes in policy claims and other benefits payable were as follows: Year ended December 31, 2022 2021 2020 (In thousands) Policy claims and other benefits payable, beginning of period $ 585,382 $ 519,711 $ 339,954 Less reinsured policy claims and other benefits payable 637,139 545,030 388,797 Net balance, beginning of period ( 51,757 ) ( 25,319 ) ( 48,843 ) Incurred related to current year 248,127 284,719 236,157 Incurred related to prior years (1) ( 4,363 ) ( 216 ) ( 4,033 ) Total incurred 243,764 284,503 232,124 Claims paid related to current year, net of reinsured policy claims received ( 263,114 ) ( 345,130 ) ( 268,914 ) Reinsured policy claims received related to prior years, net of claims paid 67,267 34,128 60,144 Total paid ( 195,847 ) ( 311,002 ) ( 208,770 ) Foreign currency translation ( 531 ) 61 170 Net balance, end of period ( 4,371 ) ( 51,757 ) ( 25,319 ) Add reinsured policy claims and other benefits payable 542,621 637,139 545,030 Balance, end of period $ 538,250 $ 585,382 $ 519,711 (1) Includes the difference between our estimate of claims incurred but not yet reported at year end and the actual incurred claims reported after year end.

Debt (Tables)

Debt (Tables)	12 Months Ended
	Dec. 31, 2022
Debt Disclosure [Abstract]
Schedule of Debt	Notes Payable – Long Term. Notes payable consisted of the following: December 31, 2022 December 31, 2021 (In thousands) 2.80 % Senior Notes, due November 19, 2031 $ 600,000 $ 600,000 Unamortized issuance discount on notes payable ( 2,385 ) ( 2,655 ) Total notes payable $ 597,615 $ 597,345

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Provision for Income Taxes	Income tax expense. Income tax expense (benefit) consists of the following: Current Deferred Total (In thousands) Year ended December 31, 2022 Federal $ 149,034 $ ( 49,683 ) $ 99,351 Foreign 51,692 ( 27,163 ) 24,529 State and local 5,029 ( 3,134 ) 1,895 Total tax expense $ 205,755 $ ( 79,980 ) $ 125,775 Year ended December 31, 2021 Federal $ 115,657 $ ( 10,589 ) $ 105,068 Foreign 43,687 ( 13,890 ) 29,797 State and local 5,440 ( 1,114 ) 4,326 Total tax expense $ 164,784 $ ( 25,593 ) $ 139,191 Year ended December 31, 2020 Federal $ 88,837 $ 853 $ 89,690 Foreign 26,749 ( 547 ) $ 26,202 State and local 4,714 ( 40 ) $ 4,674 Total tax expense $ 120,300 $ 266 $ 120,566
Schedule of Income before Income Taxes by Domestic and Foreign	Income before income taxes. Income before income taxes by domestic and foreign were as follows: Year ended December 31, 2022 2021 2020 (In thousands) Income before income taxes by domestic and foreign Domestic $ 394,773 $ 399,149 $ 411,751 Foreign 98,976 112,022 94,979 Total income before income taxes $ 493,749 $ 511,171 $ 506,730
Schedule of Effective Income Tax Rate Reconciliation	The reconciliation for such difference follows: Year ended December 31, 2022 2021 2020 Amount Percentage Amount Percentage Amount Percentage (Dollars in thousands) Computed tax expense $ 103,687 21.0 % $ 107,346 21.0 % $ 106,413 21.0 % Goodwill impairment loss 12,600 2.6 % 15,960 3.1 % - 0.0 % Difference between foreign statutory 5,571 1.1 % 5,871 1.1 % 5,075 1.0 % Other 3,917 0.8 % 10,014 2.0 % 9,078 1.8 % Total tax expense / $ 125,775 25.5 % $ 139,191 27.2 % $ 120,566 23.8 %
Schedule of Deferred Tax Assets and Liabilities	Deferred tax assets and liabilities. The main components of deferred income tax assets and liabilities were as follows: December 31, 2022 2021 (In thousands) Deferred tax assets: Future policy benefit reserves and unpaid policy claims $ 428,438 $ 353,677 Net operating loss and interest carryforwards 28,675 36,343 Investments 59,085 - Future deductible liabilities 23,217 20,883 Foreign tax credits 36,424 46,455 Other 23,809 27,610 Total deferred tax assets before valuation allowance 599,648 484,968 Valuation allowance ( 36,511 ) ( 46,542 ) Total deferred tax assets after valuation allowance $ 563,137 $ 438,426 Deferred tax liabilities: Deferred policy acquisition costs ( 385,351 ) ( 383,163 ) Renewal commissions receivable ( 53,874 ) ( 60,782 ) Intangibles ( 47,806 ) ( 50,310 ) Investments - ( 17,952 ) Reinsurance deposit asset ( 47,118 ) ( 48,587 ) Other ( 19,112 ) ( 21,833 ) Total deferred tax liabilities ( 553,261 ) ( 582,627 ) Net deferred tax liabilities $ 9,876 $ ( 144,201 )
Summary of Reconciliation of Change in Unrecognized Income Tax Benefit	A reconciliation of the change in the unrecognized income tax benefit for the years ended December 31, 2022 and 2021 is as follows: December 31, 2022 2021 2020 (In thousands) Unrecognized tax benefits, beginning of period $ 19,224 $ 17,104 $ 15,805 Change in prior period unrecognized tax benefits ( 944 ) ( 103 ) 40 Change in current period unrecognized tax benefits 3,993 3,777 3,296 Reductions as a result of a lapse in statute of limitations ( 2,093 ) ( 1,554 ) ( 2,037 ) Unrecognized tax benefits, end of period $ 20,180 $ 19,224 $ 17,104

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2022
Stockholders Equity Note [Abstract]
Reconciliation of Number of Shares of Common Stock	A reconciliation of the number of shares of our common stock follows: Year ended December 31, 2022 2021 2020 (In thousands) Common stock, beginning of period 39,368 39,306 41,207 Shares issued for stock options exercised - 10 - Shares of common stock issued upon lapse of sales restrictions on RSUs 236 225 335 Common stock retired ( 2,780 ) ( 173 ) ( 2,236 ) Common stock, end of period 36,824 39,368 39,306

Earnings Per Share (Tables)

Earnings Per Share (Tables)	12 Months Ended
	Dec. 31, 2022
Earnings Per Share [Abstract]
Calculation of Basic and Diluted Earnings Per Share	The calculation of basic and diluted EPS was as follows: Year ended December 31, 2022 2021 2020 (In thousands, except per-share amounts) Basic EPS: Numerator: Net income attributable to Primerica, Inc. $ 373,012 $ 373,357 $ 386,164 Income attributable to unvested participating securities ( 1,684 ) ( 1,533 ) ( 1,671 ) Net income used in calculating basic EPS $ 371,328 $ 371,824 $ 384,493 Denominator: Weighted-average vested shares 37,997 39,530 40,065 Basic EPS $ 9.77 $ 9.41 $ 9.60 Diluted EPS: Numerator: Net income attributable to Primerica, Inc. $ 373,012 $ 373,357 $ 386,164 Income attributable to unvested participating securities ( 1,680 ) ( 1,529 ) ( 1,667 ) Net income used in calculating diluted EPS $ 371,332 $ 371,828 $ 384,497 Denominator: Weighted-average vested shares 37,997 39,530 40,065 Dilutive effect of incremental shares to be issued for 109 122 120 Weighted-average shares used in calculating diluted EPS 38,106 39,652 40,185 Diluted EPS $ 9.74 $ 9.38 $ 9.57

Share-Based Transactions (Table

Share-Based Transactions (Tables)	12 Months Ended
	Dec. 31, 2022
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity	The following table summarizes employee and director RSU activity during the years ended December 31, 2022, 2021, and 2020. Shares Weighted-average measurement-date fair value per share (Shares in thousands) Unvested employee and director RSUs, December 31, 2019 180 $ 107.59 Granted 94 119.03 Forfeited - (1) 121.42 Vested ( 108 ) 101.75 Unvested employee and director RSUs, December 31, 2020 166 117.87 Granted 84 144.95 Forfeited ( 4 ) 147.23 Vested ( 93 ) 116.55 Unvested employee and director RSUs, December 31, 2021 153 132.85 Granted 113 117.06 Forfeited ( 3 ) 123.38 Vested ( 90 ) 129.89 Unvested employee and director RSUs, December 31, 2022 173 131.78 (1) Less than 1,000 shares
Schedule of Share-Based Transactions, PSU Activity	The following table summarizes PSU activity during the years ended December 31, 2022, 2021, and 2020. Shares Weighted-average measurement-date fair value per share (Shares in thousands) Unvested employee PSUs, December 31, 2019 (1) 91 $ 98.79 Granted 26 121.42 Forfeited - - Performance Adjustment 5 80.45 Vested ( 41 ) 80.45 Unvested employee PSUs, December 31, 2020 (1) 81 113.99 Granted 22 143.04 Forfeited - - Performance Adjustment 3 100.55 Vested ( 33 ) 100.55 Unvested employee PSUs, December 31, 2021 (1) 73 128.30 Granted 27 130.30 Forfeited - - Performance Adjustment 2 122.62 Vested ( 28 ) 122.62 Unvested employee PSUs, December 31, 2022 (1) 74 130.97 (1) The 2020 PSU awards outstanding are based on the actual performance. As a result of the performance achieved during the performance period, recipients will receive an aggregate of 20,559 shares of common stock on the vesting date of March 1, 2023, reflecting a payout rate of 79.9 %. The 2021 PSU awards outstanding are based on target. Depending upon the performance achieved during the performance period, recipients may receive between 0 and 32,768 shares of common stock. The 2022 PSU awards outstanding are based on target. Depending upon the performance achieved during the performance period, recipients may receive between 0 and 39,713 shares of common stock.
Summary of Activity Related to Stock Options Outstanding and Exercisable	The following table summarizes activity related to stock options outstanding and exercisable during the years ended December 31, 2022, 2021, and 2020: Outstanding Exercisable Number of shares Weighted average exercise price Number of shares Weighted average exercise price (Shares in thousands) Outstanding at December 31, 2019 70 $ 44.23 70 $ 44.23 Granted - - Exercised - - Outstanding at December 31, 2020 70 44.23 70 44.23 Granted - - Exercised ( 10 ) 41.88 Outstanding at December 31, 2021 60 44.62 60 44.62 Granted - - Exercised - - Outstanding at December 31, 2022 60 44.62 60 44.62 Range of granted option exercise prices outstanding at December 31, 2022 $ 41.20 (average term remaining - 1.1 years) 3 $ 41.20 3 $ 41.20 $ 53.50 (average term remaining - 2.2 years) 14 53.50 14 53.50 $ 41.88 (average term remaining - 3.2 years) 42 41.88 42 41.88
Summary of Intrinsic Value, Tax Benefit Realized and Value of Shares Withheld Related to Option Exercise Activity	The intrinsic value, tax benefit realized and value of shares withheld related to option exercise activity are summarized as follows: Year ended December 31, 2022 2021 2020 (In thousands) Intrinsic value of options exercised $ - $ 1,156 $ - Tax benefit realized from the options exercised - - - Value of issued shares withheld to satisfy option - 419 -
Schedule of Share-based Goods and Nonemployee Services Transaction by Supplier	The following table summarizes non-employee RSU activity during the years ended December 31, 2022, 2021, and 2020. Shares Weighted-average measurement-date fair value per share (Shares in thousands) Unvested non-employee RSUs, December 31, 2019 24 $ 132.68 Granted 128 106.65 Vested ( 126 ) 105.71 Unvested non-employee RSUs, December 31, 2020 26 134.75 Granted 99 150.72 Vested ( 94 ) 145.03 Unvested non-employee RSUs, December 31, 2021 31 154.59 Granted 118 129.99 Vested ( 117 ) 133.25 Unvested non-employee RSUs, December 31, 2022 32 141.60
Schedule of Compensation Cost and Tax Benefits for Share Based Payment Arrangements Nonemployee Equity Awards	Details on the granting and valuation of these awards were as follows: Year ended December 31, 2022 2021 2020 (In thousands) Quarterly incentive awards expense recognized currently $ 4,060 $ 4,036 $ 3,630 Quarterly incentive awards expense deferred 11,260 10,807 10,071 Tax benefit associated with incentive awards 3,056 2,904 2,692
Restricted stock units (RSUs) [Member] | Employee and Director [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Schedule of Share-Based Compensation, Recognized Expense and Tax Benefit Offsets	We recognized expense and tax benefit offsets as follows for employee and director RSU share-based compensation: Year ended December 31, 2022 2021 2020 (In thousands) Total equity awards expense recognized $ 12,626 $ 11,779 $ 11,218 Tax benefit associated with total employee and director 1,642 1,638 1,455
Performance share units (PSUs) [Member] | Employee [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Schedule of Share-Based Compensation, Recognized Expense and Tax Benefit Offsets	In connection with our granting of PSU awards, we recognized expense and tax benefit offsets as follows: Year ended December 31, 2022 2021 2020 (In thousands) Total employee PSU award expense $ 2,092 $ 3,494 $ 4,179 Tax benefit associated with total employee PSU award expense - - -
Employee Stock Option [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Schedule of Share-Based Compensation, Recognized Expense and Tax Benefit Offsets	Compensation expense and related tax benefits recognized for stock option awards were as follows: Year ended December 31, 2022 2021 2020 (In thousands) Expense recognized for stock option awards $ - $ - $ - Tax benefit recognized for stock option awards - - -

Statutory Accounting and Divi_2

Statutory Accounting and Dividend Restrictions (Tables)	12 Months Ended
	Dec. 31, 2022
Insurance [Abstract]
Statutory Accounting Practices Disclosure	Primerica Life’s statutory capital and surplus as of December 31, 2022 and 2021 were as follows: December 31, 2022 December 31, 2021 (In thousands) Statutory capital and surplus $ 834,565 $ 779,620

Revenue from Contracts with C_2

Revenue from Contracts with Customers (Tables)	12 Months Ended
	Dec. 31, 2022
Revenue From Contract With Customer [Abstract]
Summary of Disaggregation of Revenues from Contracts	The disaggregation of our revenues from contracts with customers were as follows: Year ended December 31, 2022 2021 2020 (In thousands) Term Life Insurance segment revenues: Other, net $ 50,320 $ 48,970 $ 46,079 Total segment revenues from contracts with customers 50,320 48,970 46,079 Revenues from sources other than contracts with customers 1,636,806 1,526,716 1,336,691 Total Term Life Insurance segment revenues $ 1,687,126 $ 1,575,686 $ 1,382,770 Investment and Savings Products segment revenues: Commissions and fees: Sales-based revenues $ 326,378 $ 401,508 $ 284,651 Asset-based revenues 375,502 376,751 282,080 Account-based revenues 90,391 86,939 83,041 Other, net 12,610 12,097 11,271 Total segment revenues from contracts with customers 804,881 877,295 661,043 Revenues from sources other than contracts 58,551 64,552 57,824 Total Investment and Savings Products segment revenues $ 863,432 $ 941,847 $ 718,867 Senior Health segment revenues: Commissions and fees $ 47,420 $ 50,903 N/A Other, net 15,262 9,537 N/A Total Senior Health segment revenues 62,682 60,440 N/A Corporate and Other Distributed Products segment revenues: Commissions and fees $ 46,434 $ 62,160 $ 43,675 Other, net 4,967 3,971 3,719 Total segment revenues from contracts with customers 51,401 66,131 47,394 Revenues from sources other than contracts with customers 55,492 65,628 68,510 Total Corporate and Other Distributed Products segment revenues $ 106,893 $ 131,759 $ 115,904
Summary of Renewal Commissions Receivable	Activity in the Renewal commissions receivable account was as follows: December 31, 2022 December 31, 2021 (In thousands) Senior Health segment: Balance, beginning of period $ 172,308 $ - Contract balances acquired as part of business combination - 199,575 Measurement period adjustment ( 11,863 ) ( 46,128 ) Commissions revenue 42,628 37,225 Less: collections ( 40,740 ) ( 13,442 ) Tail revenue adjustment from change in estimate ( 22,934 ) ( 4,922 ) Balance, at the end of period $ 139,399 $ 172,308 Corporate and Other Distributed Products segment: Balance, beginning of period $ 59,443 $ 54,845 Commissions revenue 25,325 27,618 Less: collections ( 24,124 ) ( 23,020 ) Balance, at the end of period $ 60,644 $ 59,443

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2022
Lessee Disclosure [Abstract]
Schedule of Components of Lease Expense	The components of lease expense were as follows: Year ended December 31, 2022 2021 2020 (In thousands) Operating lease cost Operating lease cost $ 9,686 $ 8,620 $ 7,638 Variable lease cost (includes taxes, common area maintenance and insurance) 1,099 980 725 Finance lease cost Depreciation of finance lease assets 271 280 280 Interest on lease liabilities 55 60 56 Total lease cost $ 11,111 $ 9,940 $ 8,699
Schedule of Other Information Related to Leases	Other information related to leases was as follows: December 31, 2022 December 31, 2021 December 31, 2020 (In thousands) Supplemental Cash Flows Information Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows used in operating leases (1) $ 9,960 $ 8,878 $ 7,737 Operating cash flows used in finance leases (1) 55 60 56 Financing cash flows used in finance leases 262 264 274 (1) Included in change in other operating assets and liabilities, net in the accompanying consolidated statements of cash flows. December 31, 2022 December 31, 2021 (In thousands) Weighted Average Remaining Lease Term Operating leases 6 years 6 years Finance leases 3 years 4 years Weighted Average Discount Rate Operating leases 4.2 % 4.1 % Finance leases 6.0 % 6.2 %
Schedule of Future Minimum Lease Payments Under Non-Cancellable Leases	Future minimum lease payments under non-cancellable leases were as follows: Operating Leases Finance Leases Year Ended December 31, (In thousands) 2023 $ 10,009 $ 302 2024 9,745 269 2025 8,446 192 2026 8,199 78 2027 8,098 - Thereafter 7,290 - Total minimum rental commitments for operating leases 51,787 841 Less imputed interest 5,792 66 Total lease liabilities $ 45,995 $ 775

Acquisition (Tables)

Acquisition (Tables)	12 Months Ended
	Dec. 31, 2022
Business Combinations [Abstract]
Summary of Identified Assets Acquired and Liabilities Assumed at Acquisition Date	The following table presents the preliminary purchase price allocation recorded in the Company’s consolidated balance sheets as of the Acquisition Date, adjustments made during the measurement period that ended June 30, 2022, and the final purchase price allocation: Preliminary Purchase Price Allocation 2021 Measurement Period Adjustments 2022 Measurement Period Adjustments Revised Preliminary Purchase Price Allocation (In thousands) Assets: Cash and cash equivalent $ 1,080 $ - $ - $ 1,080 Accounts receivables 692 ( 389 ) - 303 Renewal commissions receivable 199,575 ( 46,128 ) ( 11,863 ) 141,584 Other assets 15,705 - - 15,705 Intangible assets 162,000 ( 6,000 ) - 156,000 Goodwill 224,180 30,973 8,553 263,706 Total assets $ 603,232 $ ( 21,544 ) $ ( 3,310 ) $ 578,378 Liabilities: Accounts payable and accrued expenses 8,785 ( 4,195 ) (1) - 4,590 Deferred tax liability 65,425 ( 13,482 ) ( 3,310 ) 48,633 Other liabilities 10,046 - - 10,046 Total liabilities 84,256 ( 17,677 ) ( 3,310 ) 63,269 Net assets acquired $ 518,976 $ ( 3,867 ) $ - $ 515,109 Temporary Stockholders' Equity: Redeemable noncontrolling interests $ 8,437 $ - $ - $ 8,437 Total temporary stockholders' equity $ 8,437 $ - $ - $ 8,437 (1) The Company also recognized an adjustment during the measurement period to reclassify certain amounts from a payable to a reduction in the renewal commissions receivable.
Summary of Unaudited Proforma Information	The following unaudited pro forma consolidated financial information combines the audited results of the Company for the years ended December 31, 2021 and 2020 and the unaudited results of e-TeleQuote for the year ended December 31, 2021 and 2020, and assumes that the Acquisition, which closed on July 1, 2021, was completed on January 1, 2020 (the first day of fiscal year 2020). The pro forma consolidated financial information has been calculated after applying adjustments for amortization expense of acquired intangible assets and the consequential tax effect. These pro forma results have been prepared for comparative purpose only and do not purport to be indicative of the operating results of the Company that would have been achieved had the e-TeleQuote acquisition actually taken place on January 1, 2020. Year ended December 31, 2021 2020 (in thousands) Revenue $ 2,774,991 $ 2,369,811 Net income (loss) 361,783 391,527

Description of Business, Basi_4

Description of Business, Basis of Presentation, and Summary of Significant Accounting Policies - Narrative (Details) - USD ($) $ in Thousands			12 Months Ended
	Jul. 01, 2022	Jul. 01, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Organization Consolidation Basis Of Presentation Business Description And Accounting Policies [Line Items]
Percentage of net premium ratio capped			100%
Future policy benefits reserve percentage of net premium ratio			100%
Future policy benefits reserve retained earnings			$ 50,000
Increase in AOCI upon application of market observable rates			150,000
Decrease in AOCI upon application of market observable rates			150,000
Goodwill impairment loss			60,000	$ 76,000
Goodwill			127,707	179,154
Accumulated goodwill impairment charges			136,000
Depreciation expense			$ 24,100	$ 24,600	$ 18,000
Guarantee maturity value as percentage of net premiums			75%
Accounting standards update [extensible enumeration]			us-gaap:AccountingStandardsUpdate201812Member
Term Life Insurance Segment [Member]
Organization Consolidation Basis Of Presentation Business Description And Accounting Policies [Line Items]
Percentage of net premium ratio capped			100%
Accounting standards update [extensible enumeration]			us-gaap:AccountingStandardsUpdate201812Member
Minimum [Member]
Organization Consolidation Basis Of Presentation Business Description And Accounting Policies [Line Items]
AOCI and equity, net of income tax			$ 1,200,000
Interest rate reserve assumptions			2.50%	2.50%
Maximum [Member]
Organization Consolidation Basis Of Presentation Business Description And Accounting Policies [Line Items]
AOCI and equity, net of income tax			$ 1,500,000
Interest rate reserve assumptions			7%	7%
Etelequote Bermuda [Member]
Organization Consolidation Basis Of Presentation Business Description And Accounting Policies [Line Items]
Business acquisition, date of acquisition agreement		Jul. 01, 2021
Business acquisition, effective date of acquisition	Jul. 01, 2022
Percentage of interest acquired		80%
Remaining percentage of interest acquired	20%
Goodwill		$ 263,700
Intangible asset amortization expense			$ 10,300	$ 5,500
Amortization expense expected year one			10,500
Amortization expense expected year two			10,500
Amortization expense expected year three			10,500
Amortization expense expected year four			10,500
Amortization expense expected year five			$ 10,500
Etelequote Bermuda [Member] | Customer Relationships [Member]
Organization Consolidation Basis Of Presentation Business Description And Accounting Policies [Line Items]
Estimated useful life		15 years	15 years

Description of Business, Basi_5

Description of Business, Basis of Presentation, and Summary of Significant Accounting Policies - Intangible Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Indefinite-lived intangible asset	$ 45,275	$ 45,275
Amortizing intangible assets, Gross carrying value	156,000	156,000
Amortizing intangible assets, Accumulated amortization	(15,750)	(5,450)
Amortizing intangible assets, Net carrying amount	140,250	150,550
Total intangible assets, Gross carrying amount	201,275	201,275
Total intangible assets, Net carrying amount	$ 185,525	$ 195,825

Description of Business, Basi_6

Description of Business, Basis of Presentation, and Summary of Significant Accounting Policies - Property, Plant and Equipment Useful Life (Details)	12 Months Ended
	Dec. 31, 2022
Data Processing Equipment and Software [Member] | Minimum [Member]
Finite Lived Intangible Assets [Line Items]
Property and equipment, useful life	3 years
Data Processing Equipment and Software [Member] | Maximum [Member]
Finite Lived Intangible Assets [Line Items]
Property and equipment, useful life	7 years
Leasehold Improvements [Member] | Maximum [Member]
Finite Lived Intangible Assets [Line Items]
Property and equipment, useful life	15 years
Furniture and Fixtures [Member] | Minimum [Member]
Finite Lived Intangible Assets [Line Items]
Property and equipment, useful life	5 years
Furniture and Fixtures [Member] | Maximum [Member]
Finite Lived Intangible Assets [Line Items]
Property and equipment, useful life	15 years

Description of Business, Basi_7

Description of Business, Basis of Presentation, and Summary of Significant Accounting Policies - Property, Plant, and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Data processing equipment and software	$ 132,596	$ 127,151
Leasehold improvements	18,137	18,631
Other, principally furniture and equipment	35,592	36,460
Total property, plant and equipment, Gross	186,325	182,242
Accumulated depreciation	(133,668)	(115,220)
Net property and equipment	$ 52,657	$ 67,022

Other Comprehensive Income (Det

Other Comprehensive Income (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Foreign currency translation adjustments:
Change in unrealized foreign currency translation gains (losses)	$ (20,015)	$ 7,033	$ 7,343
Change in unrealized foreign currency translation gains (losses), net of income taxes	(20,015)	7,033	7,343
Unrealized gain (losses) on available-for-sale securities:
Change in unrealized holding gains (losses) arising during period before income taxes	(385,735)	(78,348)	78,533
Income tax expense (benefit) on unrealized holding gains (losses) arising during period	(82,185)	(17,038)	17,033
Change in unrealized holding gains (losses) on available-for-sale securities arising during period, net of income taxes	303,550	61,310	(61,500)
Reclassification from accumulated OCI to net income for (gains) losses realized on available-for-sale securities	(1,387)	(3,849)	2,614
Income tax (expense) benefit on (gains) losses reclassified from accumulated OCI to net income	(292)	(808)	549
Reclassification from accumulated OCI to net income for (gains) losses realized on available-for-sale securities, net of income taxes	(1,095)	(3,041)	2,065
Change in unrealized gains (losses) on available-for-sale securities, net of income taxes and reclassification adjustment	$ (304,645)	$ (64,351)	$ 63,565

Segment and Geographical Info_3

Segment and Geographical Information - Narrative (Details)	12 Months Ended
	Dec. 31, 2022 Segment
Segment Reporting Information [Line Items]
Number of operating segments	3
Vidalia Re Coinsurance Agreement [Member]
Segment Reporting Information [Line Items]
Percentage of coinsurance costs	10%

Segment and Geographical Info_4

Segment and Geographical Information - Summary of Assets and Profit or Loss by Segment (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Segment Reporting Information [Line Items]
Revenues		$ 2,720,133	$ 2,709,732	$ 2,217,541
Net investment income		93,065	80,588	83,814
Amortization of deferred policy acquisition costs		356,143	251,179	224,321
Non-cash share-based compensation expense		22,361	16,842	19,027
Income (loss) before income taxes		493,749	511,171	506,730
Assets		15,348,877	16,123,223	14,905,285
Term Life Insurance Segment [Member]
Segment Reporting Information [Line Items]
Revenues		1,687,126	1,575,686	1,382,770
Net investment income		51,160	36,486	27,030
Amortization of deferred policy acquisition costs		342,925	241,451	216,208
Non-cash share-based compensation expense		4,133	4,153	3,612
Income (loss) before income taxes		448,540	414,619	372,551
Assets		7,175,746	7,274,820	6,985,086
Investment and Savings Products Segment [Member]
Segment Reporting Information [Line Items]
Revenues		863,432	941,847	718,867
Amortization of deferred policy acquisition costs		12,141	8,668	7,055
Non-cash share-based compensation expense		3,212	3,206	3,045
Income (loss) before income taxes		239,330	274,585	202,644
Assets	[1]	2,415,041	2,920,271	2,769,445
Senior Health Segment [Member]
Segment Reporting Information [Line Items]
Revenues		62,682	60,440
Non-cash share-based compensation expense		210
Income (loss) before income taxes		(98,673)	(85,050)
Assets		431,993	528,974
Corporate and Other Distributed Products Segment [Member]
Segment Reporting Information [Line Items]
Revenues		106,893	131,759	115,904
Net investment income		41,905	44,102	56,784
Amortization of deferred policy acquisition costs		1,077	1,060	1,058
Non-cash share-based compensation expense		14,806	9,483	12,370
Income (loss) before income taxes		(95,448)	(92,983)	(68,465)
Assets		$ 5,326,097	$ 5,399,158	$ 5,150,754
[1] The Investment and Savings Products segment includes assets held in separate accounts. Excluding separate accounts, the Investment and Savings Products segment assets were $ 109.3 million, $ 120.3 million, and $ 110.0 million as of December 31, 2022, 2021, and 2020 , respectively.

Segment and Geographical Info_5

Segment and Geographical Information - Summary of Assets and Profit or Loss by Segment (Parenthetical) (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Investment and Savings Products Segment [Member]
Segment Reporting Information [Line Items]
Assets, excluding separate account assets	$ 109.3	$ 120.3	$ 110

Segment and Geographical Info_6

Segment and Geographical Information - Long Lived Assets and Continuing Operations by Country (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Revenues From External Customers And Long Lived Assets [Line Items]
Revenues	$ 2,720,133	$ 2,709,732	$ 2,217,541
Long-lived assets	52,657	67,022	57,727
United States [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Revenues	2,355,139	2,311,051	1,895,708
Long-lived assets	49,637	62,921	53,281
Canada [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Revenues	364,994	398,681	321,833
Long-lived assets	2,803	3,871	$ 4,446
Other [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Long-lived assets	$ 217	$ 230

Investments - Schedule of AFS S

Investments - Schedule of AFS Securities (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale debt securities, at fair value	$ 2,495,456	$ 2,702,567
U.S. Government and Agencies [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale debt securities, amortized cost basis	31,217	32,292
Available-for-sale debt securities gross unrealized gain	18	187
Available-for-sale debt securities, gross unrealized loss	(767)	(79)
Available-for-sale debt securities, at fair value	30,468	32,400
Foreign Government [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale debt securities, amortized cost basis	163,725	147,288
Available-for-sale debt securities gross unrealized gain	780	6,283
Available-for-sale debt securities, gross unrealized loss	(11,590)	(595)
Available-for-sale debt securities, at fair value	152,915	152,976
States and Political Subdivisions [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale debt securities, amortized cost basis	142,189	147,455
Available-for-sale debt securities gross unrealized gain	112	6,326
Available-for-sale debt securities, gross unrealized loss	(20,056)	(254)
Available-for-sale debt securities, at fair value	122,245	153,527
Corporates [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale debt securities, amortized cost basis	1,665,962	1,649,334
Available-for-sale debt securities gross unrealized gain	2,439	72,418
Available-for-sale debt securities, gross unrealized loss	(171,552)	(8,068)
Available-for-sale debt securities, at fair value	1,496,849	1,713,684
Residential Mortgage-backed Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale debt securities, amortized cost basis	473,309	373,753
Available-for-sale debt securities gross unrealized gain	370	5,108
Available-for-sale debt securities, gross unrealized loss	(71,949)	(3,230)
Available-for-sale debt securities, at fair value	401,730	375,631
Commercial Mortgage-backed Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale debt securities, amortized cost basis	139,306	142,631
Available-for-sale debt securities gross unrealized gain	3	3,314
Available-for-sale debt securities, gross unrealized loss	(16,342)	(420)
Available-for-sale debt securities, at fair value	122,967	145,525
Other Asset-backed Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale debt securities, amortized cost basis	185,707	128,635
Available-for-sale debt securities gross unrealized gain	108	1,409
Available-for-sale debt securities, gross unrealized loss	(17,533)	(1,220)
Available-for-sale debt securities, at fair value	168,282	128,824
Fixed Maturities [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale debt securities, amortized cost basis	2,801,415	2,621,388
Available-for-sale debt securities gross unrealized gain	3,830	95,045
Available-for-sale debt securities, gross unrealized loss	(309,789)	(13,866)
Available-for-sale debt securities, at fair value	2,495,456	2,702,567
Short Term Investments [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale debt securities, amortized cost basis	69,393	85,246
Available-for-sale debt securities gross unrealized gain	20	1
Available-for-sale debt securities, gross unrealized loss	(7)	(4)
Available-for-sale debt securities, at fair value	69,406	85,243
Fixed-Maturity Securities and Short-term Investments [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale debt securities, amortized cost basis	2,870,808	2,706,634
Available-for-sale debt securities gross unrealized gain	3,850	95,046
Available-for-sale debt securities, gross unrealized loss	(309,796)	(13,870)
Available-for-sale debt securities, at fair value	$ 2,564,862	$ 2,787,810

Investments - Fixed-maturity Se

Investments - Fixed-maturity Securities Classified by Contractual Maturity Securities (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Available-for-sale Securities, Debt Maturities [Abstract]
Available-for-sale debt securities, at fair value	$ 2,495,456	$ 2,702,567
Fixed Maturities
Available-for-sale Securities, Debt Maturities [Abstract]
Due in one year or less, amortized cost	165,117
Due after one year through five years, amortized cost	783,376
Due after five years through 10 years, amortized cost	763,273
Due after 10 years, amortized cost	291,327
Total fixed-maturity securities with single maturity dates, amortized cost	2,003,093
Mortgage and asset-backed securities, amortized cost	798,322
Available-for-sale debt securities, amortized cost basis	2,801,415	2,621,388
Due in one year or less, fair value	163,831
Due after one year through five years, fair value	740,167
Due after five years through 10 years, fair value	658,194
Due after 10 years, fair value	240,285
Total fixed-maturity securities with single maturity dates, fair value	1,802,477
Mortgage and asset-backed securities, fair value	692,979
Available-for-sale debt securities, at fair value	$ 2,495,456	$ 2,702,567

Investments - Costs and Fair Va

Investments - Costs and Fair Values of Fixed-Maturity Securities Classified as Trading Securities (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Schedule Of Trading Securities And Other Trading Assets [Line Items]
Total trading securities, cost	$ 4,229	$ 24,769
Fixed Maturities
Schedule Of Trading Securities And Other Trading Assets [Line Items]
Total trading securities, cost	4,229	24,769
Total trading securities, Fair value	$ 3,698	$ 24,355

Investments - Held-to-maturity

Investments - Held-to-maturity Security - Narrative (Details)	12 Months Ended
	Dec. 31, 2022 USD ($)
Schedule Of Held To Maturity Securities [Line Items]
Held-to-maturity debt security estimated unrealized holding loss	$ (104,700,000)
Held-to-maturity debt security Credit losses	$ 0
LLC Note [Member]
Schedule Of Held To Maturity Securities [Line Items]
Debt instrument, maturity date	Dec. 31, 2030
Debt instrument, interest rate, stated percentage	4.50%
Surplus Note [Member]
Schedule Of Held To Maturity Securities [Line Items]
Debt instrument, maturity date	Dec. 31, 2030
Debt instrument, interest rate, stated percentage	4.50%

Investments - Fair Value of Inv

Investments - Fair Value of Investments on Deposit with Governmental Authorities - Narrative (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Investments Debt And Equity Securities [Abstract]
Fair values of investments on deposit	$ 7.1	$ 7.6

Investments - Securities Lendin

Investments - Securities Lending Collateral - Narrative (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Securities Received as Collateral [Abstract]
Securities loaned, minimum collateral to loan ratio	102%
Securities loaned, additional collateral requirement, decline in collateral value threshold percentage	100%
Cash collateral received and reinvested	$ 100.9	$ 94.5

Investments - Net Investment In

Investments - Net Investment Income (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Schedule of Net Investment Income, Reported Amounts, by Category [Line Items]
Gross investment income, operating		$ 163,330	$ 147,551	$ 148,728
Investment expenses		(6,343)	(4,756)	(7,441)
Investment income net of investment expenses		156,987	142,795	141,287
Interest expense on surplus note		(63,922)	(62,207)	(57,473)
Net investment income		93,065	80,588	83,814
Equity Securities [Member]
Schedule of Net Investment Income, Reported Amounts, by Category [Line Items]
Gross investment income, operating		1,509	1,632	1,751
Policy Loans and Other Invested Assets [Member]
Schedule of Net Investment Income, Reported Amounts, by Category [Line Items]
Gross investment income, operating		1,046	1,019	1,244
Cash, Cash Equivalents and Short-Term Investments [Member]
Schedule of Net Investment Income, Reported Amounts, by Category [Line Items]
Gross investment income, operating		5,943	456	1,202
Total return on deposit asset underlying 10% insurance agreement [Member]
Schedule of Net Investment Income, Reported Amounts, by Category [Line Items]
Gross investment income, operating	[1]	(65)	1,875	4,253
Available-for-Sale [Member] | Fixed Maturities
Schedule of Net Investment Income, Reported Amounts, by Category [Line Items]
Gross investment income, operating		90,975	80,362	82,805
Held-to-Maturity [Member] | Fixed Maturities
Schedule of Net Investment Income, Reported Amounts, by Category [Line Items]
Gross investment income, operating		$ 63,922	$ 62,207	$ 57,473
[1] Includes $( 3.8 ) million, $( 2.5 ) million, and $ 2.0 million of net gains (losses) recognized for the change in fair value of the deposit asset underlying the 10 % coinsurance agreement for the years ended December 31, 2022, 2021, and 2020, respectively.

Investments - Net Investment _2

Investments - Net Investment Income (Parenthetical) (Details) - Deposit asset underlying 10% coinsurance agreement [Member] - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Schedule of Net Investment Income, Reported Amounts, by Category [Line Items]
Gains (Losses) recognized for change in fair value of deposit asset underlying the 10% coinsurance agreement	$ (3.8)	$ (2.5)	$ 2
Fair Value, Asset, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Realized Investment Gains Losses	Realized Investment Gains Losses	Realized Investment Gains Losses
Percentage of coinsurance costs	10%	10%	10%

Investments - Schedule of Inves

Investments - Schedule of Investment Gains and Losses (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Realized investment gains (losses):
Gross gains from sales of available-for-sale fixed maturity and equity securities	$ 2,036	$ 7,060	$ 2,595
Gross gains from sales of available-for-sale fixed maturity and equity securities			12
Gross losses from sales of available-for-sale fixed maturity and equity securities	(592)	(2,395)	(955)
Gross losses from sales of available-for-sale fixed maturity and equity securities			(293)
Realized investment gains (losses)	1,444	4,665	1,359
Other investment gains (losses):
Credit losses impairment of available-for-sale securities	(57)	(816)	(4,254)
Market gains (losses) recognized in net income during the period on equity securities	(2,375)	2,362	(2,154)
Gains (losses) from bifurcated options		(57)	57
Gains (losses) on trading securities	(7)	(282)	(4)
Other investment gains (losses):	(2,439)	1,207	(6,355)
Investment gains (losses)	$ (995)	$ 5,872	$ (4,996)

Investments - Schedule of Proce

Investments - Schedule of Proceeds from Sales or Other Redemptions of Available-For-Sale Securities (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Proceeds From Sale And Maturity Of Available For Sale Securities [Abstract]
Proceeds from sales or other redemptions	$ 496,898	$ 676,153	$ 496,907

Investments - Schedule of Secur

Investments - Schedule of Securities in Unrealized Loss Position (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities, continuous unrealized loss position, less than 12 months, fair value	$ 1,512,436	$ 839,581
Available-for-sale securities, continuous unrealized loss position, less than 12 months, aggregate losses	(118,080)	(10,309)
Available-for-sale securities, continuous unrealized loss position, 12 months or longer, fair value	891,530	70,909
Available-for-sale securities, continuous unrealized loss position, 12 months or longer, aggregate losses	(191,716)	(3,561)
Fixed Maturities
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities, continuous unrealized loss position, less than 12 months, fair value	1,482,313	764,334
Available-for-sale securities, continuous unrealized loss position, less than 12 months, aggregate losses	(118,073)	(10,305)
Available-for-sale securities, continuous unrealized loss position, 12 months or longer, fair value	891,530	70,909
Available-for-sale securities, continuous unrealized loss position, 12 months or longer, aggregate losses	(191,716)	(3,561)
Short-Term Investments
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities, continuous unrealized loss position, less than 12 months, fair value	30,123	75,247
Available-for-sale securities, continuous unrealized loss position, less than 12 months, aggregate losses	(7)	(4)
U.S. Government and Agencies [Member] | Fixed Maturities
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities, continuous unrealized loss position, less than 12 months, fair value	4,927	24,928
Available-for-sale securities, continuous unrealized loss position, less than 12 months, aggregate losses	(204)	(45)
Available-for-sale securities, continuous unrealized loss position, 12 months or longer, fair value	25,209	1,557
Available-for-sale securities, continuous unrealized loss position, 12 months or longer, aggregate losses	(563)	(34)
U.S. Government and Agencies [Member] | Short-Term Investments
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities, continuous unrealized loss position, less than 12 months, fair value	28,379	34,967
Available-for-sale securities, continuous unrealized loss position, less than 12 months, aggregate losses	(5)
Foreign Government [Member] | Fixed Maturities
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities, continuous unrealized loss position, less than 12 months, fair value	97,094	18,894
Available-for-sale securities, continuous unrealized loss position, less than 12 months, aggregate losses	(4,430)	(384)
Available-for-sale securities, continuous unrealized loss position, 12 months or longer, fair value	38,085	3,335
Available-for-sale securities, continuous unrealized loss position, 12 months or longer, aggregate losses	(7,160)	(211)
Foreign Government [Member] | Short-Term Investments
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities, continuous unrealized loss position, less than 12 months, fair value	1,744	4,995
Available-for-sale securities, continuous unrealized loss position, less than 12 months, aggregate losses	(2)
States and Political Subdivisions [Member] | Fixed Maturities
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities, continuous unrealized loss position, less than 12 months, fair value	71,131	15,909
Available-for-sale securities, continuous unrealized loss position, less than 12 months, aggregate losses	(10,666)	(254)
Available-for-sale securities, continuous unrealized loss position, 12 months or longer, fair value	44,324
Available-for-sale securities, continuous unrealized loss position, 12 months or longer, aggregate losses	(9,390)
States and Political Subdivisions [Member] | Short-Term Investments
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities, continuous unrealized loss position, less than 12 months, fair value		11,394
Available-for-sale securities, continuous unrealized loss position, less than 12 months, aggregate losses		(1)
Corporates [Member] | Fixed Maturities
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities, continuous unrealized loss position, less than 12 months, fair value	974,931	341,963
Available-for-sale securities, continuous unrealized loss position, less than 12 months, aggregate losses	(69,726)	(5,035)
Available-for-sale securities, continuous unrealized loss position, 12 months or longer, fair value	452,541	59,414
Available-for-sale securities, continuous unrealized loss position, 12 months or longer, aggregate losses	(101,826)	(3,033)
Corporates [Member] | Short-Term Investments
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities, continuous unrealized loss position, less than 12 months, fair value		23,891
Available-for-sale securities, continuous unrealized loss position, less than 12 months, aggregate losses		(3)
Residential Mortgage-backed Securities [Member] | Fixed Maturities
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities, continuous unrealized loss position, less than 12 months, fair value	187,158	234,911
Available-for-sale securities, continuous unrealized loss position, less than 12 months, aggregate losses	(22,171)	(3,131)
Available-for-sale securities, continuous unrealized loss position, 12 months or longer, fair value	201,595	2,707
Available-for-sale securities, continuous unrealized loss position, 12 months or longer, aggregate losses	(49,778)	(99)
Commercial Mortgage-backed Securities [Member] | Fixed Maturities
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities, continuous unrealized loss position, less than 12 months, fair value	65,165	47,220
Available-for-sale securities, continuous unrealized loss position, less than 12 months, aggregate losses	(5,069)	(419)
Available-for-sale securities, continuous unrealized loss position, 12 months or longer, fair value	56,799	117
Available-for-sale securities, continuous unrealized loss position, 12 months or longer, aggregate losses	(11,273)	(1)
Other Asset-backed Securities [Member] | Fixed Maturities
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities, continuous unrealized loss position, less than 12 months, fair value	81,907	80,509
Available-for-sale securities, continuous unrealized loss position, less than 12 months, aggregate losses	(5,807)	(1,037)
Available-for-sale securities, continuous unrealized loss position, 12 months or longer, fair value	72,977	3,779
Available-for-sale securities, continuous unrealized loss position, 12 months or longer, aggregate losses	$ (11,726)	$ (183)

Investments - Schedule of Sec_2

Investments - Schedule of Securities in Unrealized Loss Position (Parenthetical) (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities, continuous unrealized loss position, less than 12 months, aggregate losses	$ 118,080	$ 10,309
Maximum [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities, continuous unrealized loss position, less than 12 months, aggregate losses		$ 1

Investments - AFS Securities wi

Investments - AFS Securities with Cost Basis in Excess of Fair Value - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Schedule of Available-for-sale Securities [Line Items]
Available for sale securities with cost basis in excess of fair value cost basis	$ 2,713.8	$ 924.4
Available-for-sale credit losses		$ 0.8	$ 4.3
Maximum [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale credit losses	$ 0.1

Investments - Rollforward of th

Investments - Rollforward of the Allowance for Credit Losses on Available-for-sale Securities (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Investments Debt And Equity Securities [Abstract]
Allowance for credit losses, beginning of period	$ 816
Additions to the allowance for credit losses on securities for which credit losses were not previously recorded		$ 821	$ 525
Additional increases (or decreases) to the allowance for credit losses on securities that had an allowance recorded in a previous period	(81)	(5)	(51)
Write-offs charged against the allowance, if any	$ (735)		$ (474)
Allowance for credit losses, end of period		$ 816

Investments - Loss from Closed

Investments - Loss from Closed Currency Forward Contracts Recorded in Accumulated Other Comprehensive Income (Loss) - Narrative (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net [Abstract]
Deferred loss related to closed forward contracts	$ (26.4)	$ (26.4)

Fair Value of Financial Instr_3

Fair Value of Financial Instruments - Schedule of Fair Value Assets and Liabilities Measured on Recurring Basis (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total available-for-sale fixed-maturity securities	$ 2,495,456	$ 2,702,567
Equity securities	35,404	42,551
Cash and cash equivalents	489,240	392,501
Separate account assets	2,305,717	2,799,992
Separate account liabilities	2,305,717	2,799,992
Fair Value, Recurring Measurements [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total available-for-sale fixed-maturity securities	2,495,456	2,702,567
Equity securities	35,404	42,551
Trading securities	3,698	24,355
Cash and cash equivalents	489,240	392,501
Separate account assets	2,305,717	2,799,992
Assets, fair value disclosure	5,398,921	6,047,209
Separate account liabilities	2,305,717	2,799,992
Liabilities, fair value disclosure	2,305,717	2,799,992
Fair Value, Recurring Measurements [Member] | Level 1 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total available-for-sale fixed-maturity securities	3,586	5,898
Equity securities	32,727	37,912
Cash and cash equivalents	489,240	351,508
Assets, fair value disclosure	525,553	395,318
Fair Value, Recurring Measurements [Member] | Level 2 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total available-for-sale fixed-maturity securities	2,491,870	2,696,642
Equity securities	967	1,070
Trading securities	3,698	24,355
Cash and cash equivalents		40,993
Separate account assets	2,305,717	2,799,992
Assets, fair value disclosure	4,871,658	5,648,295
Separate account liabilities	2,305,717	2,799,992
Liabilities, fair value disclosure	2,305,717	2,799,992
Fair Value, Recurring Measurements [Member] | Level 3 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total available-for-sale fixed-maturity securities		27
Equity securities	1,710	3,569
Assets, fair value disclosure	1,710	3,596
Fair Value, Recurring Measurements [Member] | U.S. Government and Agencies [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total available-for-sale fixed-maturity securities	30,468	32,400
Fair Value, Recurring Measurements [Member] | U.S. Government and Agencies [Member] | Level 2 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total available-for-sale fixed-maturity securities	30,468	32,400
Fair Value, Recurring Measurements [Member] | Foreign Government [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total available-for-sale fixed-maturity securities	152,915	152,976
Fair Value, Recurring Measurements [Member] | Foreign Government [Member] | Level 2 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total available-for-sale fixed-maturity securities	152,915	152,976
Fair Value, Recurring Measurements [Member] | States and Political Subdivisions [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total available-for-sale fixed-maturity securities	122,245	153,527
Fair Value, Recurring Measurements [Member] | States and Political Subdivisions [Member] | Level 2 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total available-for-sale fixed-maturity securities	122,245	153,527
Fair Value, Recurring Measurements [Member] | Corporates [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total available-for-sale fixed-maturity securities	1,496,849	1,713,684
Fair Value, Recurring Measurements [Member] | Corporates [Member] | Level 1 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total available-for-sale fixed-maturity securities	3,586	5,898
Fair Value, Recurring Measurements [Member] | Corporates [Member] | Level 2 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total available-for-sale fixed-maturity securities	1,493,263	1,707,786
Fair Value, Recurring Measurements [Member] | Residential Mortgage-backed Securities [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total available-for-sale fixed-maturity securities	401,730	375,631
Fair Value, Recurring Measurements [Member] | Residential Mortgage-backed Securities [Member] | Level 2 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total available-for-sale fixed-maturity securities	401,730	375,604
Fair Value, Recurring Measurements [Member] | Residential Mortgage-backed Securities [Member] | Level 3 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total available-for-sale fixed-maturity securities		27
Fair Value, Recurring Measurements [Member] | Commercial Mortgage-backed Securities [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total available-for-sale fixed-maturity securities	122,967	145,525
Fair Value, Recurring Measurements [Member] | Commercial Mortgage-backed Securities [Member] | Level 2 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total available-for-sale fixed-maturity securities	122,967	145,525
Fair Value, Recurring Measurements [Member] | Other Asset-backed Securities [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total available-for-sale fixed-maturity securities	168,282	128,824
Fair Value, Recurring Measurements [Member] | Other Asset-backed Securities [Member] | Level 2 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total available-for-sale fixed-maturity securities	168,282	128,824
Fair Value, Recurring Measurements [Member] | Fixed-Maturity Securities and Short-term Investments [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total available-for-sale fixed-maturity securities	2,564,862	2,787,810
Fair Value, Recurring Measurements [Member] | Fixed-Maturity Securities and Short-term Investments [Member] | Level 1 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total available-for-sale fixed-maturity securities	3,586	5,898
Fair Value, Recurring Measurements [Member] | Fixed-Maturity Securities and Short-term Investments [Member] | Level 2 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total available-for-sale fixed-maturity securities	2,561,276	2,781,885
Fair Value, Recurring Measurements [Member] | Fixed-Maturity Securities and Short-term Investments [Member] | Level 3 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total available-for-sale fixed-maturity securities		27
Fair Value, Recurring Measurements [Member] | Short-Term Investments
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total available-for-sale fixed-maturity securities	69,406	85,243
Fair Value, Recurring Measurements [Member] | Short-Term Investments | Level 2 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total available-for-sale fixed-maturity securities	$ 69,406	$ 85,243

Fair Value of Financial Instr_4

Fair Value of Financial Instruments - Rollforward of Level 3 Assets Measured on Recurring Basis (Details) - Fair Value, Recurring Measurements [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Level 3 assets, beginning of period	$ 3,596	$ 2,047
Net unrealized gains (losses) included in other comprehensive income	$ (1)
Fair Value, Asset, Recurring Basis, Unobservable Input Reconciliation, Asset, Gain (Loss), Statement of Other Comprehensive Income or Comprehensive Income [Extensible Enumeration]	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
Realized gains (losses) and accretion (amortization) recognized in earnings	$ (204)	$ (493)
Fair Value, Asset, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Realized Investment Gains Losses	Realized Investment Gains Losses
Purchases	$ 1,661	$ 2,067
Settlements		(25)
Transfers out of Level 3	(3,342)
Level 3 assets, end of period	$ 1,710	$ 3,596

Fair Value of Financial Instr_5

Fair Value of Financial Instruments - Narrative (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Fair Value Disclosures [Abstract]
Fair value security, level 1 to level 2 transfers, amount	$ 0	$ 0
Fair Value security, level 1 to level 3 transfers, amount	$ 0	$ 0

Fair Value of Financial Instr_6

Fair Value of Financial Instruments - Carrying Values and Estimated Fair Values of Financial Instruments (Details) - USD ($) $ in Thousands		Dec. 31, 2022	Dec. 31, 2021
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Available-for-sale debt securities, at fair value		$ 2,495,456	$ 2,702,567
Equity securities		35,404	42,551
Separate account assets		2,305,717	2,799,992
Surplus note		1,444,469	1,378,585
Separate account liabilities		2,305,717	2,799,992
Fixed-maturity security (held-to-maturity)		1,444,920	1,379,100
Reported Value Measurement [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Available-for-sale debt securities, at fair value		2,495,456	2,702,567
Short-term investments (available-for-sale)		69,406	85,243
Equity securities		35,404	42,551
Trading securities		3,698	24,355
Separate account assets		2,305,717	2,799,992
Separate account liabilities		2,305,717	2,799,992
Reported Value Measurement [Member] | Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Policy loans	[1]	35,940	30,612
Surplus note	[1],[2]	1,444,469	1,378,585
Fixed-maturity security (held-to-maturity)	[1]	1,444,920	1,379,100
Reported Value Measurement [Member] | Level 3 [Member] | Deposits [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Deposit asset underlying 10% coinsurance agreement	[1]	224,371	231,368
Reported Value Measurement [Member] | Senior Notes [Member] | Level 2 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Notes payable ? Long term	[2],[3]	592,905	592,102
Estimate of Fair Value Measurement [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Available-for-sale debt securities, at fair value		2,495,456	2,702,567
Short-term investments (available-for-sale)		69,406	85,243
Equity securities		35,404	42,551
Trading securities		3,698	24,355
Separate account assets		2,305,717	2,799,992
Separate account liabilities		2,305,717	2,799,992
Estimate of Fair Value Measurement [Member] | Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fixed-maturity security held to maturity, fair value	[1]	1,340,265	1,551,113
Policy loans	[1]	35,940	30,612
Surplus note	[1],[2]	1,333,047	1,545,854
Estimate of Fair Value Measurement [Member] | Level 3 [Member] | Deposits [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Deposit asset underlying 10% coinsurance agreement	[1]	224,371	231,368
Estimate of Fair Value Measurement [Member] | Senior Notes [Member] | Level 2 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Notes payable ? Long term	[2],[3]	$ 491,753	$ 605,667
[1] Classified as level 3 fair value measurement. Carrying value amounts shown are net of issuance costs. Classified as level 2 fair value measurement.

Fair Value of Financial Instr_7

Fair Value of Financial Instruments - Carrying Values and Estimated Fair Values of Financial Instruments (Parenthetical) (Details)	Dec. 31, 2022	Dec. 31, 2021
Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Percentage of coinsurance costs	10%	10%

Reinsurance - Narrative (Detail

Reinsurance - Narrative (Details) - USD ($) $ in Thousands		12 Months Ended
	Mar. 30, 2010	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Reinsurance Retention Policy [Line Items]
Amount of life insurance retained on the life of one person		$ 1,000
Reinsurance recoverable on paid losses		7,500	$ 26,000
Benefits and claims ceded to reinsurers		1,570,800	2,017,000	$ 1,653,600
Deposit asset underlying 10% coinsurance agreement		$ 224,400	231,400
Percentage of finance charge for statutory reserves		0.50%
Reinsurance, loss on uncollectible accounts in period, amount			$ 4,651
Pecan Re Inc [Member]
Reinsurance Retention Policy [Line Items]
Percentage of risks and rewards of term life insurance policies in force		10%
IPO coinsurance agreements [Member]
Reinsurance Retention Policy [Line Items]
Percentage of risks and rewards of term life insurance policies in force		10%
Minimum [Member] | IPO coinsurance agreements [Member]
Reinsurance Retention Policy [Line Items]
Percentage of risks and rewards of term life insurance policies in force	80%
Maximum [Member] | IPO coinsurance agreements [Member]
Reinsurance Retention Policy [Line Items]
Percentage of risks and rewards of term life insurance policies in force	90%

Reinsurance - In-force Life Ins

Reinsurance - In-force Life Insurance (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Reinsurance Disclosures [Abstract]
Direct life insurance in-force	$ 919,081,738	$ 905,819,671	$ 861,392,223
Amounts ceded to other companies	(787,907,229)	(777,826,233)	(742,356,917)
Net life insurance in-force	$ 131,174,509	$ 127,993,438	$ 119,035,306
Percentage of reinsured life insurance in-force	86%	86%

Reinsurance - Reinsurance Recov

Reinsurance - Reinsurance Recoverables and Financial Strength Ratings by Reinsurer (Details) - USD ($) $ in Thousands		Dec. 31, 2022	Dec. 31, 2021
Ceded Credit Risk [Line Items]
Reinsurance recoverables		$ 4,015,909	$ 4,268,419
Swiss Re Life Health America Inc Novated From Pecan Re Inc [Member] | AM Best, A+ Rating [Member]
Ceded Credit Risk [Line Items]
Reinsurance recoverables	[1],[2]	2,440,274
Pecan Re Inc [Member] | External credit rating, not rated [Member]
Ceded Credit Risk [Line Items]
Reinsurance recoverables	[1],[2]		2,567,602
SCOR Global Life Reinsurance Companies [Member] | AM Best, A+ Rating [Member]
Ceded Credit Risk [Line Items]
Reinsurance recoverables	[3]	394,171	426,634
Munich Re of Malta [Member] | External credit rating, not rated [Member]
Ceded Credit Risk [Line Items]
Reinsurance recoverables	[2],[4]	251,078	278,591
Swiss Re Life & Health America Inc. [Member] | AM Best, A+ Rating [Member]
Ceded Credit Risk [Line Items]
Reinsurance recoverables	[5]	244,056	259,239
American Health and Life Insurance Company [Member] | AM Best, B++ Rating [Member]
Ceded Credit Risk [Line Items]
Reinsurance recoverables	[2]	146,779	157,837
Munich American Reassurance Company [Member] | AM Best, A+ Rating [Member]
Ceded Credit Risk [Line Items]
Reinsurance recoverables		134,570	142,705
Korean Reinsurance Company [Member] | AM Best, A Rating [Member]
Ceded Credit Risk [Line Items]
Reinsurance recoverables		123,026	134,048
RGA Reinsurance [Member] | AM Best, A+ Rating [Member]
Ceded Credit Risk [Line Items]
Reinsurance recoverables		128,443	140,953
Hannover Life Reassurance Company [Member] | AM Best, A+ Rating [Member]
Ceded Credit Risk [Line Items]
Reinsurance recoverables		47,870	49,749
TOA Reinsurance Company [Member] | AM Best, A Rating [Member]
Ceded Credit Risk [Line Items]
Reinsurance recoverables		35,762	38,909
All Other Reinsurers [Member]
Ceded Credit Risk [Line Items]
Reinsurance recoverables		72,816	75,094
Allowance for Credit Losses [Member]
Ceded Credit Risk [Line Items]
Reinsurance recoverables		$ (2,936)	$ (2,942)
[1] Effective April 1, 2022, the coinsurance agreement with Pecan Re Inc. was novated and replaced by an agreement with Swiss Re Life and Health America, Inc. Reinsurance recoverables include balances ceded under coinsurance transactions of term life insurance policies that were in force as of December 31, 2009. Amounts shown are net of their share of the reinsurance receivable from other reinsurers. Arrangements with these reinsurers include collateral trust agreements held in support of reinsurance recoverables. Includes amounts ceded to Transamerica Reinsurance Companies and fully retroceded to SCOR Global Life Reinsurance Companies. Entity is rated AA- by S&P. Includes amounts ceded to Lincoln National Life Insurance and fully retroceded to Swiss Re Life & Health America Inc.

Reinsurance - Allowance for Cre

Reinsurance - Allowance for Credit Loss on Reinsurance Recoverable (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Reinsurance Disclosures [Abstract]
Balance, beginning of period	$ 2,942	$ 7,144	$ 3,917
Current period provision for expected credit losses	164	502	3,235
Less: Writeoffs charged against the ACL, if any		(4,651)
Less: Recoveries of expected credit losses previously recorded	(170)	(53)	(8)
Balance, at the end of period	$ 2,936	$ 2,942	$ 7,144

Deferred Policy Acquisition C_3

Deferred Policy Acquisition Costs - Balance RollForward (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Deferred Policy Acquisition Costs Disclosures [Abstract]
DAC balance, beginning of period	$ 2,943,782	$ 2,629,644	$ 2,325,750
Capitalization	514,597	562,999	522,705
Amortization	(356,143)	(251,179)	(224,321)
Foreign exchange translation and other	20,350	2,318	5,510
DAC balance, end of period	$ 3,081,886	$ 2,943,782	$ 2,629,644

Separate Accounts - Narrative (

Separate Accounts - Narrative (Details)	12 Months Ended
	Dec. 31, 2022
Separate Accounts Narrative [Abstract]
Separate accounts contract's minimum guaranteed payments, percentage of policyholder's contribution	75%
Separate accounts contract minimum maturity, years	10 years
Separate accounts contract maximum maturity, date	Dec. 31, 2070
Separate accounts contract maturity, years	20 years
Separate accounts contracts minimum guaranteed payments, decline in percentage of policyholder's contribution	25%

Separate Accounts - Schedule of

Separate Accounts - Schedule of Fair Value of Separate Accounts by Major Category of Investment (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Schedule Of Fair Value Of Separate Accounts By Major Category Of Investment [Line Items]
Separate accounts assets	$ 2,305,717	$ 2,799,992
Fixed Income Securities [Member]
Schedule Of Fair Value Of Separate Accounts By Major Category Of Investment [Line Items]
Separate accounts assets	796,384	1,172,425
Equity Securities [Member]
Schedule Of Fair Value Of Separate Accounts By Major Category Of Investment [Line Items]
Separate accounts assets	1,340,541	1,534,993
Cash and Cash Equivalents [Member]
Schedule Of Fair Value Of Separate Accounts By Major Category Of Investment [Line Items]
Separate accounts assets	181,162	92,648
Due To/From Funds [Member]
Schedule Of Fair Value Of Separate Accounts By Major Category Of Investment [Line Items]
Separate accounts assets	(12,399)	(112)
Other [Member]
Schedule Of Fair Value Of Separate Accounts By Major Category Of Investment [Line Items]
Separate accounts assets	$ 29	$ 38

Policy Claims and Other Benef_3

Policy Claims and Other Benefits Payable - Schedule of Liability For Policy Claims and Other Benefits Payable (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Roll Forward In Liability For Unpaid Claims And Claims Adjustment Expense [Abstract]
Policy claims and other benefits payable, beginning of period		$ 585,382	$ 519,711	$ 339,954
Reinsured policy claims and other benefits payable, beginning of period		637,139	545,030	388,797
Net balance, beginning of period		(51,757)	(25,319)	(48,843)
Incurred related to current year		248,127	284,719	236,157
Incurred related to prior years	[1]	(4,363)	(216)	(4,033)
Total incurred		243,764	284,503	232,124
Claims paid related to current year, net of reinsured policy claims received		(263,114)	(345,130)	(268,914)
Reinsured policy claims received related to prior years, net of claims paid		67,267	34,128	60,144
Total paid		(195,847)	(311,002)	(208,770)
Foreign currency translation		(531)	61	170
Net balance, end of period		(4,371)	(51,757)	(25,319)
Reinsured policy claims and other benefits payable, end of period		542,621	637,139	545,030
Policy claims and other benefits payable, end of period		$ 538,250	$ 585,382	$ 519,711
[1] Includes the difference between our estimate of claims incurred but not yet reported at year end and the actual incurred claims reported after year end.

Debt - Schedule of Notes Payabl

Debt - Schedule of Notes Payable (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Unamortized issuance discount on notes payable	$ (2,385)	$ (2,655)
Total notes payable	597,615	597,345
2.80% Senior Notes, due November 19, 2031
Debt Instrument [Line Items]
Senior Notes	$ 600,000	$ 600,000

Debt - Schedule of Notes Paya_2

Debt - Schedule of Notes Payable (Parenthetical) (Details) - 2.80% Senior Notes, due November 19, 2031	12 Months Ended
	Dec. 31, 2022
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage	2.80%
Debt instrument maturity date	Nov. 19, 2031

Debt - Narrative (Details)

Debt - Narrative (Details) - USD ($)		1 Months Ended	12 Months Ended
	Jun. 22, 2021	Nov. 30, 2021	Dec. 31, 2022	Dec. 31, 2021	Jul. 01, 2021
Debt Instrument [Line Items]
Repayments of lines of credit				$ 125,000,000
Loss on extinguishment of debt				8,927,000
Proceeds from revolving credit facility				$ 125,000,000
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Debt instrument, face amount	$ 200,000,000
Debt instrument maturity date	Jun. 22, 2026
Debt instrument, frequency of commitment fee payable	quarterly
Proceeds from revolving credit facility			$ 0
Maximum [Member]
Debt Instrument [Line Items]
Debt instrument, face amount			1,500,000,000
Maximum [Member] | Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Debt instrument, commitment fee percentage	0.225%
Maximum [Member] | LIBOR Rate [Member] | Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate margin	1.625%
Maximum [Member] | Base Rate [Member] | Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate margin	0.625%
Minimum [Member] | Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Debt instrument, commitment fee percentage	0.10%
Minimum [Member] | LIBOR Rate [Member] | Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate margin	1%
Minimum [Member] | Base Rate [Member] | Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate margin	0%
Etelequote Bermuda [Member] | Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Proceeds from revolving credit facility			0
Senior Notes [Member]
Debt Instrument [Line Items]
Debt instrument, face amount			600,000,000
Issue price of senior notes		99.55%
Debt instrument, interest rate, stated percentage		2.80%
Debt instrument maturity date		Nov. 19, 2031
Unsecured Subordinated Note [Member] | Etelequote Bermuda [Member]
Debt Instrument [Line Items]
Debt instrument, face amount					$ 15,000,000
Surplus Note [Member]
Debt Instrument [Line Items]
Debt instrument, face amount			$ 1,400,000,000
Debt instrument, interest rate, stated percentage			4.50%
Debt instrument maturity date			Dec. 31, 2030

Income Taxes - Provision for In

Income Taxes - Provision for Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Current federal tax expense (benefit)	$ 149,034	$ 115,657	$ 88,837
Current foreign tax expense (benefit)	51,692	43,687	26,749
Current state and local tax expense (benefit)	5,029	5,440	4,714
Current income tax expense (benefit)	205,755	164,784	120,300
Deferred federal income tax expense (benefit)	(49,683)	(10,589)	853
Deferred foreign income tax expense (benefit)	(27,163)	(13,890)	(547)
Deferred state and local income tax expense (benefit)	(3,134)	(1,114)	(40)
Deferred income tax expense (benefit)	(79,980)	(25,593)	266
Federal income tax expense (benefit)	99,351	105,068	89,690
Foreign income tax expense (benefit)	24,529	29,797	26,202
State and local income tax expense (benefit)	1,895	4,326	4,674
Income tax expense (benefit)	$ 125,775	$ 139,191	$ 120,566

Income Taxes - Schedule of Inco

Income Taxes - Schedule of Income before Income Taxes by Domestic and Foreign (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Domestic	$ 394,773	$ 399,149	$ 411,751
Foreign	98,976	112,022	94,979
Income before income taxes	$ 493,749	$ 511,171	$ 506,730

Income Taxes - Narrative (Detai

Income Taxes - Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Tax [Line Items]
Federal Statutory Tax Rate	21%	21%	21%
Deferred tax assets, operating loss and interest carryforwards, federal	$ 11,800
Deferred tax assets, operating loss carryforwards, state and local	16,800
Deferred tax assets valuation allowance	36,511	$ 46,542
Unrecognized tax benefits that would impact effective tax rate	18,800	17,900
Unrecognized tax benefits, income tax penalties and interest accrued	3,400	3,100
Unrecognized tax benefits, interest benefit	300	300	$ 300
Investment in qualified affordable housing projects	12,800	3,500
Foreign [Member]
Income Tax [Line Items]
Tax credits	36,400
Deferred tax assets valuation allowance	0	0
Unfunded Commitments [Member]
Income Tax [Line Items]
Investment in qualified affordable housing projects	$ 9,700	$ 0

Income Taxes - Schedule of Effe

Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Income tax reconciliation, income tax expense (benefit), at federal statutory income tax rate	$ 103,687	$ 107,346	$ 106,413
Income tax reconciliation, goodwill impairment loss	12,600	15,960
Income tax rate reconciliation, foreign income tax rate differential amount	5,571	5,871	5,075
Income tax reconciliation, other reconciling items	3,917	10,014	9,078
Income tax expense (benefit)	$ 125,775	$ 139,191	$ 120,566
Effective income tax rate reconciliation, at federal statutory income tax rate	21%	21%	21%
Effective income tax rate reconciliation, goodwill impairment loss	2.60%	3.10%	0%
Effective income tax rate reconciliation, foreign income tax rate differential	1.10%	1.10%	1%
Effective income tax rate reconciliation, other adjustments	0.80%	2%	1.80%
Effective income tax rate	25.50%	27.20%	23.80%

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Income Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Deferred tax assets:
Deferred tax assets, future policy benefit reserves and unpaid policy claims	$ 428,438	$ 353,677
Net operating loss and interest carryforwards	28,675	36,343
Deferred tax assets, investments	59,085
Deferred tax assets, future deductible liabilities	23,217	20,883
Deferred tax assets, foreign tax credits	36,424	46,455
Deferred tax assets, other	23,809	27,610
Total deferred tax assets before valuation allowance	599,648	484,968
Valuation allowance	(36,511)	(46,542)
Total deferred tax assets after valuation allowance	563,137	438,426
Deferred tax liabilities:
Deferred tax liabilities, deferred policy acquisition costs	(385,351)	(383,163)
Renewal commissions receivable	(53,874)	(60,782)
Intangibles	(47,806)	(50,310)
Investments	0	(17,952)
Deferred tax liabilities, reinsurance deposit asset	(47,118)	(48,587)
Deferred tax liabilities, other	(19,112)	(21,833)
Total deferred tax liabilities	(553,261)	(582,627)
Net deferred tax liabilities	$ (9,876)	$ (144,201)

Income Taxes - Summary of Recon

Income Taxes - Summary of Reconciliation of Change in Unrecognized Income Tax Benefit (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Unrecognized tax benefits, beginning of period	$ 19,224	$ 17,104	$ 15,805
Unrecognized tax benefits, resulting from prior period tax positions	(944)	(103)	40
Unrecognized tax benefits, increases resulting from current period tax positions	3,993	3,777	3,296
Unrecognized tax benefits, reductions resulting from lapse of applicable statute of limitations	(2,093)	(1,554)	(2,037)
Unrecognized tax benefits, end of period	$ 20,180	$ 19,224	$ 17,104

Stockholders' Equity - Reconcil

Stockholders' Equity - Reconciliation of Number of Shares of Common Stock (Details) - shares	1 Months Ended	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Stockholders Equity Note [Abstract]
Common stock, beginning of period		39,368,000	39,306,000	41,207,000
Shares issued for stock options exercised		0	10,000	0
Shares of common stock issued upon lapse of sales restrictions on RSUs		236,000	225,000	335,000
Common stock retired	(2,864,394)	(2,780,000)	(173,000)	(2,236,000)
Common stock, end of period	36,824,000	36,824,000	39,368,000	39,306,000

Stockholders' Equity - Narrativ

Stockholders' Equity - Narrative (Details) - USD ($)	1 Months Ended	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Nov. 17, 2022	Aug. 11, 2022	Feb. 14, 2022	Nov. 17, 2021
Class Of Stock [Line Items]
Stock repurchased program, authorized amount	$ 375,000,000	$ 375,000,000			$ 375,000,000	$ 50,000,000	$ 50,000,000	$ 275,000,000
Stock repurchased and retired during period, shares	2,864,394	2,780,000	173,000	2,236,000
Stock repurchased and retired during period, value	$ 375,000,000
Stock repurchase program, remaining authorized repurchase amount	$ 0	$ 0
Restricted stock units (RSUs) [Member]
Class Of Stock [Line Items]
Share-based compensation arrangement by share-based payment award, non-option equity instruments, outstanding, number	297,583	297,583
Performance share units (PSUs) [Member]
Class Of Stock [Line Items]
Share-based compensation arrangement by share-based payment award, non-option equity instruments, outstanding, number	74,054	74,054

Earnings Per Share - Calculatio

Earnings Per Share - Calculation of Basic and Diluted Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Earnings Per Share [Abstract]
Net income	$ 373,012	$ 373,357	$ 386,164
Income attributable to unvested participating securities, basic EPS	(1,684)	(1,533)	(1,671)
Net income used in calculating basic EPS	$ 371,328	$ 371,824	$ 384,493
Weighted-average vested shares	37,997	39,530	40,065
Basic EPS	$ 9.77	$ 9.41	$ 9.60
Income attributable to unvested participating securities, diluted EPS	$ (1,680)	$ (1,529)	$ (1,667)
Net income used in calculating diluted EPS	$ 371,332	$ 371,828	$ 384,497
Dilutive effect of incremental shares to be issued for contingently-issuable shares	109	122	120
Weighted-average shares used in calculating diluted EPS	38,106	39,652	40,185
Diluted EPS	$ 9.74	$ 9.38	$ 9.57

Share-Based Transactions - Narr

Share-Based Transactions - Narrative (Details) - USD ($)		12 Months Ended
	Jan. 01, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2013
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, number of shares available for grant		1,400,000
Share-based compensation arrangement by share-based payment award, options, outstanding, weighted average remaining contractual term					10 years
Stock options exercise term, description		Upon retirement, employees have the lesser of three years or the remaining option term to exercise any vested options.
Aggregate intrinsic value of exercisable stock options		$ 5,800,000
Subsequent Event
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares, vested	31,819
Restricted stock units (RSUs) [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized		$ 5,700,000
Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized, period for recognition		10 months 24 days
Performance share units (PSUs) [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, award vesting period		3 years
Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized		$ 0
Shares, vested		28,000	33,000	41,000
Performance share units (PSUs) [Member] | Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of granted PSUs to be issued based on performance		0%
Performance share units (PSUs) [Member] | Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of granted PSUs to be issued based on performance		150%
Employee Stock Option [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, award vesting period					3 years
Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized		$ 0
Number of stock options issued		$ 0	$ 0	$ 0
Management [Member] | Restricted stock units (RSUs) [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, award vesting period		3 years
Director | Restricted stock units (RSUs) [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, award vesting period		12 months

Share-Based Transactions - Empl

Share-Based Transactions - Employee and Director Share-Based Transactions, Cost and Tax Benefit (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Restricted stock units (RSUs) [Member] | Employee and Director [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total equity awards expense recognized	$ 12,626	$ 11,779	$ 11,218
Tax benefit associated with total employee and director share-based compensation share-based compensation	1,642	1,638	1,455
Performance share units (PSUs) [Member] | Employee [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total equity awards expense recognized	$ 2,092	$ 3,494	$ 4,179

Share-Based Transactions - Em_2

Share-Based Transactions - Employee and Director Share-Based Transactions, Restricted Stock and RSU Activity (Details) - Employee and Director [Member] - Restricted Stock and Restricted Stock Units RSU [Member] - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share Based Compensation Arrangement [Abstract]
Shares, beginning balance	153	166	180
Shares, granted	113	84	94
Shares, forfeited	(3)	(4)
Shares, vested	(90)	(93)	(108)
Shares, ending balance	173	153	166
Weighted-Average Exercise Price Per Share [Abstract]
Weighted-average measurement-date fair value per share, beginning balance	$ 132.85	$ 117.87	$ 107.59
Weighted-average measurement-date fair value per share, granted	117.06	144.95	119.03
Weighted-average measurement-date fair value per share, forfeited	123.38	147.23	121.42
Weighted-average measurement-date fair value per share, vested	129.89	116.55	101.75
Weighted-average measurement-date fair value per share, ending balance	$ 131.78	$ 132.85	$ 117.87

Share-Based Transactions - Em_3

Share-Based Transactions - Employee and Director Share-Based Transactions, Restricted Stock and RSU Activity (Parenthetical) (Details)	12 Months Ended
	Dec. 31, 2022 shares
Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares, forfeited	1,000

Share-Based Transactions - Em_4

Share-Based Transactions - Employee Share-Based Transactions, PSU Activity (Details) - Performance share units (PSUs) [Member] - $ / shares shares in Thousands		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share Based Compensation Arrangement [Abstract]
Shares, beginning balance	[1]	73	81	91
Shares, granted		27	22	26
Shares, performance adjustment		2	3	5
Shares, vested		(28)	(33)	(41)
Shares, ending balance	[1]	74	73	81
Weighted-Average Exercise Price Per Share [Abstract]
Weighted-average measurement-date fair value per share, beginning balance	[1]	$ 128.30	$ 113.99	$ 98.79
Weighted-average measurement-date fair value per share, granted		130.30	143.04	121.42
Weighted-average measurement-date fair value per share, performance adjustment		122.62	100.55	80.45
Weighted-average measurement-date fair value per share, vested		122.62	100.55	80.45
Weighted-average measurement-date fair value per share, ending balance	[1]	$ 130.97	$ 128.30	$ 113.99
[1] The 2020 PSU awards outstanding are based on the actual performance. As a result of the performance achieved during the performance period, recipients will receive an aggregate of 20,559 shares of common stock on the vesting date of March 1, 2023, reflecting a payout rate of 79.9 %. The 2021 PSU awards outstanding are based on target. Depending upon the performance achieved during the performance period, recipients may receive between 0 and 32,768 shares of common stock. The 2022 PSU awards outstanding are based on target. Depending upon the performance achieved during the performance period, recipients may receive between 0 and 39,713 shares of common stock.

Share-Based Transactions - Em_5

Share-Based Transactions - Employee Share-Based Transactions, PSU Activity (Parenthetical) (Details) - Performance share units (PSUs) [Member] - ROAE Achieved Within Vesting Period [Member] - shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Minimum number of shares of common stock may be received by recipients	0	0
Maximum number of shares of common stock may be received by recipients	39,713	32,768	20,559
Payout rate			79.90%

Share-Based Transactions - Em_6

Share-Based Transactions - Employee Share-based Transactions, Stock Option Cost and Tax Benefit (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2020 USD ($)
Employee Stock Option [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expense recognized for stock option awards	$ 0

Share-Based Transactions - Summ

Share-Based Transactions - Summary of Activity Related to Stock Options Outstanding and Exercisable (Details) - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares, outstanding beginning balance	60	70	70
Number of shares, granted	0	0	0
Number of shares, exercised	0	(10)	0
Number of shares, outstanding ending balance	60	60	70
Weighted average exercise price, outstanding beginning balance	$ 44.62	$ 44.23	$ 44.23
Weighted average exercise price, exercised		41.88
Weighted average exercise price, outstanding ending balance	$ 44.62	$ 44.62	$ 44.23
Number of shares, exercisable	60	60	70	70
Weighted average exercise price, exercisable	$ 44.62	$ 44.62	$ 44.23	$ 44.23
$41.20 (average term remaining - 1.1 years) [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares, vested option exercise prices outstanding	3
Weighted average exercise price, vested option exercise prices outstanding	$ 41.20
Number of shares, vested option exercise prices exercisable	3
Weighted average exercise price, vested option exercise prices exercisable	$ 41.20
$53.50 (average term remaining - 2.2 years) [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares, vested option exercise prices outstanding	14
Weighted average exercise price, vested option exercise prices outstanding	$ 53.50
Number of shares, vested option exercise prices exercisable	14
Weighted average exercise price, vested option exercise prices exercisable	$ 53.50
$41.88 (average term remaining - 3.2 years) [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares, vested option exercise prices outstanding	42
Weighted average exercise price, vested option exercise prices outstanding	$ 41.88
Number of shares, vested option exercise prices exercisable	42
Weighted average exercise price, vested option exercise prices exercisable	$ 41.88

Share-Based Transactions - Su_2

Share-Based Transactions - Summary of Activity Related to Stock Options Outstanding and Exercisable (Parenthetical) (Details)	12 Months Ended
	Dec. 31, 2022 $ / shares
$41.20 (average term remaining - 1.1 years) Option [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vested option exercise price	$ 41.20
Vested option exercise, average life	1 year 1 month 6 days
$53.50 (average term remaining - 2.2 years) Option [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vested option exercise price	$ 53.50
Vested option exercise, average life	2 years 2 months 12 days
$41.88 (average term remaining - 3.2 years) Option [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vested option exercise price	$ 41.88
Vested option exercise, average life	3 years 2 months 12 days

Share-Based Transactions - Su_3

Share-Based Transactions - Summary of Intrinsic Value, Tax Benefit Realized and Value of Shares Withheld Related to Option Exercise Activity (Details) - Employee Stock Option [Member] $ in Thousands	12 Months Ended
	Dec. 31, 2021 USD ($)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Intrinsic value of options exercised	$ 1,156
Value of issued shares withheld to satisfy option exercise price	$ 419

Share-Based Transactions - None

Share-Based Transactions - Nonemployee Share-Based Transactions, RSU Activity (Details) - Nonemployee Shares [Member] - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share Based Compensation Arrangement [Abstract]
Shares, beginning balance	31	26	24
Shares, granted	118	99	128
Shares, vested	(117)	(94)	(126)
Shares, ending balance	32	31	26
Weighted-Average Exercise Price Per Share [Abstract]
Weighted-average measurement-date fair value per share, beginning balance	$ 154.59	$ 134.75	$ 132.68
Weighted-average measurement-date fair value per share, granted	129.99	150.72	106.65
Weighted-average measurement-date fair value per share, vested	133.25	145.03	105.71
Weighted-average measurement-date fair value per share, ending balance	$ 141.60	$ 154.59	$ 134.75

Share-Based Transactions - No_2

Share-Based Transactions - Nonemployee Share-Based Transactions, Cost and Tax Benefit (Details) - Nonemployee Shares [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share Based Goods And Nonemployee Services Transaction [Line Items]
Quarterly incentive awards expense recognized currently	$ 4,060	$ 4,036	$ 3,630
Quarterly incentive awards expense deferred	11,260	10,807	10,071
Tax benefit associated with incentive awards	$ 3,056	$ 2,904	$ 2,692

Statutory Accounting and Divi_3

Statutory Accounting and Dividend Restrictions - Statutory Accounting Practices Disclosure (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Primerica Life [Member] | TENNESSEE
Statutory Accounting Practices [Line Items]
Statutory capital and surplus	$ 834,565	$ 779,620

Statutory Accounting and Divi_4

Statutory Accounting and Dividend Restrictions - Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Jan. 01, 2023
Statutory Accounting Practices [Line Items]
Payments of dividends	$ 255,000
Primerica Life [Member] | TENNESSEE
Statutory Accounting Practices [Line Items]
Statutory accounting practices, statutory net income amount	446,100	$ 257,300	$ 395,400
Payments of ordinary dividends	0
Statutory capital and surplus	834,565	779,620
Primerica Life [Member] | TENNESSEE | Subsequent Event
Statutory Accounting Practices [Line Items]
Statutory accounting practices, statutory amount available for dividend payments without regulatory approval				$ 336,800
Peach Re [Member] | VERMONT
Statutory Accounting Practices [Line Items]
State insurance department, statutory to NAIC, amount of reconciling item	90,800
Primerica Life Canada [Member] | Canada [Member]
Statutory Accounting Practices [Line Items]
Payments of ordinary dividends	23,100
Statutory capital and surplus	$ 511,400	$ 417,700
Primerica Life Canada [Member] | Canada [Member] | Subsequent Event
Statutory Accounting Practices [Line Items]
Statutory accounting practices, statutory amount available for dividend payments without regulatory approval				$ 65,700

Commitments and Contingent Li_2

Commitments and Contingent Liabilities - Narrative (Details) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2014
Commitments And Contingent Liabilities [Line Items]
Letter of credit, outstanding	$ 90.8
Letter of Credit [Member]
Commitments And Contingent Liabilities [Line Items]
Letter of credit, outstanding	$ 450	$ 507

Benefit Plans - Narrative (Deta

Benefit Plans - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Compensation And Retirement Disclosure [Abstract]
Defined Contribution Plan, expenses	$ 10.5	$ 10.5	$ 10

Revenue from Contracts with C_3

Revenue from Contracts with Customers - Summary of Disaggregation of Revenues from Contracts (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disaggregation Of Revenue [Line Items]
Disaggregation of revenues from contracts with customers	$ 2,720,133	$ 2,709,732	$ 2,217,541
Term Life Insurance Segment [Member]
Disaggregation Of Revenue [Line Items]
Disaggregation of revenues from contracts with customers	1,687,126	1,575,686	1,382,770
Term Life Insurance Segment [Member] | Total Segment Revenues from Contracts with Customers [Member]
Disaggregation Of Revenue [Line Items]
Disaggregation of revenues from contracts with customers	50,320	48,970	46,079
Term Life Insurance Segment [Member] | Total Segment Revenues from Contracts with Customers [Member] | Other, Net [Member]
Disaggregation Of Revenue [Line Items]
Disaggregation of revenues from contracts with customers	50,320	48,970	46,079
Term Life Insurance Segment [Member] | Revenues from Sources Other Than Contracts with Customers (Segregated Funds) [Member]
Disaggregation Of Revenue [Line Items]
Disaggregation of revenues from contracts with customers	1,636,806	1,526,716	1,336,691
Investment and Savings Products Segment [Member]
Disaggregation Of Revenue [Line Items]
Disaggregation of revenues from contracts with customers	863,432	941,847	718,867
Investment and Savings Products Segment [Member] | Total Segment Revenues from Contracts with Customers [Member]
Disaggregation Of Revenue [Line Items]
Disaggregation of revenues from contracts with customers	804,881	877,295	661,043
Investment and Savings Products Segment [Member] | Total Segment Revenues from Contracts with Customers [Member] | Other, Net [Member]
Disaggregation Of Revenue [Line Items]
Disaggregation of revenues from contracts with customers	12,610	12,097	11,271
Investment and Savings Products Segment [Member] | Total Segment Revenues from Contracts with Customers [Member] | Commissions and Fees [Member] | Sales-based Revenues [Member]
Disaggregation Of Revenue [Line Items]
Disaggregation of revenues from contracts with customers	326,378	401,508	284,651
Investment and Savings Products Segment [Member] | Total Segment Revenues from Contracts with Customers [Member] | Commissions and Fees [Member] | Asset-based Revenues [Member]
Disaggregation Of Revenue [Line Items]
Disaggregation of revenues from contracts with customers	375,502	376,751	282,080
Investment and Savings Products Segment [Member] | Total Segment Revenues from Contracts with Customers [Member] | Commissions and Fees [Member] | Account-based Revenues [Member]
Disaggregation Of Revenue [Line Items]
Disaggregation of revenues from contracts with customers	90,391	86,939	83,041
Investment and Savings Products Segment [Member] | Revenues from Sources Other Than Contracts with Customers (Segregated Funds) [Member]
Disaggregation Of Revenue [Line Items]
Disaggregation of revenues from contracts with customers	58,551	64,552	57,824
Senior Health Segment [Member]
Disaggregation Of Revenue [Line Items]
Disaggregation of revenues from contracts with customers	62,682	60,440
Senior Health Segment [Member] | Total Segment Revenues from Contracts with Customers [Member]
Disaggregation Of Revenue [Line Items]
Disaggregation of revenues from contracts with customers	62,682	60,440
Senior Health Segment [Member] | Total Segment Revenues from Contracts with Customers [Member] | Other, Net [Member]
Disaggregation Of Revenue [Line Items]
Disaggregation of revenues from contracts with customers	15,262	9,537
Senior Health Segment [Member] | Total Segment Revenues from Contracts with Customers [Member] | Commissions and Fees [Member]
Disaggregation Of Revenue [Line Items]
Disaggregation of revenues from contracts with customers	47,420	50,903
Corporate and Other Distributed Products Segment Revenues [Member]
Disaggregation Of Revenue [Line Items]
Disaggregation of revenues from contracts with customers	106,893	131,759	115,904
Corporate and Other Distributed Products Segment Revenues [Member] | Total Segment Revenues from Contracts with Customers [Member]
Disaggregation Of Revenue [Line Items]
Disaggregation of revenues from contracts with customers	51,401	66,131	47,394
Corporate and Other Distributed Products Segment Revenues [Member] | Total Segment Revenues from Contracts with Customers [Member] | Other, Net [Member]
Disaggregation Of Revenue [Line Items]
Disaggregation of revenues from contracts with customers	4,967	3,971	3,719
Corporate and Other Distributed Products Segment Revenues [Member] | Total Segment Revenues from Contracts with Customers [Member] | Commissions and Fees [Member]
Disaggregation Of Revenue [Line Items]
Disaggregation of revenues from contracts with customers	46,434	62,160	43,675
Corporate and Other Distributed Products Segment Revenues [Member] | Revenues from Sources Other Than Contracts with Customers (Segregated Funds) [Member]
Disaggregation Of Revenue [Line Items]
Disaggregation of revenues from contracts with customers	$ 55,492	$ 65,628	$ 68,510

Revenue from Contracts with C_4

Revenue from Contracts with Customers - Summary of Contract Asset Account (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Senior Health Segment [Member]
Disaggregation Of Revenue [Line Items]
Balance, beginning of period	$ 172,308
Contract balances acquired as part of business combination		$ 199,575
Measurement period adjustment	(11,863)	(46,128)
Commissions revenue	42,628	37,225
Less: collections	(40,740)	(13,442)
Tail revenue adjustment from change in estimate	(22,934)	(4,922)
Balance, at the end of period	139,399	172,308
Corporate and Other Distributed Products Segment [Member]
Disaggregation Of Revenue [Line Items]
Balance, beginning of period	59,443	54,845
Commissions revenue	25,325	27,618
Less: collections	(24,124)	(23,020)
Balance, at the end of period	$ 60,644	$ 59,443

Revenue from Contracts with C_5

Revenue from Contracts with Customers - Narrative (Details)	Dec. 31, 2022 USD ($)
Revenue From Contract With Customer [Abstract]
Assets recognized for incremental costs	$ 0

Leases - Narratives (Details)

Leases - Narratives (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Lessee Lease Description [Line Items]
Lease renewal term	10 years
Lease termination period	1 year
Finance lease right-of-use assets	$ 700	$ 1,000
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Other assets	Other assets
Finance lease liabilities	$ 775	$ 1,000
Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]	us-gaap:OtherLiabilitiesMember	us-gaap:OtherLiabilitiesMember
Minimum [Member]
Lessee Lease Description [Line Items]
Remaining lease term	1 year
Maximum [Member]
Lessee Lease Description [Line Items]
Remaining lease term	8 years

Leases - Schedule of Components

Leases - Schedule of Components of Lease Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Operating lease cost
Operating lease cost	$ 9,686	$ 8,620	$ 7,638
Variable lease cost (includes taxes, common area maintenance and insurance)	1,099	980	725
Finance lease cost
Depreciation of finance lease assets	271	280	280
Interest on lease liabilities	55	60	56
Total lease cost	$ 11,111	$ 9,940	$ 8,699

Leases - Schedule of Other Info

Leases - Schedule of Other Information Related to Leases (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows used in operating leases	[1]	$ 9,960	$ 8,878	$ 7,737
Operating cash flows used in finance leases	[1]	55	60	56
Financing cash flows used in finance leases		$ 262	$ 264	$ 274
Operating leases weighted average remaining lease term		6 years	6 years
Finance leases weighted average remaining lease term		3 years	4 years
Operating leases weighted average discount rate		4.20%	4.10%
Finance leases weighted average discount rate		6%	6.20%
[1] Included in change in other operating assets and liabilities, net in the accompanying consolidated statements of cash flows.

Leases - Schedule of Future Min

Leases - Schedule of Future Minimum Lease Payments Under Non-Cancellable Leases (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Operating Leases
2023	$ 10,009
2024	9,745
2025	8,446
2026	8,199
2027	8,098
Thereafter	7,290
Total minimum rental commitments for operating leases	51,787
Less imputed interest	5,792
Operating lease liabilities	45,995	$ 53,920
Finance Leases
2023	302
2023	269
2024	192
2025	78
Total minimum rental commitments for operating leases	841
Less imputed interest	66
Finance lease liabilities	$ 775	$ 1,000

Acquisition - (Narrative) (Deta

Acquisition - (Narrative) (Details) - USD ($)			12 Months Ended
	Jul. 01, 2022	Jul. 01, 2021	Dec. 31, 2022	Dec. 31, 2021
Business Acquisition [Line Items]
Payments to Acquire Business			$ (3,867,000)	$ 494,459,000
Goodwill			127,707,000	179,154,000
Goodwill impairment loss			60,000,000	76,000,000
Etelequote Bermuda [Member]
Business Acquisition [Line Items]
Business acquisition, date of acquisition agreement		Jul. 01, 2021
Percentage of interest acquired		80%
Percentage of voting interests acquired		100%
Amount paid-off in acquisition		$ 146,000,000
Payments to Acquire Business	$ 0	$ 350,000,000
Percentage of common stock issued and outstanding		20%
Cash consideration		$ 3,900,000
Remaining percentage of interest acquired	20%
Business acquisition, effective date of acquisition	Jul. 01, 2022
Business combination, recognized identifiable assets acquired and liabilities assumed, intangible assets		156,000,000
Goodwill		263,700,000
Etelequote Bermuda [Member] | Other Operating Expenses [Member]
Business Acquisition [Line Items]
Transaction costs related to acquisition			$ (2,000,000)	$ 12,900,000
Etelequote Bermuda [Member] | Customer Relationships [Member]
Business Acquisition [Line Items]
Business combination, recognized identifiable assets acquired and liabilities assumed, intangible assets		$ 153,000,000
Estimated useful life		15 years	15 years
Etelequote Bermuda [Member] | Unsecured Subordinated Note [Member]
Business Acquisition [Line Items]
Debt instrument, face amount		$ 15,000,000

Acquisition - Summary of Identi

Acquisition - Summary of Identified Assets Acquired and Liabilities Assumed at Acquisition Date (Details) - Etelequote Bermuda [Member] - USD ($) $ in Thousands		Jun. 30, 2022	Dec. 31, 2021	Jul. 01, 2021
Assets:
Cash and cash equivalent				$ 1,080
Accounts receivables				303
Renewal commissions receivable				141,584
Other assets				15,705
Intangible assets				156,000
Goodwill				263,706
Total assets				578,378
Liabilities:
Accounts payable and accrued expenses				4,590
Deferred tax liability				48,633
Other liabilities				10,046
Total liabilities				63,269
Net assets acquired				515,109
Temporary Stockholders' Equity:
Redeemable noncontrolling interests				8,437
Total temporary stockholders' equity				8,437
Preliminary Purchase Price Adjustment [Member]
Assets:
Cash and cash equivalent				1,080
Accounts receivables				692
Renewal commissions receivable				199,575
Other assets				15,705
Intangible assets				162,000
Goodwill				224,180
Total assets				603,232
Liabilities:
Accounts payable and accrued expenses				8,785
Deferred tax liability				65,425
Other liabilities				10,046
Total liabilities				84,256
Net assets acquired				518,976
Temporary Stockholders' Equity:
Redeemable noncontrolling interests				8,437
Total temporary stockholders' equity				$ 8,437
2021 Measurement Period Adjustments [Member]
Assets:
Accounts receivables			$ (389)
Renewal commissions receivable			(46,128)
Intangible assets			(6,000)
Goodwill			30,973
Total assets			(21,544)
Liabilities:
Accounts payable and accrued expenses	[1]		(4,195)
Deferred tax liability			(13,482)
Total liabilities			(17,677)
Net assets acquired			$ (3,867)
2022 Measurement Period Adjustments [Member]
Assets:
Renewal commissions receivable		$ (11,863)
Goodwill		8,553
Total assets		(3,310)
Liabilities:
Deferred tax liability		(3,310)
Total liabilities		$ (3,310)
[1] The Company also recognized an adjustment during the measurement period to reclassify certain amounts from a payable to a reduction in the renewal commissions receivable.

Acquisition - Summary of Unaudi

Acquisition - Summary of Unaudited Proforma Information (Details) - Etelequote Bermuda [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Business Acquisition [Line Items]
Revenue	$ 2,774,991	$ 2,369,811
Net income (loss)	$ 361,783	$ 391,527

Goodwill - (Narrative) (Details

Goodwill - (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill impairment loss	$ 60,000	$ 76,000
Goodwill	127,707	$ 179,154
Accumulated goodwill impairment charges	$ 136,000

Schedule I Summary of Investm_2

Schedule I Summary of Investments - Other Than Investments in Related Parties (Details) $ in Thousands	Dec. 31, 2022 USD ($)
Summary of Investments Other Than Investments In Related Parties
Summary of investments, other than investments in related parties, cost	$ 4,397,569
Summary of investments, other than investments in related parties, fair value	3,992,942
Summary of investments, other than investments in related parties, carrying amount	4,097,597
US Government and Government Agencies and Authorities [Member]
Summary of Investments Other Than Investments In Related Parties
Summary of investments, other than investments in related parties, cost	111,419
Summary of investments, other than investments in related parties, fair value	105,841
Summary of investments, other than investments in related parties, carrying amount	105,841
US States and Political Subdivisions Debt Securities [Member]
Summary of Investments Other Than Investments In Related Parties
Summary of investments, other than investments in related parties, cost	142,189
Summary of investments, other than investments in related parties, fair value	122,245
Summary of investments, other than investments in related parties, carrying amount	122,245
Foreign Government Debt [Member]
Summary of Investments Other Than Investments In Related Parties
Summary of investments, other than investments in related parties, cost	163,725
Summary of investments, other than investments in related parties, fair value	152,915
Summary of investments, other than investments in related parties, carrying amount	152,915
All Other Corporate Bonds [Member]
Summary of Investments Other Than Investments In Related Parties
Summary of investments, other than investments in related parties, cost	3,828,276
Summary of investments, other than investments in related parties, fair value	3,454,656
Summary of investments, other than investments in related parties, carrying amount	3,559,311
Certificates of Deposit [Member]
Summary of Investments Other Than Investments In Related Parties
Summary of investments, other than investments in related parties, cost	176
Summary of investments, other than investments in related parties, fair value	176
Summary of investments, other than investments in related parties, carrying amount	176
Mandatorily Redeemable Preferred Stock [Member]
Summary of Investments Other Than Investments In Related Parties
Summary of investments, other than investments in related parties, cost	4,248
Summary of investments, other than investments in related parties, fair value	3,586
Summary of investments, other than investments in related parties, carrying amount	3,586
Fixed Maturities [Member]
Summary of Investments Other Than Investments In Related Parties
Summary of investments, other than investments in related parties, cost	4,250,033
Summary of investments, other than investments in related parties, fair value	3,839,419
Summary of investments, other than investments in related parties, carrying amount	3,944,074
Public Utility, Equities [Member]
Summary of Investments Other Than Investments In Related Parties
Summary of investments, other than investments in related parties, cost	6,469
Summary of investments, other than investments in related parties, fair value	9,719
Summary of investments, other than investments in related parties, carrying amount	9,719
Banks, Trust and Insurance, Equities [Member]
Summary of Investments Other Than Investments In Related Parties
Summary of investments, other than investments in related parties, cost	13,934
Summary of investments, other than investments in related parties, fair value	13,979
Summary of investments, other than investments in related parties, carrying amount	13,979
Industrial, Miscellaneous, and All Others [Member]
Summary of Investments Other Than Investments In Related Parties
Summary of investments, other than investments in related parties, cost	7,189
Summary of investments, other than investments in related parties, fair value	10,739
Summary of investments, other than investments in related parties, carrying amount	10,739
Nonredeemable Preferred Stock [Member]
Summary of Investments Other Than Investments In Related Parties
Summary of investments, other than investments in related parties, cost	1,838
Summary of investments, other than investments in related parties, fair value	967
Summary of investments, other than investments in related parties, carrying amount	967
Equity Securities, Investment Summary [Member]
Summary of Investments Other Than Investments In Related Parties
Summary of investments, other than investments in related parties, cost	29,430
Summary of investments, other than investments in related parties, fair value	35,404
Summary of investments, other than investments in related parties, carrying amount	35,404
Policy Loans and Other Invested Assets [Member]
Summary of Investments Other Than Investments In Related Parties
Summary of investments, other than investments in related parties, cost	48,713
Summary of investments, other than investments in related parties, fair value	48,713
Summary of investments, other than investments in related parties, carrying amount	48,713
Short-Term Investments
Summary of Investments Other Than Investments In Related Parties
Summary of investments, other than investments in related parties, cost	69,393
Summary of investments, other than investments in related parties, fair value	69,406
Summary of investments, other than investments in related parties, carrying amount	$ 69,406

Schedule II - Primerica, Inc. (

Schedule II - Primerica, Inc. (Parent Only) - Condensed Balance Sheet (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Investments:
Fixed-maturity securities available-for-sale, at fair value (amortized cost: $2,801,415 in 2022 and $2,621,388 in 2021)	$ 2,495,456	$ 2,702,567
Short-term investments available-for-sale, at fair value (amortized cost: $69,393 in 2022 and $85,246 in 2021)	69,406	85,243
Equity securities, at fair value (historical cost: $29,430 in 2022 and $34,255 in 2021)	35,404	42,551
Total investments	4,097,597	4,264,428
Cash and cash equivalents	489,240	392,501
Other receivables	254,276	257,675
Deferred income taxes	101,333	81,799
Other assets	428,259	441,253
Total assets	15,348,877	16,123,223	$ 14,905,285
Liabilities:
Notes payable	592,905	592,102
Current income tax payable	36,876	15,311
Deferred income taxes	91,457	226,000
Other liabilities	580,780	615,710
Commitments and contingent liabilities (see Note F)
Total liabilities	13,627,378	14,033,440
Temporary Stockholders’ Equity
Redeemable noncontrolling interests in consolidated entities		7,271
Equity attributable to Primerica, Inc.:
Common stock ($0.01 par value; authorized 500,000 in 2022 and 2021; issued and outstanding 36,824 shares in 2022 and 39,368 shares in 2021)	368	394
Paid-in capital		5,224
Retained earnings	1,973,403	2,004,506
Total permanent stockholders’ equity	1,721,499	2,082,512	$ 1,835,885
Total liabilities and temporary and permanent stockholders’ equity	15,348,877	16,123,223
Parent Company [Member]
Investments:
Fixed-maturity securities available-for-sale, at fair value (amortized cost: $2,801,415 in 2022 and $2,621,388 in 2021)	107,538	109,547
Short-term investments available-for-sale, at fair value (amortized cost: $69,393 in 2022 and $85,246 in 2021)	39,285	85,243
Equity securities, at fair value (historical cost: $29,430 in 2022 and $34,255 in 2021)	2,572	3,059
Total investments	149,395	197,849
Cash and cash equivalents	157,462	97,513
Due from affiliates	9,825	184,733
Other receivables	785	4,348
Income tax receivable	493	4,330
Deferred income taxes	6,902	8,475
Investment in subsidiaries	1,994,309	2,190,437
Other assets	946	1,005
Total assets	2,320,117	2,688,690
Liabilities:
Notes payable	592,905	592,102
Deferred income taxes	2,434	2,482
Interest payable	1,913	1,913
Other liabilities	1,366	2,410
Commitments and contingent liabilities (see Note F)
Total liabilities	598,618	598,907
Temporary Stockholders’ Equity
Redeemable noncontrolling interests in consolidated entities		7,271
Equity attributable to Primerica, Inc.:
Common stock ($0.01 par value; authorized 500,000 in 2022 and 2021; issued and outstanding 36,824 shares in 2022 and 39,368 shares in 2021)	368	394
Paid-in capital		5,224
Retained earnings	1,973,403	2,004,506
AOCI and equity, net of income tax	(252,272)	72,388
Total permanent stockholders’ equity	1,721,499	2,082,512
Total liabilities and temporary and permanent stockholders’ equity	$ 2,320,117	$ 2,688,690

Schedule II - Primerica, Inc._2

Schedule II - Primerica, Inc. (Parent Only) - Condensed Financial Information Parentheticals (Details) - USD ($) $ / shares in Units, $ in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Condensed Financial Statements, Captions [Line Items]
Equity securities, at fair value, cost	$ 29,430	$ 34,255
Common stock, par or stated value per share	$ 0.01	$ 0.01
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	36,824,000	39,368,000
Common stock, shares outstanding	36,824,000	39,368,000	39,306,000	41,207,000
Fixed Maturities
Condensed Financial Statements, Captions [Line Items]
Fixed-maturity securities and Short-term investments available-for-sale, amortized cost	$ 2,801,415	$ 2,621,388
Short-Term Investments
Condensed Financial Statements, Captions [Line Items]
Fixed-maturity securities and Short-term investments available-for-sale, amortized cost	69,393	85,246
Parent Company [Member]
Condensed Financial Statements, Captions [Line Items]
Equity securities, at fair value, cost	$ 2,517	$ 2,486
Common stock, par or stated value per share	$ 0.01	$ 0.01
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	36,824,000	39,368,000
Common stock, shares outstanding	36,824,000	39,368,000
Parent Company [Member] | Fixed Maturities
Condensed Financial Statements, Captions [Line Items]
Fixed-maturity securities and Short-term investments available-for-sale, amortized cost	$ 112,052	$ 107,969
Parent Company [Member] | Short-Term Investments
Condensed Financial Statements, Captions [Line Items]
Fixed-maturity securities and Short-term investments available-for-sale, amortized cost	$ 39,270	$ 85,246

Schedule II - Primerica, Inc._3

Schedule II - Primerica, Inc. (Parent Only) - Condensed Statements of Income (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Revenues:
Net investment income	$ 93,065	$ 80,588	$ 83,814
Realized investment gains (losses)	1,444	4,665	1,359
Other investment gains (losses)	(2,439)	1,207	(6,355)
Investment gains (losses)	(995)	5,872	(4,996)
Total revenues	2,720,133	2,709,732	2,217,541
Expenses:
Interest expense, net	27,237	30,618	28,839
Loss on extinguishment of debt		8,927
Other operating expenses	320,394	296,851	245,195
Income before income taxes	493,749	511,171	506,730
Income taxes	125,775	139,191	120,566
Net income (loss) attributable to Primerica, Inc.	373,012	373,357	386,164
Parent Company [Member]
Revenues:
Dividends from subsidiaries	450,929	387,355	378,063
Net investment income	3,916	1,503	3,670
Realized investment gains (losses)	872	115	112
Other investment gains (losses)	(519)	259	63
Investment gains (losses)	353	374	175
Total revenues	455,198	389,232	381,908
Expenses:
Interest expense, net	11,066	15,675	18,673
Loss on extinguishment of debt		8,927
Other operating expenses	13,358	26,421	13,903
Total expenses	24,424	51,023	32,576
Income before income taxes	430,774	338,209	349,332
Income taxes	(1,504)	(5,786)	(3,540)
Income before equity in undistributed earnings of subsidiaries	432,278	343,995	352,872
Equity in undistributed earnings of subsidiaries	(59,266)	29,362	33,292
Net income (loss) attributable to Primerica, Inc.	$ 373,012	$ 373,357	$ 386,164

Schedule II - Primerica, Inc._4

Schedule II - Primerica, Inc. (Parent Only) - Condensed Statements of Comprehensive Income (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Condensed Financial Statements, Captions [Line Items]
Net income	$ 373,012	$ 373,357	$ 386,164
Unrealized investment gains (losses):
Change in unrealized holding gains (losses) on investment securities	(385,735)	(78,348)	78,533
Reclassification adjustment for realized investment (gains) losses included in net income	(1,387)	(3,849)	2,614
Foreign currency translation adjustments:
Equity in unrealized foreign currency translation gains (losses) of subsidiaries	(20,015)	7,033	7,343
Total other comprehensive income (loss) before income taxes	(407,137)	(75,164)	88,490
Income tax expense (benefit) related to items of other comprehensive income (loss)	(82,477)	(17,846)	17,582
Other comprehensive income (loss), net of income taxes	(324,660)	(57,318)	70,908
Total comprehensive income	43,314	314,662	457,072
Parent Company [Member]
Condensed Financial Statements, Captions [Line Items]
Net income	373,012	373,357	386,164
Unrealized investment gains (losses):
Equity in unrealized holding gains (losses) on investment securities held by subsidiaries	(299,847)	(63,089)	62,618
Change in unrealized holding gains (losses) on investment securities	(5,201)	(1,483)	1,372
Reclassification adjustment for realized investment (gains) losses included in net income	(872)	(115)	(175)
Foreign currency translation adjustments:
Equity in unrealized foreign currency translation gains (losses) of subsidiaries	(20,015)	7,033	7,343
Total other comprehensive income (loss) before income taxes	(325,935)	(57,654)	71,158
Income tax expense (benefit) related to items of other comprehensive income (loss)	(1,275)	(336)	250
Other comprehensive income (loss), net of income taxes	(324,660)	(57,318)	70,908
Total comprehensive income	$ 48,352	$ 316,039	$ 457,072

Schedule II - Primerica, Inc._5

Schedule II - Primerica, Inc. (Parent Only) - Condensed Statements of Cash Flow (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities:
Net income	$ 367,974	$ 371,980	$ 386,164
Adjustments to reconcile net income to cash provided by (used in) operating activities:
Deferred tax provision	(79,980)	(25,593)	266
Change in income taxes	26,414	1,426	(5,008)
Investment (gains) losses	995	(5,872)	4,996
Accretion and amortization of investments	3,329	5,118	751
Share-based compensation	22,361	16,842	19,027
Trading securities sold, matured, or called (acquired), net	19,962	(8,817)	26,694
Change in other operating assets and liabilities, net	(27,539)	34,490	42,760
Loss on extinguishment of debt		8,927
Net cash provided by (used in) operating activities	757,665	656,956	643,417
Available-for-sale investments sold, matured or called:
Fixed-maturity securities — sold	23,628	131,953	67,760
Fixed-maturity securities — matured or called	359,717	454,135	429,147
Short-term investments — sold	28,251	50,065
Short-term investments — matured or called	85,302	40,000
Equity securities — sold	3,063
Available-for-sale investments acquired:
Fixed-maturity securities	(580,485)	(901,591)	(522,123)
Short-term investments	(97,415)	(176,125)
Equity securities — acquired	(187)	(3,391)	(3,272)
Purchase of business, net of cash acquired	3,867	(494,459)
Net cash provided by (used in) investing activities	(200,048)	(923,383)	(53,529)
Cash flows from financing activities:
Dividends paid	(83,783)	(74,636)	(64,346)
Common stock repurchased	(356,306)	(18,751)	(231,431)
Proceeds from revolving credit facility		125,000
Repayment of revolving credit facility		(125,000)
Proceeds from issuance of debt		597,300
Debt issuance costs		(5,332)
Repayment of debt		(383,691)
Tax withholdings on share-based compensation	(5,135)	(6,652)	(5,739)
Net cash provided by (used in) financing activities	(457,850)	107,974	(301,790)
Change in cash and cash equivalents	96,739	(155,068)	290,693
Cash and cash equivalents, beginning of period	392,501	547,569	256,876
Cash and cash equivalents, end of period	489,240	392,501	547,569
Supplemental disclosures of cash flow information:
Interest paid	27,060	33,905	27,853
Parent Company [Member]
Cash flows from operating activities:
Net income	373,012	373,357	386,164
Adjustments to reconcile net income to cash provided by (used in) operating activities:
Equity in undistributed earnings of subsidiaries	29,960	(283)	(42,030)
Deferred tax provision	2,800	(3,751)	2,553
Change in income taxes	3,837	(1,696)	(1,607)
Investment (gains) losses	(353)	(374)	(175)
Accretion and amortization of investments	205	1,448	1,777
Share-based compensation	1,592	1,559	1,447
Change in due to/from affiliates	4,458	(34,886)	(2,580)
Trading securities sold, matured, or called (acquired), net			(6)
Change in other operating assets and liabilities, net	1,967	(9,519)	3,030
Loss on extinguishment of debt		8,927
Net cash provided by (used in) operating activities	417,478	334,782	348,573
Available-for-sale investments sold, matured or called:
Fixed-maturity securities — sold	409		26,256
Fixed-maturity securities — matured or called	94,960	91,710	131,894
Short-term investments — sold		50,065
Short-term investments — matured or called	85,302	40,000
Equity securities — sold	16	718	212
Available-for-sale investments acquired:
Fixed-maturity securities	(57,762)	(84,564)	(36,190)
Short-term investments	(39,090)	(176,125)
Equity securities — acquired	(7)	(1,155)	(76)
Purchase of business, net of cash acquired	3,867	(494,459)
Net cash provided by (used in) investing activities	87,695	(573,810)	122,096
Cash flows from financing activities:
Dividends paid	(83,783)	(74,636)	(64,346)
Common stock repurchased	(356,306)	(18,751)	(231,431)
Proceeds from revolving credit facility		125,000
Repayment of revolving credit facility		(125,000)
Proceeds from issuance of debt		597,300
Debt issuance costs		(5,332)
Repayment of debt		(383,691)
Tax withholdings on share-based compensation	(5,135)	(6,652)	(5,739)
Net cash provided by (used in) financing activities	(445,224)	108,238	(301,516)
Change in cash and cash equivalents	59,949	(130,790)	169,153
Cash and cash equivalents, beginning of period	97,513	228,303	59,150
Cash and cash equivalents, end of period	157,462	97,513	228,303
Supplemental disclosures of cash flow information:
Interest paid	$ 17,053	$ 20,150	$ 18,118

Schedule II - Primerica, Inc._6

Schedule II - Primerica, Inc. (Parent Only) - Condensed Statements of Cash Flow Parenthetical (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Condensed Financial Information Of Parent Company Only Disclosure [Abstract]
Fixed-maturity securities transferred	$ 41,300,000	$ 0	$ 33,600,000
Debt forgiveness	$ 170,500,000

Schedule II - Primerica, Inc._7

Schedule II - Primerica, Inc. (Parent Only) - Notes to Condensed Financial Statements (Details) - USD ($)					1 Months Ended	12 Months Ended
	Jul. 01, 2022	Nov. 19, 2021	Jul. 01, 2021	Jun. 22, 2021	Nov. 30, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Condensed Financial Statements, Captions [Line Items]
Repayments of lines of credit							$ 125,000,000
Loss on extinguishment of debt							8,927,000
Proceeds from revolving credit facility							125,000,000
Non-life Insurance Subsidiaries [Member]
Condensed Financial Statements, Captions [Line Items]
Cash dividends paid to parent company						$ 173,000,000	217,100,000	$ 185,500,000
Life Insurance Subsidiaries [Member]
Condensed Financial Statements, Captions [Line Items]
Cash dividends paid to parent company						277,900,000	170,200,000	$ 192,500,000
Etelequote Bermuda [Member]
Condensed Financial Statements, Captions [Line Items]
Percentage of interest acquired			80%
Business acquisition, date of acquisition agreement			Jul. 01, 2021
Remaining percentage of interest acquired	20%
Business acquisition, effective date of acquisition	Jul. 01, 2022
Maximum [Member]
Condensed Financial Statements, Captions [Line Items]
Debt instrument, face amount						1,500,000,000
Revolving Credit Facility [Member]
Condensed Financial Statements, Captions [Line Items]
Debt instrument, face amount				$ 200,000,000
Debt instrument maturity date				Jun. 22, 2026
New unsecured revolving credit facility				$ 200,000,000
Debt instrument, frequency of commitment fee payable				quarterly
Proceeds from revolving credit facility						0
Revolving Credit Facility [Member] | Etelequote Bermuda [Member]
Condensed Financial Statements, Captions [Line Items]
Proceeds from revolving credit facility						0
Revolving Credit Facility [Member] | Minimum [Member]
Condensed Financial Statements, Captions [Line Items]
Debt instrument, commitment fee percentage				0.10%
Revolving Credit Facility [Member] | Maximum [Member]
Condensed Financial Statements, Captions [Line Items]
Debt instrument, commitment fee percentage				0.225%
Revolving Credit Facility [Member] | LIBOR Rate [Member] | Minimum [Member]
Condensed Financial Statements, Captions [Line Items]
Debt instrument, interest rate margin				1%
Revolving Credit Facility [Member] | LIBOR Rate [Member] | Maximum [Member]
Condensed Financial Statements, Captions [Line Items]
Debt instrument, interest rate margin				1.625%
Revolving Credit Facility [Member] | Base Rate [Member] | Minimum [Member]
Condensed Financial Statements, Captions [Line Items]
Debt instrument, interest rate margin				0%
Revolving Credit Facility [Member] | Base Rate [Member] | Maximum [Member]
Condensed Financial Statements, Captions [Line Items]
Debt instrument, interest rate margin				0.625%
Senior Notes [Member]
Condensed Financial Statements, Captions [Line Items]
Debt instrument, face amount						600,000,000
Issue price of senior notes					99.55%
Debt instrument, interest rate, stated percentage					2.80%
Debt instrument maturity date					Nov. 19, 2031
Parent Company [Member]
Condensed Financial Statements, Captions [Line Items]
Debt instrument, face amount						600,000,000
Repayments of lines of credit							125,000,000
Loss on extinguishment of debt							8,927,000
Proceeds from revolving credit facility							$ 125,000,000
Guarantor obligations, maximum exposure, undiscounted						20,000,000
Parent Company [Member] | Etelequote Bermuda [Member]
Condensed Financial Statements, Captions [Line Items]
Percentage of interest acquired			80%
Business acquisition, date of acquisition agreement			Jul. 01, 2021
Remaining percentage of interest acquired	20%
Business acquisition, effective date of acquisition	Jul. 01, 2022
Parent Company [Member] | Senior Notes [Member]
Condensed Financial Statements, Captions [Line Items]
Debt instrument, face amount						$ 600,000,000
Issue price of senior notes		99.55%
Debt instrument, interest rate, stated percentage		2.80%
Debt instrument maturity date		Nov. 19, 2031

Schedule III - Supplementary _2

Schedule III - Supplementary Insurance Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Supplementary Insurance Information, by Segment [Line Items]
Deferred policy acquisition costs	$ 3,081,886	$ 2,943,782
Liability for future policy benefits, losses, claims and loss expense reserves	7,390,800	7,138,649
Unearned and advance premiums	15,422	16,437
Policy claims and other benefits payable	538,250	585,382
Separate account liabilities	2,305,717	2,799,992
Premium revenue	1,600,228	1,505,884	$ 1,326,383
Net investment income	93,065	80,588	83,814
Benefits, claims, losses and settlement expense	665,749	722,753	615,569
Amortization of deferred policy acquisition costs	356,143	251,179	224,321
Other operating expense	1,204,492	1,224,629	870,921
Premiums written	602	670	701
Term Life Insurance [Member]
Supplementary Insurance Information, by Segment [Line Items]
Deferred policy acquisition costs	3,008,330	2,859,758
Liability for future policy benefits, losses, claims and loss expense reserves	7,181,525	6,927,789
Unearned and advance premiums	14,992	15,982
Policy claims and other benefits payable	525,877	573,316
Premium revenue	1,585,646	1,490,230	1,309,661
Net investment income	51,160	36,486	27,030
Benefits, claims, losses and settlement expense	649,530	703,897	593,948
Amortization of deferred policy acquisition costs	342,925	241,451	216,208
Other operating expense	246,131	215,719	200,063
Investment and Savings Products [Member]
Supplementary Insurance Information, by Segment [Line Items]
Deferred policy acquisition costs	53,127	62,278
Separate account liabilities	2,305,688	2,799,954
Amortization of deferred policy acquisition costs	12,141	8,668	7,055
Other operating expense	611,961	658,595	509,167
Senior Health [Member]
Supplementary Insurance Information, by Segment [Line Items]
Other operating expense	161,355	145,490
Corporate and Other Distributed Products Segment [Member]
Supplementary Insurance Information, by Segment [Line Items]
Deferred policy acquisition costs	20,429	21,746
Liability for future policy benefits, losses, claims and loss expense reserves	209,275	210,860
Unearned and advance premiums	430	455
Policy claims and other benefits payable	12,373	12,066
Separate account liabilities	29	38
Premium revenue	14,582	15,654	16,722
Net investment income	41,905	44,102	56,784
Benefits, claims, losses and settlement expense	16,219	18,856	21,621
Amortization of deferred policy acquisition costs	1,077	1,060	1,058
Other operating expense	185,045	204,825	161,691
Premiums written	$ 602	$ 670	$ 701

Schedule IV - Reinsurance (Deta

Schedule IV - Reinsurance (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Reinsurance Premiums for Insurance Companies, by Product Segment [Line Items]
Direct premiums, life insurance in force	$ 919,081,738	$ 905,819,671	$ 861,392,223
Direct premiums	3,230,120	3,122,148	2,907,149
Ceded premiums, life insurance in force	787,907,229	777,826,233	742,356,917
Ceded premiums	1,629,892	1,616,264	1,580,766
Net life insurance in-force	131,174,509	127,993,438	119,035,306
Premiums earned, net	1,600,228	1,505,884	1,326,383
Life Insurance [Member]
Reinsurance Premiums for Insurance Companies, by Product Segment [Line Items]
Direct premiums	3,229,229	3,121,167	2,906,083
Ceded premiums	1,629,634	1,615,966	1,580,427
Premiums earned, net	1,599,595	1,505,201	1,325,656
Accident and Health Insurance [Member]
Reinsurance Premiums for Insurance Companies, by Product Segment [Line Items]
Direct premiums	891	981	1,066
Ceded premiums	258	298	339
Premiums earned, net	$ 633	$ 683	$ 727